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Abstract
Nanotechnology has tremendous potential to improve the selectivity of cancer detection and
therapy. Over the past three decades, advances in nanomaterial synthesis have produced
impressive nanostructures with unique electromagnetic and therapeutic properties. These
represent a powerful toolkit of building blocks through which multi-component nanosystems
could be constructed. Yet, while biological systems produce higher-order functions through
coordinated interactions between multiple nanoscale components, biomedical
nanotechnologies to date have largely lacked systems-scale complexity. Considering that
typical in vivo doses of diagnostic or therapeutic nanoparticles exceed I trillion nanoparticles,
there is considerable opportunity to construct multi-component, interactive nanoparticle
systems that perform sophisticated new functions in vivo.
This thesis takes a systems approach to engineering cancer nanotechnologies, where
interactions between multiple nanoparticle populations are designed to generate emergent
system properties for enhancing the sensing and targeting of cancer cells.
In the first section of this thesis, direct nanoparticle interactions are engineered to produce
emergent properties for cancer sensing. Three classes of magnetic particles are developed
that respectively enable: MRI detection of single cancer-associated proteases, performance of
logical AND/OR operations using two cancer-associated proteases, and reversible sensing of
antagonistic kinase/phosphatase enzyme pairs.
In the second section of this thesis, indirect mechanisms of nanoparticle interaction-where
nanoparticles communicate at a distance via intermediates-are engineered to amplify
nanoparticle targeting to regions of tumor invasion in vivo. Two nanosystems are synthesized
wherein intravenously administered nanoparticles that have successfully targeted tumors
broadcast the tumor's location to other nanoparticles in circulation to recruit their amplified
local accumulation. In mice, one of these systems intravenously delivers >40-fold higher
drug doses to tumors than non-communicating controls, leading to durable repression of
tumor growth and significantly improved host survival.
Together, these systems highlight the potential for interactive nanoparticle systems to
perform highly complex functions in vivo. In contrast to the current strategy of injecting large
populations of nanoparticles that carry out identical, often competitive functions in vivo, this
work promotes a paradigm of 'systems nanotechnology,' directed toward the construction of
nanoparticle systems that produce emergent behaviors for enhancing in vivo diagnostics,
regenerative medicines, and therapeutics.
Thesis Supervisor: Sangeeta N. Bhatia
Title: Professor
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Figure 4.1. Dynamic light scattering detection of nanoparticle assembly. Phosphopeptide
(pY) NP assembly with SH2 NPs. Upon addition of SH2 NPs to pY-peptide NPs, rapid
increase in hydrodynamic radius was observed by DLS (filled circles). In the presence
of free pY-peptide, NP assembly was not observed (vertical lines). Non-
phosphorylated peptide and non-binding pY-peptide remain dispersed with SH2 NPs,
demonstrating both sequence- and phosphate- specific peptide recognition by SH2 NPs
(hollow square and hollow dot, respectively). Assembly was reversed by addition of
excess free pY-peptide to the mixture after 8 min incubation (hollow triangles). ....... 77
Figure 4.2. Kinase-directed nanoparticle assembly. (A). Abl kinase (5 U/pl) (yellow
dots) was added to a mixture of SH2 NPs and tyrosine-containing, Abl substrate NPs at
2 min and NP radius was observed over time using dynamic light scattering (DLS).
Controls without kinase (red dots) with phenylalanine-Abl substrate NPs (green
triangle) did not assemble. (B) In MRI, T2 relaxation was enhanced by Abl kinase-
directed assembly (bottom two wells) and was reversed by addition of 200 ptM free
phosphopeptide, but not by mixing alone. Controls lacking enzyme (top), containing
phenylalanine substrate NPs (second from top), or 200 pM free pY substrate (third
from top) did not show enhancement. (C) Dose dependent T2 relaxation enhancement
of SH2 NPs and Y-peptide NPs 3 hours following Abl kinase addition (12 nM NPs). 79
Figure 4.3. Phosphatase reversal of nanoparticle assembly in DLS and MRI. (A) SH2
NPs and pY-Abl substrate NPs were allowed to assemble prior to addition of
phosphatase (2U/ptl) (red) or vehicle control at 25 min (blue). (B) NPs were exposed to
Abl kinase (2.5 U/ l), followed by phosphatase (5 U/pl). (C) Kinase-directed assembly
(2.5 U/pl) and phosphatase disassembly (5 U/pl) was visualized via T2 relaxation
enhancem ent in M R I.................................................................................................. 80
Scheme II. Inspired by mechanisms ofremote communication in biology, the second
section of this thesis describes nanoparticles that remotely communicate with one
another via biological intermediates to amplify tumor targeting. A) In areas of
infection, tissue resident macrophages engulf microbes and produce cytokines to
remotely stimulate the infiltration of circulating leukocytes in the blood stream (where
concentrations exceed >106 cells/ml blood). This process occurs as chemokines diffuse
to the local blood vessels and stimulate upregulation of integrins to recruit neutrophil
rolling, firm adhesion, and local transmigration into the tissue to amplify cellular
assistance. B) Inspired by this process, we set out to engineer mechanisms by which
two distinct populations of nanoparticle could communicate to improve tumor imaging
and drug delivery. Here, an initial population of 'Signaling' nanoparticles has homed
to tumors and, after arrival, remotely signals to 'Receiving' nanoparticles in circulation
to extravasate and bind............................................................................................. 87
Scheme 5.1. Design of a "click" nanoparticle that targets tumor cells in vitro and in
vivo. Cross-linked, fluorescent, superparamagnetic iron oxide nanoparticles are
modified to display azido-PEG groups. Conjugation of cyclic targeting peptides
(purple circles) bearing pendant alkynes to azido-PEG nanoparticles via the copper(I)-
catalyzed Huisgen 1,3-dipolar cycloaddition ("click" reaction) allows specific targeting
of the nanoparticles to cells expressing the receptor (red)......................................... 89
Figure 5.1. Native and alkyne-bearing LyP-1 peptides target p32-expressing MDA-MB-
435 cells in vitro. (A) Structures of LyP-1, propargylglycine-LyP-1, and Heptynoic
acid-LyP-1, all labeled with a TAMRA fluorophore (red). The cyclic nonapeptide is in
blue. The pendant alkyne moieties were conjugated to the N-terminus of the peptide
during standard FMOC peptide synthesis. (B) Flow cytometry shows that peptides
bearing different alkyne groups target MDA-MB-435 cancer cells similarly, while a
scrambled control (LyP- 1 CTL) do not target (P=propargylglycine, H=6-heptynoic
acid, *p<0. 01, unpaired Student's t-test ). (C) Flow cytometry histogram shows LyP-1,
P-LyP-1, and H-LyP-1 peptides (in different shades of blue) target MDA-MB-435 cells
in vitro, while LyP- 1 CTL peptide (green) did not show targeting relative to peptide-
free control cells (red)............................................................................................... 90
Scheme 5.2. Synthesis of LyP-1 -coated nanoparticles using "click" chemistry. (A)
Synthesis of Succinimidyl 4-azidobutyrate. (B) Synthesis of azide-PEG-thiol by
linking Succinimidyl 4-azidobutyrate to a 5kDa thiol-PEG-amine. (C) Aminated,
cross-linked, fluorochrome-labeled superparamagnetic iron-oxide nanoparticles are
activated with GMBS, filtered, and then reacted with the thiol-PEG-azide from (B) to
yield azido-PEG bearing nanoparticles. After purification, the particle solutions were
reacted with alkyne-bearing LyP-1 peptides with CuSO4 / Na Ascorbate as catalysts to
yield LyP- 1-coated nanoparticles for in vitro and in vivo use. ................................ 91
Figure 5.2: Fluorophore-labeled LyP-] Peptide Spectra. UV-Vis spectra for LyP-1 and
LyP- 1 CTL peptides synthesized with varying pendant alkyne groups (prop=
propargylglycine; Hep=heptynoic acid) ................................................................... 93
Figure 5.3. LyP-] -conjugated nanoparticles target p32-expressing MDA-MB-435 cells in
vitro, while nanoparticles conjugated to control cyclic peptides (LyP-JCTL) do not
target. (A) The amount of peptide bound per particle was quantified
spectrophotometrically by measuring the absorbance of the TAMRA dyes added
following the click reaction. With the addition of catalyst CuSO 4/Na ascorbate (dark
circles), the TAMRA absorbance at 555nm was quantified to equal approximately 30
peptides per particle, whereas no TAMRA signal was observed without catalyst (light
circles). (B) LyP-1-nanoparticles or control LyP-1CTL-nanoparticles (both at ~30
peptides per particle), or parent azido-bearing particles (N3), were added to MDA-435-
MB cancer cells in normal 10% serum (dark green) and 0.1% serum-starved (light
green) conditions. Flow cytometry histogram shows marked increase in uptake of LyP-
1 -nanoparticles (blue) vs. LyP- 1 CTL-nanoparticles (green) and particle-free control
cells (red). Each error bar represents 6 parallel experiments. (C) Addition of free LyP- 1
peptides at concentrations from 10 to 100 uM inhibited cellular uptake of LyP- 1-coated
nanoparticles, suggesting that the LyP- 1 peptide and LyP-1-labeled particles target the
sam e receptor. ............................................................................................................... 9 5
Figure 5.4. Tumor cell targeting with LyP-1 nanoparticles. LyP-1-nanoparticles target
MDA-MB-435 cancer cells (right). Fluorescence imaging of cells incubated with LyP-
1 -nanoparticles showed increased near-infrared fluorescence (red). Uptake of azido-
bearing or scrambled control peptide (LyP- 1 CTL)-bearing nanoparticles are not visible
or show minor background (left and middle). ......................................................... 97
Figure 5.5: LyP-1-nanoparticles target MDA-MB-435 cancer cells and become localized
in endosome-like compartments over 24hrs in vitro. Cells were incubated with LyP-1-
nanoparticles for 30min, washed, and incubated for 24hrs before nuclear staining and
imaging. PEG-LyP- 1 nanoparticles no longer show diffuse membranous staining, but
have become localized into punctuate compartments, implying endosomal
sequestration away from cell surface ........................................................................ 98
Figure 5.6: Probing "Click" Nanoparticle Cytotoxicity to Human Cell Cultures. Human
HeLa cervical cancer cells were incubated with parent NH2-PEG-NPs, PEG-N3-NPs,
or PEG-LyP- 1 CTL-NPs at varying concentrations for 24 hrs, rinsed, and incubated
with media containing thiazolyl blue tetrazolium bromide (MTT reagent) at 0.5mg/ml.
After 3hr, blue precipitates begin to form within cells as a result of mitochondrial
activity. Quantitaion of cellular viability via absorbance of DMSO:isopropanol-
solubilized MTT reagent showed that all three NP peparations have TC50 values of
greater than 7mM, which is over 35-times that used in vitro here (lOOnM NPs used in
cell culture and FACS expts = 0.2mM Fe) and greater than sixteen times the maximum
blood concentrations during in vivo experiments (200nM NP concentration in blood
immediately after injection = 0.4mM Fe) ................................................................. 99
Figure 5.7: Near-Infrared Fluorescence Analysis of LyP-1- and Azido-Nanoparticle
Tumor Accumulation. Near-infrared fluorochrome-labeled nanoparticles bearing
terminal azide groups (red) or LyP-1 peptides (blue) were injected intravenously via
the tail vein into mice bearing human MDA-MB-435 cancer xenografts (4 mice). After
particles had cleared the systemic circulation (24hrs), mice were sacrificed and tumor,
liver, spleen, and kidneys were fluorescently imaged for nanoparticle accumulation
(LI-COR Odyssey). As expected for nanoparticles above the renal filtration limit,
clearance was predominately via reticuloendothelial system uptake (liver and spleen).
Nanoparticle accumulation in tumors was slightly decreased for peptide-modified
nanoparticles, likely due to a decrease in the particle circulation time following
cationic peptide attachment and concomitant decrease in the passive targeting. ....... 100
Figure 5.8: "Click" LyP-1-nanoparticle targeting to tumor cells in vivo. Nanoparticles
bearing only azide groups (top) or labeled with LyP- 1 peptides (bottom) that are
matched in circulation time were injected intravenously via the tail vein into mice
bearing human MDA-MB-435 cancer xenografts. Histological sections were obtained
24 hours post injection. (A) Light reflectance images of mice bearing the tumor
xenografts. (B) Fluorescent LyP- 1 -nanoparticles (VT680 fluorescence pseudocolored
as green) did not colocalize with CD3 1, a blood vessel marker (red) while untargeted
azide-PEG nanoparticles remained localized to the blood vessels or their immediate
periphery. (C) LyP- 1 -nanoparticles (green) accumulated in regions of high p32
expression (red), whereas untargeted, azido-bearing nanoparticles did not accumulate
in these areas. D) Histological quantitation using CD31 stain to assess nanoparticle
localization to immediate periphery of blood vessels. The fraction of LyP- 1
nanoparticles outside of the perivascular space of CD3 1-stained blood vessels is
significantly higher than azido-nanoparticles (P<0.005) as assessed from 3 randomly
chosen views in each set of mice (n=3). Together, LyP-1-coated nanoparticles
penetrate into the tumor interstitium to target p32-expressing cells........................... 103
Figure 6.1: Structure and synthesis of highly absorbing, polyethylene glycol (PEG)-
protected gold nanorods. A) Near-infrared absorbing (810 nm longitudinal plasmon
resonance peak) gold nanorods were imaged via transmission electron microscopy
(TEM). B) Schematic of process to drive CTAB-nanorod conversion to PEG-nanorods
under dialysis with rendering and molecular schematic of PEG coating on nanorod
surface C) PEG-nanorods show prolonged stability in biological media (>1000 hrs)
while CTAB-coated nanorods precipitated over time. ............................................... 113
Figure 6.2: PEG-Nanorod Synthesis and Stability In vitro. A) The plasmon resonance of
gold nanomaterials is highly sensitive to aggregation-mediated red-shifting. By
monitoring plasmon resonance peak over >1000 hrs in biological solutions, we find
that PEG-nanorods show prolonged stability in biological media while CTAB-coated
nanorods aggregated over time in PBS (0.15 M NaCl 0.1 M Na Phosphate, pH 7.2) or
10% human serum monitored for over 1000 hrs in vitro. B) PEG-NRs were readily
dispersed in a variety of solvents, including acetone, acetonitrile, dimethyl sulfoxide
(DMSO), dimethylformamide (DMF), ethanol, methanol, or PBS. ........................... 114
Figure 6.3: Probing Nanorod Cytotoxicity to Primary Rat Hepatocyte cocultures. A)
Primary rat hepatocyte: 3T3-J2 human fibroblast co-cultures were incubated with
PEG-NRs at varying concentrations for 24 hrs (left column), rinsed, and incubated
with media containing thiazolyl blue tetrazolium bromide (MTT reagent) at 0.5 mg/ml.
After 1 hr, blue precipitates begin to form within hepatocytes as a result of
mitochondrial activity (right column). B) Microscopy shows cultures incubated with
PEG-NRs at maximal concentrations to show similar morphology to controls. C)
Quantitaion of cellular viability via absorbance of DMSO:isopropanol-solubilized
MTT reagent shows no cytotoxicity of PEG-NRs, even at concentrations of 20-times
that used in vitro here and approximately equal to maximum blood concentrations
during in vivo experim ents.......................................................................................... 114
Figure 6.4: Spectral and photothermal properties of highly-absorbing gold nanorods
compared to gold nanoshells. A) Schematic of photothermal heating of gold nanorods.
The dimensions of gold nanorods are tuned to have a near-infrared plasmon resonance,
at which point nanoparticle electrons resonantly oscillate and dissipate energy as heat.
B) Spectra for PEG-gold nanorods (red) and PEG-gold nanoshells (blue), a benchmark
for tunable plasmonic nanomaterials, at equal gold concentrations. C) Rate of
temperature increase for triplicate PEG-nanorod and PEG-gold nanoshell solutions (7
ig Au/mL, 810 nm laser, 2 W/cm 2, n=3 each) (top). Infrared thermographic image of
PEG-nanorods vs PEG-gold nanoshells following 2 minutes of irradiation (scale bar-5
mm) (bottom). D) In vitro photothermal toxicity of PEG-nanorods over human cancer
cells in culture (MDA-MB-435). Tumor cells were incubated with PEG-nanorods (14
pg/mL; above), PEG- nanoshells (14 pg/mL; middle), or media alone (below) and
treated with laser irradiation (2 W/cm 2 , 810 nm, 5 min). Calcein AM staining indicates
destruction of cells with PEG-nanorods, while cells irradiated in the presence of
nanoshells or media remained viable. Phase region of calcein staining inset (all scale
b ars= 10 im )................................................................................................................ 1 15
Figure 6.5: X-ray computed tomography, quantitative photothermal modeling, and near-
infrared photothermal heating of gold nanorods in vivo. A) Schematic of x-ray
absorption by gold nanorods in x-ray CT. B) X-ray CT number of PEG-nanorods
compared to an iodine standard (Isovue-370) C) PEG-nanorods were intratumorally
administered to mice bearing bilateral MDA-MB-435 tumors and imaged using x-ray
CT to visualize 3D PEG-nanorod distribution in tumors (left). A 3D solid model of the
complete geometry was rapidly reconstructed by image processing for use with
computational photothermal modeling (middle, red=PEG-nanorods). Experimental
thermographic surveillance of NIR-irradiation after x-ray CT (-.75 W/cm2, 1 min)
(right) D) Meshed geometry of the left tumor chosen as the computational domain
(left). Plot of theoretical heat flux propagation inside the tumor upon irradiation
(middle-left). Predicted internal temperature distribution at 3 different planes inside the
tumor (middle-right) along with surface temperature map (right) matching the left
tum or in C ) .................................................................................................................. 1 18
Figure 6.6: X-ray Absorption, Optical Spectra, and Photothermal Comparison between
PEG-Nanorods and Clinical Iodine X-ray Computed Tomography Reagent. A) X-ray
computed tomography number of PEG-nanorods compared to an iodine standard
(Isovue-370). Linear x-axis plot of the same data presented in Figure 2B, clarifying
linearity of PEG-gold nanorod detection via x-ray CT B) Optical extinction spectra of
PEG- Nanorods (0.045 mg/ml Au) vs solution of an iodine-based clinical regent (350
mg/ml iodine) and saline. Notably, iodine reagents lack absorbance in the near-infrared
that could allow remote photothermal heating. B) Photothermal heating comparison
between PEG-Nanorods, iodine, and saline monitored using infrared thermography
(810 nm NIR light, 2 W/cm 2)......................................119
Figure 6.7: Linking PEG-Nanorod X-ray Tomography with Computational Modeling. A)
Transverse and sagittal slices showing PEG-Nanorod distributions following
intratumoral administration into bilateral breast tumors B) 3D reconstructions
depicting geometry of PEG-NR injections C) Importation of 3D x-ray CT data into
geometries for 4D photothermal modeling (red= PEG-nanorods, white=skeletal
stru ctu re). .................................................................................................................... 12 0
Figure 6.8: X-ray CT-Fused Computational Modeling of Photothermal Tumor Heating.
A) X-ray CT image of PEG-Nanorod distribution in tumor B) A 3D solid model of the
complete geometry was reconstructed by image processing for use with computational
photothermal modeling. C) Meshed geometry of the injected tumor chosen as the
computational domain with laser orientation and intensity matching that used (1
W/cm 2) (laser direction signified by curved arrows) D) Plot of theoretical surface
temperature distribution (left) and the internal predicted temperature profiles inside the
computational geometry of the tumor (right) 240 sec following the onset of irradiation.
E) Graphical comparison between simulated and thermographically measured
maximum surface temperatures over time after the onset of irradiation. ................... 121
Figure 6.9: Long circulation time, passive tumor targeting, and photothermal heating of
passively-targeted gold nanorod antennas in tumors. A) PEG-nanorods were
intravenously administered (20 mg/kg) to 3 mice bearing MDA-MB-435 tumors and
blood was withdrawn over time to monitor clearance from circulation. B) PEG-
nanorod biodistribution and targeting to MDA-MB-435 tumors 72hrs following
intravenous administration, quantified via ICP-MS (3 mice). (T=tumor, Br=brain,
Bl=bladder, M=muscle, H=heart, Lu=lung, K=kidney, Li=liver, Sp=spleen) (Data is
tabulated in STI) C) PEG-nanorods or saline were intravenously administered (20
mg/kg) to mice bearing MDA-MB-435 tumors on opposing flanks. After nanorods had
cleared from circulation (72 hrs after injection) the right flank was irradiated using an
81 Onm diode laser (2 W/cm 2; beam size indicated by dotted circle). D) Thermographic
surveillance of photothermal heating in PEG-NR-injected (top) and saline-injected
(bottom ) m ice.............................................................................................................. 12 3
Figure 6.10: Assessing PEG-NR concentration in plasma via plasmon resonance peak
height. A) PEG-NRs at various concentration were diluted into plasma and
spectrophotometrically analyzed to assess NR concentration via the NIR plasmon
resonance peak. NRs could be rapidly quantified between -0.2 mg/ml (the
approximate concentration in plasma immediately following injection in mice) and
-0.02 mg/ml. B) Following injection, this method could be applied to rapidly detect
PEG-NRs in the plasma of injected mice over time, showing that PEG-NRs maintain
their plasmon resonance throughout their blood circulation in vivo........................... 124
Figure 6.11: Assessing PEG-NR concentration in organs via ICP-MS Au quantitiation.
PEG-NRs at various concentration were diluted into buffer or into glass vials
containing 200 mg sections of liver. Samples were all prepared for ICP-MS
quantitation to assess the linearity of Au detection and whether the presence of organs
affected quantitation. The samples were made to approximate a range of -2% to 70%
ID/g for 200 mg tissues. Results are plotted for triplicate samples and plotted against
the ideal relationship of y=x. ...................................................................................... 125
Figure 6.11: PEG-NR biodistribution in tumor-free mice at 2 months following
intravenous injection. PEG-nanorod biodistribution 2 months following intravenous
administration, quantified via ICP-MS (3 mice). Percent values indicate the clearance
(or decrease in %ID/g) that occurred during this time period compared to values of
organs collected 72 hrs after particle injection (Br=brain, Bl=bladder, M=muscle,
H=heart, Lu=lung, K=kidney, Li=liver, Sp=spleen). ................................................. 127
Figure 6.12: Compuatational domain for modeling photothermal therapy following
intravenous administration ofPEG-Nanorods. For intravenous photothermal
modeling, a cylindrical domain of 20 mm diameter around the tumor with a depth of
12 mm for the muscle domain was considered for computation. The outer shell of the
tumor was considered to be of 0.5 mm thickness ....................................................... 127
Figure 6.13: Photothermal destruction of human tumors in mice using long-circulating
gold nanorods. A) Mice harboring two MDA-MB-435 human tumors on opposite
flanks were injected with either saline or PEG-nanorods. After PEG-nanorods had
cleared from circulation (72 hrs after injection), the right flank of each mouse was
exposed to the computationally-designed irradiation regimen (810 nm, 2 W/cm2, 5
min). Volumetric changes in tumor sizes are plotted over time following irradiation. B)
Mice harboring one MDA-MB-435 human tumor were injected with either saline or
PEG-nanorods and irradiated as in A). Survival of mice following irradiation is plotted
versus time after irradiation. C) At 20 days following irradiation, NIR-irradiated, all
PEG-nanorod-injected mice showed only a minor scar and no evidence of tumor
regrowth, while all other treatment groups harbored thriving tumors........................ 131
Figure 6.14: Weight of irradiated, PEG-NR-injected mice during tumor resorption
following treatment. A) Body weight curve of mice bearing unilateral MDA-MB-435
tumors from the survival study (Figure 5C). No obvious body weight loss was
observed following PEG-NR-mediated tumor therapy. C) Close view of site of tumor
resportion showing only evidence of minor scar........................................................ 132
Figure 6.15: Hematological effects ofPEG-NR irradiation in mice. To explore the effects
of NR administration and near-infrared ablation, mice bearing bilateral MDA-MB-435
tumors were injected with either saline or PEG-NRs and, 72 hrs later, either exposed to
the therapeutic tumor irradiation protocol under anaesthetic (-2 W/cm2, 5 min, 810
nm) or anaesthetized without irradiation (n=3 each set). Following irradiation or
comparable time under anaesthetic, blood was collected for hematology and mice were
sacrificed. The only statistically-significant change observed in response to NR-
mediated tumor ablation was a slight increase in the percent of band neutrophils
(p<0.05 for NR+ Laser vs NR, Saline + Laser, and Saline), likely due to an acute
inflamm atory response to tum or ablation. .................................................................. 133
Schematic 7.0. Architecture and information flow in nanoparticle signaling networks. A)
Generic architecture for nanoparticle signaling networks. Extravascular nanoparticles
that have targeted tumors signal remotely to recruit intravascular nanoparticles. B)
Information flow in nanoparticle signaling networks. Extravascular Signaling
nanoparticles convert an electromagnetic signal into a local physical signal that is
biologically-transduced into a local biochemical signal for circulating therapeutic or
diagnostic Receiving nanoparticles. C) Signaling pathway between Signaling and
Receiving nanoparticles. Tumor-targeted, extravascular plasmonic gold nanorods
(Signaling nanoparticle (NP)) initiate coagulation cascade activation by photothermally
disrupting tumor vessels and activating the extrinsic and intrinsic coagulation
pathways, respectively. The resulting biomolecular amplification of the coagulation
cascade is channeled to recruit organic (drug-loaded liposomes) or inorganic (iron
oxide nanoworms) via activity of the coagulation transglutaminase FXIII (solid path on
right) or via targeting of polymerized fibrin (dotted path on left). ............................. 146
Figure 7.1. 'Signaling nanoparticle' characterization. A) Schematic of nanorod-directed
stimulation of the coagulation cascade. Gold nanorods (NRs) are passively targeted to
tumors to photothermally specify coagulation cascade activation in tumors. B)
Transmission electron microscopy of near-infrared absorbing NRs. C) Probing the
coagulation-dependent and -independent protein tropism to heated tumors. Fibrinogen
and albumin were labelled with unique near-infrared fluorochromes and injected into
mice bearing bi-lateral MDA-MB-435 tumors. Immediately following injection, one
tumor on each mouse was heated using a temperature-controlled water bath. At 24 hrs
post-injection, mice were dissected and both tumors imaged for the relative abundance
of fibrinogen (green) and albumin (red). Both heated (+ row) and unheated (- row)
tumors are displayed across the temperatures tested. D) Experimental timeline for
exploring fibrinogen deposition in PEG-NR heated tumors. E) Thermographic imaging
of PEG-NR- and saline-injected mice under broad NIR irradiation of the right flank. F)
Visible light image of mice 24 hrs after NIR-irradiation. G) Fluorescence reflectance
imaging of mice to visualize fibrinogen tropism to PEG-NR-heated tumors............. 149
Figure 7.2. Specificfibrinogen tropism to heated tumors. A) Probing the coagulation-
dependent and -independent protein tropism to heated tumors. Fibrinogen and albumin
were labelled with unique near-infrared fluorochromes in the opposite channels as in
Figure 1A (VT680 and VT750, respectively) and injected in mice under identical
conditions. Reversing the fluorophore labelling on fibrinogen and albumin enables
quantitation of protein tropism to heated tumors independent of any potential optical or
molecular fluorophore bias. At 24 hrs post-injection, mice were dissected and both
tumors imaged for the relative abundance of fibrinogen (red) and albumin (green).
Both heated (+ row) and unheated (- row) tumors are displayed across the temperatures
tested. B) Quantitation of fibrinogen:albumin fluorescence ratio across tested tumor
temperatures. Data taken under conditions of 1A and SlA were utilized to quantify the
relative abundance of fibrinogen and albumin in heated tumors vs unheated. At 45-
53C, fibrinogen abundance in tumors was significantly enhanced over albumin
(P<0.05; 1-sided t-test; 4-mice per temperature). ....................................................... 150
Figure 7.3. Histopathological analysis of anti-fibrin(ogen) binding to unheated and
heated tumors. Quantitation of anti-fibrin(ogen) binding to sections from unheated and
externally-heated tumors. As an independent measure of fibrin(ogen) deposition in
heated tumors, uninjected mice bearing bilateral MDA-MB-435 tumors had one tumor
immersed in a temperature-controlled water bath for 20 minutes and were sacrificed 24
hrs later for histological sectioning. Fluorescent quantification showed significantly
enhanced abundance of antibody binding at both 45 and 53'C (P<0.0001, 1-sided t-
test, 6 separate regions analyzed in each condition)................................................... 151
Figure 7.4. Histopathological analysis ofNR-directedfibrinogen deposition in tumors.
Mice bearing bilateral MDA-MB-435 tumors were injected with PEG-NRs (10 mg
Au/kg) or saline and, 72 hrs later, injected with fluorescently-labeled fibrinogen
(VT750) and broadly irradiated on their right side (~1 W/cm 2, 810 nm, 20 min). At 24
hrs post-injection, mice were sacrificed and tumors isolated for histological analysis of
fibrinogen distribution (Red=CD31 antibody stain, Blue= DAPI nuclear stain,
G reen=fibrinogen distribution)................................................................................... 152
Figure 7.5. 'Receiving nanoparticle' synthesis and testing. A) Schematic of Receiving NP
homing to regions of coagulation cascade activity. Multimodal nanoworm (NW)
imaging agents and drug-loaded liposomes (Lps) (top and bottom, respetively) were
derivatized with coagulation-targeting peptides to form Receiving NPs that accumulate
in regions of fibrin deposition (fibrin in grey). Receiving NP characterization utilized
temperature-controlled water baths to initially probe the thermal sensitivity of
Receiving NP homing to tumors. B) Nanostructure and biological activity of Receiving
NPs. Transmission electron microscopy images of the two classes of nanomaterials
utilized in Receiving NP synthesis: iron oxide nanoworms (NWs; scale bar=50 nm)
and doxorubicin-loaded liposomes (Lps; scale bar=400 nm). Two peptides were
utilized to direct Receiving NPs with targeting specificity for coagulation: a fibrin-
binding peptide and a glutamine-containing substrate for the coagulation
transglutaminase FXIII to respectively direct particle binding and covalent attachment
in regions of coagulation. C) Fluoresence reflectance imaging of Receiving NP homing
to externally-heated tumors. Mixtures of targeted (green) and untargeted (red) NWs,
labelled with the unique NIR-fluorochromes VT750 and VT680, respectively, were
intravenously injected into mice bearing bilateral MDA-MB-435 tumors. Immediately
following injection, one tumor was submerged in a temperature-controlled water bath
for 20 min and mice were dissected at 24 hrs for fluorescent organ imaging. Overlaid
fluorescence images are shown for targeted (green) and untargeted (red) Receiving NP
accumulation in both heated (+, 45'C heating) and naive (-) tumors from the same
mouse. D) Histopathological analysis of Receiving NP homing to heated tumors.
Histological sections from naive (top) and heated (bottom, 45"C) tumors in FXIII-NW-
injected mice were stained for CD31 (red) and nuclei (blue) and imaged to reveal
Receiving NP distribution (green). E) Quantifying the amplification of FXIII-Substrate
and Control NW Receiving NP homing to heated over unheated tumors. The fold
enhancement of NW targeting is plotted across the range of temperatures tested (n=4,
p<0.05 for the difference between FXIII-substrate-NWs and Control substrate NWs at
45"C, 49"C, and 53*C; paired, one-sided t-test). F) Quantifying the amplification of
FXIII-Substrate and Control Drug-loaded Liposome Receiving NP homing to heated
over unheated tumors. The fold enhancement of doxorubicin accumulation in tumors is
plotted across the range of temperatures tested for FXIII-substrate Lps and Control-
substrate Lps (n=3, p<0.05 for the difference between FXIII-substrate-NWs and
Control substrate NWs at 45"C and 49'C, respectively; unpaired, one-sided t-test).. 153
Figure 7.6. Spectrophotometric, fluorescent, and size characterization of Receiving
modules. A) Spectrophotometric characterization of NW Receiving module
functionalization. Aminated NWs were conjugated with NHS-activated NIR
fluorochromes (VT680 or VT750) to allow fluorescent imaging and subsequently
linked to thiol-containing FXIII-substrate peptides or control-peptides. The spectra
NWs were utilized to quantify the number of peptides and NIR-fluorochromes per
particle (~600 FXIII- or control-peptides/NW and -12-15 fluorochromes/NW,
respectively). Conjugation conditions were optimized to produce populations with
approximately equal numbers of peptides in the FXIII-NWs and control-NWs. B)
Dynamic light scattering characterization of FXIII-NW and control-NW Receiving
modules. After peptide functionalization with NIR-fluorochromes and peptides,
samples were analyzed via DLS to probe the hydrodynamic size of each conjugate. C)
Fluorescent characterization of FXIII-Lps and control-Lps. The fluorescence emission
spectra of Fluorescein-conataining FXIII- and control- peptides was utilized to ensure
similar surface density on Lp conjugates (excitation: 444 nm; cutoff: 455 nm; emission
480 nm-700 nm). D) Dynamic light scattering characterization of FXIII-Lp and
control-Lp Receiving modules. After peptide functionalization, Lp Receiving modules
were analyzed via DLS to probe the hydrodynamic size of each conjugate. ............. 155
Figure 7.7. Fluoresence reflectance imaging of Receiving module homing to externally-
heated tumors. Mixtures of targeted (red) and untargeted (green) NWs (labelled with
the opposite orientation of NIR-fluorochromes used in Figure 2C to control against
potential optical or molecular fluorochrome bias to Receiving module detection in
heated vs unheated tumors) VT680 and VT750, respectively, were intravenously
injected into mice bearing bilateral MDA-MB-435 tumors. Immediately following
injection, one tumor was submerged in a temperature-controlled water bath for 20 min
and mice were dissected at 24 hrs for fluorescent organ imaging. Overlaid fluorescence
images are shown for targeted (green) and untargeted (red) Receiving module
accumulation in both heated ("+", 45*C heating) and naYve ("-") tumors are shown
from the sam e m ouse.................................................................................................. 156
Figure 7.8. Fluorescent quantification offibrin-binding and untargeted-NW Receiving
module homing to heated over unheated tumors. The fold enhancement of NW
targeting is plotted across the range of temperatures tested (n=4 mice in each set,
p<0.05 for the difference between fibrin-binding-NWs and untargeted-NWs at 45'C,
490C , and 53*C, respectively). .................................................................................... 157
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mice were dissected and the fluorescence of each tumor was measured to quantify the
homing of Receiving NPs. G) Histopathological analysis of NR-directed FXIII-
Substrate Lp targeting and doxorubicin delivery. Histopathological sections from the
integrated NP signaling experiments in F). At 24 hrs post-NW injection, mice were
sacrificed and tumors were analyzed for FXIII-Lp and doxorubicin distributions in
histology. (Red= doxorubicin, Blue= DAPI nuclear stain, Green=FXIII-targeted Lp
d istribution )................................................................................................................. 16 3
Figure 7.14. Active NP signaling network experiments from Figure 3D, but with inverted
fluorophore-targeting ligand relationships to control against bias and ex-vivo imaging
of excised tumors. A) Simultaneous near-infrared imaging of co-injected: VT750-
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injection, the homing of FXIII-NWs and control-NWs was visualized using NIR
fluorescent organ imaging. ("Tumor +" indicates the irradiated tumor; "Tumor -" was
not exposed to diode irradiation) ................................................................................ 167
Figure 7.17. Tumor therapy using nanoparticle signaling networks. A) Tumor volumes
for active NP signaling networks and controls. Tumors in all treatment groups except
Saline (-laser) were exposed to near-infrared irradiation for 20 min (-0.75 W/cm2
-8 10 nm) (P<0.02 for NR + FXIII-Lps and all other treatment sets between days 5 and
24; one-sided t-test, n=6 or 7 mice in each set). B) Representative images of active
signaling network treatment results (NRs + FXIII-Lps, below) compared with
untreated controls (Saline, above) (20 days post-treatment). ..................................... 168
Figure 7.18. Animal weights for mice treated with therapeutic signaling networks
compared with those administered saline only. .......................................................... 169
Schematic 8.1. Signaling network architecture and information flow. Structure and
information flow in signaling networks. Sensors are ligand-targeted, truncated human
tissue factor proteins (tTF) proteins that are latent in circulation, but gain coagulation-
inducing activity upon binding to target receptors in tumor blood vessels (avp3 and
CD13/aminopeptidase N for tTF-RGD and tTF-NGR Sensors, respectively). Signaling
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NWs) signaling networks, FXIII-NWs alone, or NWs targeted by the peptide used to
direct Sensor tumor homing (1 mg/kg tTF-RGD; 1.5 mg Fe/kg). At 24 hrs post-
injection, mice were sacrificed and tumors were surgically removed for fluorescent
imaging of NW localization to tumors. Integrated networks show dramatic
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Figure 8.8. Microscopic and macroscopic characterization of nanoparticle targeting in
vivo using hybrid signaling network C) Histopathologic analysis of NW homing in
integrated signaling networks and controls. Green = NW fluorescence; Red = CD31
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Figure 8.9. Heparin-mediated disruption of signaling network communication. A)
Schematic of heparin's disruption of communication in hybrid signaling networks. B)
Nu/nu mice bearing a single MDA-MB-435 tumor were intravenously injected with
integrated signaling networks (tTF-RGD + FXIII-NWs; 1 mg/kg tTF-RGD; 1.5 mg
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Figure 8.10. Modularity of hybrid signaling networks: Signaling networks composed
using a distinct ligand-targeted tTF enzyme Sensor. tTF-NGR Sensors survey host
vasculature for CD13/aminopeptidase N receptors associated with tumor angiogenesis.
Upon binding, tTF-NGR sensors gain activity and transmit their signal to Receiver
nanoparticles through the extrinsic coagulation cascade. Nu/nu mice bearing a single
MDA-MB-435 tumor were intravenously injected with integrated (tTF-NGR + FXIII-
NWs) or control (tTF-RGD + Control-NWs) signaling networks, FXIII-NWs alone, or
NWs targeted by the peptide used to direct Sensor tumor homing (1 mg/kg tTF-NGR;
1.5 mg Fe/kg). At 24 hrs post-injection, mice were sacrificed and tumors were
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Chapter 1. Introduction
1.0 Scope
Materials with nanoscale features have tremendous potential to impact both
biological discovery and medicine. Nanoparticles (NPs), in particular, exhibit a number
of unique electromagnetic, structural, and biological properties compared with their
synthetic and natural mesoscopic, microscopic, and molecular complements. These
properties include superparamagnetism(1-3), surface plasmon resonance(4-7), quantum
confinement(8, 9), inherent catalytic activity(10), high surface areas for drug loading(11-
13), favorable pharmacokinetic profiles(14-17), among others. Nanoparticles operate on
the length scale of biological system components, yet leverage electromagnetic and
biological properties that are often unique from biological components. As such, they
have immense potential to improve disease diagnosis and therapy and have already
produced a spectrum of technologies for cancer applications. Still, despite matching the
size of biological components, biomedical nanoparticle systems have lacked the system-
scale complexity of biological systems. The overall goal of this thesis is to engineer
higher-order nanoparticle systems wherein distinct nanoparticle populations
interact to generate emergent system properties for enhanced cancer sensing and
therapy.
1.1 Cancer Detection and Therapy
Cancer killed more than 7 million people worldwide in 2002, surpassing the
combined toll from AIDS, malaria, and tuberculosis(18). By 2020, the World Health
Organization projects over 16 million new cancer cases per year, increased from 10 million
in 2000. Combating the growing incidence of cancer will require behavioral changes,
improved detection technologies, and more selective and potent treatments.
Currently, cancer diagnosis proceeds from the macro- to the microscale, with
progressively increasing diagnostic accuracy and invasiveness. Typically, patients
exhibiting the sequelae of cancer, including weight loss, fatigue, nausea, pain, among
many others; are identified during a physical exam and sent to undergo serological
analysis alongside an imaging session to interrogate structural changes in the suspected
regions. Serological quantification of tumor-associated biomarkers provides some initial
molecular information regarding the presence of a tumor, but cannot provide a diagnosis
in isolation. Clinical imaging modalities in use for cancer, including magnetic resonance
imaging (MRI), x-ray computed tomography (x-ray CT), ultrasound, and others; provide
structural information and can reveal aberrant regions of tissue growth to help inform
subsequent procedures for performing tumor biopsies. Due to the deficit of molecular
information provided by these techniques, remote imaging also falls short of providing a
definitive diagnosis for the majority of cancers. Further, these techniques have limited
capacity to discern early stages of neoplastic disease and to accurately predict tumor
margins, where the macroscopic tissue abnormalities that generate MRI, x-ray, and
ultrasonic contrast have yet to emerge.
Tumor biopsy provides the most direct molecular diagnosis of cancer, yet is also
the most invasive technique. Once tissue has been removed from the tumor and
neighboring lymph nodes through surgical, endoscopic, or percutaneous needle extraction
procedures, histopatholoical methods are utilized to detect hallmark molecular and
phenotypic cancer signs, identify the tissue of origin, grade the degree of differentiation
compared to normal tissue, and assess whether lymphatic metastases have been
established. At this point, therapeutic considerations can be determined.
Because the cancers typically emerge as focal diseases, the surgical removal of
early masses can be highly successful in containing further spread. Further, when
substantial removal of tissue can be tolerated (eg. for tumors arising in skin, lung, breast,
or colon), large resections of tumors and invasive margins can be successful in
controlling late stage tumors. However, surgery alone is typically insufficient when
disease has begun to metastasize and patients are prescribed regimens of radiation
(extracorporeal or via implanted brachytherapies) and chemotherapy. Various forms of
chemotherapy and radiation have served as the backbone of cancer therapies for the last
30-50 years(19). In a few cases, pharmaceutical agents have been able to exploit unique
characteristics of cancers to evoke considerable tumor responses with minimal peripheral
side effects. For example, the drug imatinib mesilate (or Gleevec T M) precisely inhibits
tyrosine kinase activity to extinguish the oncogenic function of bcr-abl fusions in chronic
myelogenous leukemia (20, 21). However, the major fraction of our modem anti-
neoplastic drug arsenal affects cancers via their propensity towards rapid cell division and
growth (eg. alkylating, microtubule-inhibiting, DNA-intercalating, and topoisomerase-
inhibiting agents, among others)(19). This feature of rapid cell division is not exclusive to
tumors, however, and systemic exposure of these compounds affects digestive function,
bone marrow proliferation, and hair growth.
Despite immense progress towards understanding the biological mechanisms of
cancer, there have been relatively few translational advances in our therapeutic
armamentarium against cancer(22). Particularly, while molecular approaches to
combating bacterial infections have proven an immense success in the past century, this
paradigm has struggled to find distinguishing characteristics of cancers that are not also
essential for normal tissue functions. A fundamental challenge facing the use of small
molecule drugs in isolation for cancer therapy is that the vast majority of administered
drugs (up to >99% of the administered dose) distribute in normal tissues and do not
accumulate in tumors(22). This paradox of utilizing drugs that distribute without
preference for focal regions of disease frequently restricts agent dosing to sub-efficacious
levels due to systemic toxicity and lowers the barriers to evolving drug resistance.
1.2 Nanoparticle Toolkit for Biomedicine
There are now nearly twenty nanoparticle formulations in clinical trials or clinical
practice(23, 24). These materials cover a diversity of applications, from cancer imaging
and therapy to immunosuppression, antimicrobials, and cosmetics. Nanoparticles may be
logically defined as synthetic or biological structures that are larger than molecular
species (>1 nm), smaller than microscale complements (<1000 nm), typically smaller
than what can be conveniently synthesized via top-down manufacturing methods (<200
nm), and have unique or improved characteristics from their bulk surroundings. To
provide a biological perspective for this length scale, small molecules are typically on the
order of a few nanometers, proteins are typically between -5-20 nm, and human cells are
generally >10,000 nm in diameter. In addition to properties derived from their ability to
operate on the length scale of biological machinery, unique chemical and physical
properties emerge in nanomaterials that distinguish them from their molecular and
mesoscopic counterparts. Over the past several decades, these unique biological,
pharmacokinetic, chemical, and electromagnetic properties have attracted increasing
interest in biomedicine for their potential to empower a diverse repertoire of functions,
from ultra-sensitive molecular imaging to disease-targeted multi-drug delivery systems.
For cancer in particular, systems of inorganic and/or organic nanoparticles may
ultimately provide paradigm-shifting improvements in our ability to remotely detect early
neoplastic changes in vivo and precisely usher drugs into established tumors with
minimal side effects.
1.21 Materials for Cancer Imaging
Nanomaterials have been described that exhibit useful properties for many non-
invasive imaging modalities, including agents for magnetic resonance (MR)(1), optical(8,
25), ultrasonic(26, 27), and x-ray computed tomography (CT) imaging(28, 29). As one of
the earliest nanoparticle imaging agents, superparamagnetic iron oxide nanocrystals were
ushered into medical imaging in the early 1980's (2, 3). Superparamagnetic nanoparticles
are useful in medicine because, while they do not possess aligned permanent magnetic
dipoles at room temperature that could drive agglomeration, in the external magnetic
field of an MRI, their dipoles are able to efficiently dephase neighboring protons to
provide locally-enhanced transverse (T2) relaxation rates compared with surrounding
tissues(30). This technology has already generated two clinical contrast agents, Feridex
IVTM and CombineXTM, comprised of iron oxide cores that are surrounded by hydrophilic
coatings of the branched polysaccharide dextran. More recent magnetic nanomaterials
with enhanced magnetic dipoles and T2 relaxivities have been synthesized to improve
MRI detection sensitivities (31-33). These new generations leverage increased control of
nanocrystal structure, more magnetic materials, and the use of doping strategies to
increase traditional magnetic dipole strength (31-33).
Conductive metal nanoparticles such as gold, silver, and copper exhibit the
property of plasmon resonance (5-7). The mobility of conduction band electrons in these
materials enables alternating electro-magnetic fields of appropriate frequencies to drive
resonant electron cloud oscillation. This process generates ultra-stable optical absorption
coefficients at plasmon resonant frequencies of 104-10 6-fold higher than conventional
organic fluorochromes(6). The frequency of nanoparticle plasmon resonance is a function
of the material composition, crystal structure, surface chemistry, and nanoparticle
size/shape (5-7). This multiparametric origin of plasmon resonance frequency has driven
intense research into precise size- and shape-selective methods of synthesizing metallic
nanocrystals, resulting in a rich spectrum of highly tunable structures such as core-shell
nanoparticles, hollow metallic nanoparticles, and rod-, cube-, pyramidal-, polyhedral- and
star-shaped nanoparticles (7, 34-36). Collectively, the electromagnetic properties of
plasmonic nanomaterials have been harnessed to develop ultra-sensitive diagnostic(37,
38), spectroscopic(39, 40), and, recently, therapeutic technologies(41-44).
The geometric tunabilty of plasmon resonance frequency has provided a facile
route towards tailoring the properties of particles for specific applications. In spherical
gold nanoparticles, for example, this resonance peak is typically centered around ~520
nm, with relatively little change with increasing size. However, by synthesizing elongated
rod-shaped, hollow, or core:shell gold nanoparticles the resonant frequency can be
controllably moved throughout the visible and into the infrared (36, 45, 46). By tuning
nanoparticle plasmon resonance into the near-infrared (-700-900 nm), where in vivo
tissue absorption coefficients drop by almost two orders of magnitude from the visible
regime, the role of gold nanomaterials for in vivo applications has been considerably
expanded. While this domain of electromagnetic energy does not provide the whole-body
penetration of modalities such as MRI and X-ray CT, it can provide highly detailed
molecular imaging within approximately a centimeter of the excitation source. Gold
nanoshells (structures with a thin gold shell surrounding a dielectric silicon dioxide inner
core) and gold nanorods have been utilized as contrast agents for the emerging medical
imaging modalities of optical coherence tomography and photoacoustic imaging (47-50).
Carbon nanotubes have also been shown to have useful near-infrared absorbance for
photoacoustic imaging applications, but concerns of their in vivo toxicity have slowed
potential clinical applications (51, 52). Given that gold nanomaterials (both molecular
and colloidal) have been utilized safely in rheumatoid arthritis therapies for over 50
years(53), these materials are likely to have attractive safety profiles for clinical
applications.
Fluorescent nanomaterials offer another useful imaging modality for interrogating
biological behaviors. Organic fluorophores have been utilized in a variety of biological
settings, both in vitro and in vivo for decades. In semiconductor nanoparticles with
dimensions below the Bohr exciton radius, the distance in bulk materials between an
excited electron and hole pair, quantum confinement occurs, which can produce highly
efficient photoluminescence(9, 54-57). Quantum confinement in semiconductor
nanoparticles has produced imaging agents with superior fluorescence intensity,
enhanced photostability, and narrower emission spectra compared with organic
fluorescent agents, as well as size-tunable fluorescence emission (58). By leveraging
these properties, semiconductor nanoparticles have already facilitated novel in vivo
telemetric and diagnostic studies in mice, but clinical translation of these materials will
require compositions without the toxic heavy-metals that are commonly utilized in their
synthesis (54, 58). The most commonly used semiconductor nanoparticles are zinc
sulfide-capped cadmium selenide quantum dots, but other quantum dots have been
synthesized indium arsenide, indium phosphide, and silicon (59). The most useful of
these materials are those that enable near-infrared imaging, due to the reduced optical
attenuation of excitation and emission light in vivo(60). As efforts to identify new safe
materials continue to progress, these materials may usher a new frontier of optical
molecular imaging technologies.
Nanoscale contrast agents have also been developed for the established clinical
modalities of ultrasound and x-ray computed tomography (CT). Ultrasound contrast
agents are typically gas-filled microbubbles that harness the acoustic impedance
mismatch at gas: liquid interfaces to generate amplified ultrasonic reflectance(61). These
agents are administered intravenously to provide vascular contrast and have been
investigated for localized delivery as well through remote-controlled acoustic cavitation
(62). Nanoscale agents have also been developed for target-mediated ultrasonic contrast
enhancement (63, 64). X-ray CT reveals tissue density differences via changes in
absorption of applied x-rays. Molecular contrast agents based on iodine have been
utilized clinically due to iodine's high biocompatibility and relatively high atomic
number (z=53). Recently, the increased atomic number and high material density of gold
(z=79, p=19.3 g/cm3) and bismuth sulfide (Bi z=83) nanomaterials have attracted interest
for x-ray CT angiography and a few nanoparticle reagents have been developed for in
vivo angiography and lymph node detection (28, 29, 65).
1.22 Materials for Cancer Therapy
Nanotechnologies can have intrinsic therapeutic properties imparted by their
carrier's structural, electromagnetic, and biochemical properties, or they can have
therapeutic properties that are extrinsically imparted by biomolecules encapsulated within
them or conjugated to their surface. In the latter category, nanoparticles provide the
opportunity to improve upon the efficacy of molecular cancer therapies by controllably
encapsulating, protecting, and programmably releasing drugs in target sites. In this
manner, the potential also exists to apply pharmaceuticals with favorable disease
activities, but which exhibit insufficient water solubility or excessive off-target toxicity as
free drugs, in an appropriately designed nanoscale carrier.
One of the first classes of synthetic nanoparticles to reach the clinic for cancer
therapy was drug-loaded liposomes. Liposomes are nanoscale carriers of various sizes
with an internal aqueous compartment that is separated from the surrounding media by at
least one enclosed lipid bilayer. Inspired by the structure of cellular membranes and
internal organelles, liposomes have been desirable carriers due to their biocompatibility,
ability to encapsulate hydrophobic and hydrophilic drugs, potential to house multiple
internal compartments, and amenability to surface modification (66-68). To improve
blood circulation times in vivo, lipids bearing polymers such as polyethylene glycol
(PEG) became widely utilized in carrier synthesis (69, 70). These polymers deter protein
opsonization to nanoparticle surfaces to delay macrophagic carrier recognition. The
clinical formulation of liposomes, DoxilTM, carries the chemotherapeutic doxorubicin
within a highly PEGylated lipid bilayer. Doxorubicin is a potent anti-tumor agent, whose
cardiac toxicity has limited its clinical use. By sequestering this drug within liposomal
carriers, cardiotoxicity was significantly diminished-enabling patient tolerance of
higher drug doses and facilitating tumor-specific delivery. These first generation carriers
have been engineered to encapsulate a diversity of drugs and slowly release them after
administration (71, 72). Next-generation formulations aim to specifically accelerate drug
release kinetics in tumors via enzyme destabilization, remote actuation, pH changes, or
combined administration of enzyme-expressing bacteria to intensify the peak active drug
concentrations in tumors and improve the potency of carriers (72-76).
Polymer-based vesicles resembling the structure of liposomes have been
synthesized as well. These 'polymerosomes' are constructed out of diblock copolymers
that are considerably larger than natural lipids in size, yet self-assemble into bilayer
structures in a similar fashion to natural lipid bilayers(77). Due to the tunabilty of diblock
polymer compositions, polymerosomes have the potential to be constructed of a diversity
of materials. Initial PLA-based copolymer formulations have shown ~10-fold lower
water permeability coefficients compared with lipid bilayers, providing highly robust
external membranes for protecting encapsulated materials (77-79). These particles have
been utilized for controlled drug delivery and encapsulation of a variety of protein and
small molecule therapeutics (79-81). PEG-PLA and PEG-PLGA (poly(lactic co-glycolic
acid)) block copolymers can also form spherical assemblies with a hydrophobic core (82-
84). In these self-assembling nanoparticles, hydrophobic drugs are sequestered in the
vehicle's PLGA core and slowly released over time. By tuning the relative lengths of the
hydrophilic and hydrophobic blocks, drug encapsulation efficiency, drug release kinetics,
carrier size, and in vivo circulation times can be readily tuned, providing a more versatile
architecture than lipid-based nanoparticle formulations(85). Moreover, because the
nanoparticle structure is driven by a thermodynamically and kinetically-controlled self-
assembly processes, the monodispersity of these nanoparticles can be optimized using
microfluidic mixing technologies to provide another dimension of control over vehicle
size and monodispersity(85, 86).
Micelles are another category of nanoparticles that have been widely composed of
lipid- and polymer-based constituents(87, 88). As opposed to vesicles that form a bilayer
structure with an aqueous interior compartment, micellar drug formulations contain a
hydrophobic core surrounded by a hydrophilic shell(88). Micelles have been constructed
from amphiphilic lipid, peptide, and polymer constituents to adopt spherical and
elongated worm-like formations (89-91). Typically, hydrophobic drugs are encapsulated
in the core of micellar formulations, but amphiphilic drugs have also been stably
delivered as well through intercalation into the carrier shells (88, 92, 93). Further,
stimuli-responsive amphiphilic block-copolymers have been developed to create
responsive drug delivery vehicles that accept external cues (temperatures, pH, etc.) and
modulate drug release kinetics accordingly (94-96).
Hybrid nanoparticles that combine the opportunities of lipid-based self-assemblies
with polymer drug delivery vehicles have also recently been developed. One example is
engineered to have a PLGA core that sequesters the anti-cancer drug doxorubicin with an
outer layer of phospholipids to protect the surface and incorporate a second vascular-
disrupting drug, combretastatin(97). This vehicle is able to temporally control the release
of these two drugs to separately direct the disruption of tumor neovascular networks and
the death of cancer cells(97). Other formulations of PLGA with lipid-PEG coatings have
been developed to improve the serum stability and provide tunable drug release
profiles(98).
Another mechanism of tumor therapy involves the local deposition of thermal
energy into tumor tissues. Thermal cancer therapies offer a means of specifically
enhancing the current paradigms for cancer therapy, either through the application of
mild (hyperthermia) or substantial (ablation) levels of heat. At high doses of energy, in
the ablative regime, heating of tumors offers the potential to directly kill cancer cells,
with broad applicability across multiple tumor types(99). In the hyperthermia regime,
clinical trials have shown that heat treatments cause a spectrum of cellular and tissue
effects that improve the efficacy of other therapies (99-101). In particular, hyperthermia
synergizes with conventional chemotherapy and radiation regiments by inhibiting DNA
replication and damage repair, preferentially killing nutrient-deficient cells, and
increasing tumor blood flow and oxygen delivery(]00-104). Furthermore, tumor
hyperthermia enhances the delivery of antibody and emerging nanoparticle therapeutics
by increasing the porosity of tumor vessels (101, 105, 106).
Recently, preparations of gold nanoshells have shown considerable efficacy for
improving the precision of tumor ablation by intravenously targeting tumors and locally
transducing otherwise benign NIR-light into heat (41, 42, 48, 107-109). The long
precedence of gold nanoparticles in clinical rheumatoid arthritis therapies, make gold
nanoshells or other gold plasmonic materials (eg. nanorods, nanocages, etc.) appealing
new candidates for cancer therapy(53). Beyond locally damaging tissues with heat, these
materials could also be utilized to actuate local drug release in vessels or specific cells in
vivo(110).
The synthesis of nanoparticles with polar domains provides the potential to
spatially separate multiple therapeutic functionalities on a single nanoparticle. Janus
nanoparticles-named for Janus, the Roman God of doorways typically depicted with
faces on the front and back of his head-have been engineered with two chemically
distinct hemispheres or surfaces(111). These nanoparticles may be spherical (with
opposing faces of unique composition), dumbbell-shaped (with two equal-sized spheres
linked together), snowman-shaped, and may have other morphologies as well (111-114).
The creation of nanoparticles with spatially separated chemical domains is a step towards
replicating the controlled polarity exhibited in nature across many length scales(115).
Separate hemispheres may be used to isolate and organize functional domains, sensing
moieties, hydrophilic and hydrophobic therapeutics, or contrast agents that might be
mutually inhibitory if randomly incorporated.
1.3 In vivo Nanoparticle Targeting for Imaging and Therapy
While the electromagnetic and therapeutic properties of nanoparticles make
them promising candidates for medical applications, their actual utility for in vivo
imaging and therapy depends on our ability to precisely direct them to regions of
disease.
After in vivo administration, unprotected nanoparticles are rapidly opsonized by
serum proteins and taken up by macrophages of the mononuclear phagocytic system
(MPS). Over the last 30 years a variety of nanoparticle coatings have been developed to
deter this process to improve biocompatibility and delay macrophagic clearance. The first
applications in nanomaterial imaging harnessed the normal uptake of nanoparticles by the
MPS system as an indirect means of tumor detection. Particularly, dextran-coated
superparamagnetic iron oxide contrast agents found a niche in the clinical detection of
hepatic carcinomas(1, 116) and lymph node metastases(117) using MRI. For these
materials, the primary regions of NP accumulation are in normal macrophage-rich liver,
spleen, and lymph tissues (1-3, 116). In regions of cancer infiltration into these tissues,
tumor cells displace normal tissue macrophages and diminish nanoparticle uptake and the
resulting signal enhancement in MRI. This diminished signal enhancement relative to
normal regions of these tissues has enabled enhanced identification of hepatocellular and
splenic carcinomas and improved surgical planning for lymph node resections
surrounding primary tumors (2, 3).
However, in order to utilize nanoparticles for cancer therapy and for remote
detection of cancers outside of the liver and spleen, mechanisms for targeting
nanoparticles into (instead of away from) tumors are required. As such, nanoparticle
targeting has been explored for over 30 years in the hopes that diagnostic and therapeutic
agents may illuminate and treat regions of neoplastic growth. The canonical approaches
for targeting nanoparticles to cancers may be divided into two categories: passive (ligand-
independent) and active (ligand-directed) targeting.
Passive targeting exploits structural, rather than biomolecular, aspects of the
tumor microenvironment to allow preferential accumulation of nanoparticles over
surrounding tissues. This mechanism for targeting tumors is also referred to as the
enhanced permeability and retention effect (EPR) and occurs because nanoparticles are
able to selectively escape malformed angiogenic tumor blood vessels through
transvascular pores that are not present in normal vessels (118-121). The pore sizes in
vessels have been empirically shown to be a function of tumor type and implantation site
and to typically enable transvascular transit of liposomal carriers between 200-400 nm in
diameter (119, 121). Extravasated nanoparticles are then selectively retained in tumor
tissues because tumors lack the functional lymphatics through which to clear them(14,
122-126). This mechanism of passive delivery has also been demonstrated to drive
enhanced nanoparticle accumulation in other sites of inflammatory disease, including
atherosclerosis(12 7, 128).
A few nanoparticle therapeutics, including DaunoXome TM, MyocetTM , DoxilTM
and AbraxaneT M, have already entered clinical use for cancer treatment based on this
mechanism of passive delivery. These formulations utilize long-circulating nanoparticle
vehicles to enhance the delivery of drugs into tumors. The increased efficacy of these
NPs compared to their small molecule and shorter-circulating counterparts illustrates the
importance of tumor delivery in driving efficient tumor response.
In the realm of active targeting, biological or chemical ligands are conjugated to
the surface of nanoparticles in an effort to program their attachment to receptors in the
tumor microenvironment (129-131). For parenchymal tumor cell targeting, this strategy
still relies on selective carrier extravasation from tumor blood vessels, but harnesses
ligand-receptor interactions to specify the cellular uptake of materials. Initial targeted
nanotechnologies leveraged the specificity of antibody-receptor interactions to provide a
high carrier affinity for tumor cells(25, 132-134). More recently, nanotechnologies have
begun to harness genetic engineering strategies for reducing the size and immunogenicity
of full antibodies, as well as alternative screening methodologies for identifying targeting
ligands. Ligand screening technologies such as phage display and nucleic acid selection
methods, for example, harness the respective amplification capabilities of bacteriophage
replication in culture or PCR-based amplification of oligonucleotides in vitro to enable
rapid screening of diverse libraries of >1014 constituents(]35-138). These techniques
enable the selection of tumor targeting ligands, even in cases where the receptor is not
known. Using such methods and others, a variety of ligand molecules have been
developed for nanoparticle targeting, including aptamers(139-141), small
molecules(142), and peptides(143-146). Importantly, polyvalent display of targeting
ligands on nanoparticle scaffolds can dramatically enhance the carrier affinity over that of
the free ligand. This effect is driven by multi-point attachment of carriers to multiple
receptors and dominantly driven by a reduction in the rate of disassociation (koff ) of the
complex(147, 148). This enables targeted nanomaterials to be constructed using low-
affinity ligands in cases where polyvalent binding is expected to occur. For example, the
affinity of polyvalently folate-modified dendrimers was found to exceed that of free folic
acid molecules by over >100,000 fold(149).
Interestingly, while targeted formulations clearly direct receptor-specific cell
targeting in vitro, a few recent studies have argued that modification of nanoparticles
with tumor targeting ligands does not increase the macroscopic nanoparticle
accumulation in tumors (150, 151). This inability for tumor cell targeting to amplify
accumulation is postulated to arise because the rate-limiting step in tumor targeting is
extravasation through trans-endothelial pores in tumor vessels(152). Therefore, while
targeting ligands on extravasated nanoparticles can direct receptor binding and
internalization into specific tumor cell types, the total concentration of particles that
escapes through pores in tumor vessels is not increased by ligand decoration. This has
partially driven efforts to target receptors in tumor vessels instead of tumor cells(153-
155), where nanoparticles in circulation may directly access target receptors.
In order to compare the published efficacy of passive and active targeting
approaches, we collected quantitative data of nanoparticle targeting in mouse tumor
models that was readily available in the literature and plotted both active and passive
accumulation levels on a common axis for comparison(31, 84, 92, 142, 156-168) (Figure
1.1). This assembly of data includes a broad spectrum of nanoparticle sizes, shapes, and
surface chemistries (spanning liposomes, iron oxide nanoparticles, dendrimers, carbon
nanotubes and others) and utilizes antibodies, peptides, small molecules, and nucleic acid
targeting moieties(31, 84, 92, 142, 156-168). While the considerable biological and
experimental variability between data points (eg. different tumor types, implantation
sites; nanoparticle carrier sizes, circulation times, etc.) prohibits quantitative comparison
of individual data points, it is clear that overall both approaches to tumor targeting have
produced very similar ranges of tumor targeting. Most strikingly, all the data points
obtained in these preclinical tests reside between 0-20% ID/g, which, considering that
experimental mouse tumor models are typically grown to -100 mgs for targeting
experiments, likely amounts to overall delivery of less than 2% of injected nanoparticles
to tumor tissues, even in optimized formulations.
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Figure 1.1. Assembly of 'active' and 'passive' nanoparticle tumor targeting data from
published sources. Quantitative nanoparticle biodistribution data was collected covering a
broad spectrum of nanoparticle sizes, shapes, and surface chemistries (spanning
liposomes, iron oxide nanoparticles, dendrimers, carbon nanotubes and others) and
diverse targeting ligands, including antibodies, peptides, small molecules, and nucleic
acids (31, 84, 92, 142, 156-168). Abscissa plotted arbitrarily to separate data points.
A common element in both passive and active approaches to in vivo nanoparticle
targeting is that nanoparticle characteristics are engineered at the scale of individual
particles, via tuning of particle shape, size, surface chemistry, ligand type and abundance,
among other considerations (14, 16, 90, 141, 142, 145, 169-172). For in vivo applications,
these materials are typically administered in intravenous doses of over 1 trillion
nanoparticles to perform identical, often competitive tasks (i.e. searching for the same
receptor). Considering the magnitude of these in vivo nanoparticle populations, we
considered whether a systems engineering approach to designing interaction and
communication between nanoparticles could improve their collective function.
1.4: 'Systems Nanotechnology' for Enhanced Cancer Imaging
and Therapy
Nature provides abundant inspiration for engineering higher-order nanosystems
with multiple nanostructured components to more effectively solve biomedical problems.
In contrast to current in vivo nanoparticle systems composed of near-identical
constituents, biological systems generate complex behaviors through collective
interactions between multiple system components-enabling emergent processes such as
computation, amplification, and dynamic communication. Indeed, complex behaviors
emerge through component interactions across molecular, cellular, organismal, and
populational length scales in nature. Three representative examples include the rapid
tissue repair in blood coagulation; inflammatory cell signaling and recruitment to sites of
infection; and ant foraging behaviors, where communication between individuals
dramatically improves the efficiency of finding and retrieving food.
In contradistinction to current strategies for nanoparticle targeting that perform
the singular function of vessel extravasation or receptor binding, the coagulation cascade
couples molecular recognition events to signal processing and amplification mechanisms
in order to orchestrate the rapid repair of injuries. The coagulation cascade consists of a
group of zymogens (or pro-enzymes) that latently circulate throughout the bloodstream to
survey for regions of vascular damage. In such regions, the enzyme tissue factor on
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Figure 1.2. Coagulation cascade molecular pathway and graphical depiction.
extravascular cells becomes exposed and initiate the activation of circulating Factor X in
the company of Factor VII and neighboring phosphatidylserine lipids. Factor X,
alongside Factor V, then activates the enzyme thrombin, which performs the task of
depositing a fibrin meshwork by cleaving short inhibitory peptides off of circulating
fibrinogen precursors. In parallel, collagen exposure in wounds activates the intrinsic
coagulation cascade, which propagates through Factors XII, XI, IX, and X to drive
additional thrombin generation. In addition to directing the polymerization of fibrin,
thrombin also performs a spectrum of other functions, including activation of additional
Factor V and other latent factors to form positive feedback loops that intensify local
signal amplification and activation of the circulating transglutaminase Factor XIII, which
'staples' fibrin polymers together by covalently linking specific glutamines to
neighboring lysines. Disruption of the signal amplification mechanisms in blood
coagulation can catastrophically diminish vessel repair kinetics-as illustrated by the
genetic disorders haemophilia A and B, where the respective deficiencies of Factor VIII
and IX impair efficient thrombin formation through the intrinsic coagulation cascade and
result in perfuse bleeding following even minor injuries (173, 174).
While individual nanoparticles have considerable biomedical promise, systems of
multiple nanomaterials with engineered mechanisms of interaction could produce
emergent, higher-level properties not exhibited by the components in isolation. Inspired
by the power of inter-component communication in natural processes, we
considered the design of nanoparticle systems that interact to produce emergent
behaviors with the capacity to enhance in vivo diagnostics, regenerative medicines,
and other therapeutics. Re-examining our emerging toolkit of nanomaterials, with the
properties of individual nanoparticles serving as distinct nodes within multi-component
systems, we can envision a vastly diversified functional space for nanoparticle systems to
occupy. Further, given the control that pharmacological nanoparticle agents can exert on
their local biological surroundings, cohesive systems of nanotechnological and biological
constituents (engineered phage, viruses, proteins, cells) could be constructed where
synthetic and endogenous bio/nanotechnological ensembles co-operate to more
intelligently locate, diagnose, and provide therapy to regions of disease.
1.5 Biomedical Nanosystems to Date
Over the past decade, a spectrum of in vitro nanoparticle systems have been
developed that utilize specific interactions between nanoparticles to emit amplified or
altered signals as a result of biomolecular interactions(37, 175-184). The majority of
these systems have been based on self-assembly mechanisms, whereby target interaction
drives the assembly or disassembly of nanoparticles. Mirkin et al. pioneered the use of
multiple nanoparticle populations to sense disease targets in vitro by modifying gold
nanoparticles to display short oligonucleotide sequences that allowed target DNA
sequences to mediate nanoparticle-assembly(37, 177). Assembly of gold nanoparticles
results in a red-shift of the -520 nm surface plasmon resonance band, enabling optical
detection either in solution or on surfaces. Improvements in this concept for sensing
biomarkers via target-mediated nanoparticle assembly have generated systems with
attomolar sensitivity for either DNA(185) or protein detection(186), as well as a broad
spectrum of other technologies(187, 188). Elsewhere, Weissleder and colleagues
developed analogous assays using magnetic nanoparticles (179, 181, 182, 189). These
particles are similarly modified with biomolecular recognition elements to allow target-
mediated assembly to occur. Here, as nanoparticles coalesce into nanoassemblies,
magnetic domains coordinate to form an amplified cumulative dipole that more
efficiently dephases protons in MRI(190, 191). These methods have facilitated the in
vitro sensing of oligonucleotides, small molecules, and proteins via nanoparticle
assembly (179, 181, 182, 189).
Extending upon this landscape of interactive nanosystems for in vitro sensing, this
thesis aims to develop nanoparticle systems with mechanisms of interaction that could
facilitate the improved sensing and targeting of disease in vivo.
Section I of thesis describes directly-interactive nanomaterials where dispersed
nanoparticle systems assemble through the action of tumor-associated enzymes. These
systems are designed to remain latent and dispersed in solution, but to rapidly assemble
with one another upon exposure to programmed enzyme inputs. We present designs that
enable nanoparticle systems to robustly respond to single proteases or to perform simple
logical operations using binary combinations of two protease targets. Finally, a
nanosystem is developed to dynamically assemble and disassemble in response to
antagonistic enzyme triggers.
Section II of this thesis describes mechanisms by which nanoparticles can
indirectly interact with one another through secondary biological messengers in vivo to
amplify tumor targeting and improve tumor therapy and imaging. Specifically, we design
signaling networks wherein synthetic devices act as artificial inputs and outputs to
endogenous biological cascades in order to robustly transmit and amplify communication
between distinct populations of tumor-targeted nanoparticles. To construct these
systems, this section initially describes the development of versatile surface chemistries
for in vivo targeting and the coating and application of a new class of nanomaterials to
cancer therapy. Finally, the construction and in vivo testing of two interactive
nanosystems for amplifying nanoparticle tumor targeting is described.
Section I: Engineering Direct Nanoparticle Interactions
for Cancer Sensing
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Scheme I. Inspired by temporally- and spatially-regulated mechanisms of direct
interactions in biology, the first section of this thesis describes nanoparticles that exist in
a latent state and rapidly assemble with one another following activation by tumor
enzymes. A) In areas of injury, platelets that are circulating in a latent form become
activated by local biochemical cues and aggregate to form an immobilized platelet plug.
B) Inspired by this process, we set out to engineer mechanisms by which nanoparticles
could latently circulated and be activated by tumor enzymes to rapidly self-assemble with
one another.
B)
Chapter 2: Protease Actuation of Nanoparticle Self-
Assembly
2.0 Introduction
Self-assembly is ubiquitous in nature, but typically proceeds under precise
temporal and spatial control. The ability to selectively induce complementarity is
essential to higher-order biological processes, including the propagation of genetic
information, cell motility, and platelet aggregation upon injury. Self-assembly of
nanoparticles has been exploited primarily to improve sensitivity for detection of
DNA(177, 179), proteins(186, 192), viruses(180), and pH changes(193) in vitro;
however, mechanisms of initiating nanoparticle assembly which mimic biological control
have yet to be described(194, 195). Development of inorganic nanoparticles that respond
to biological actuation could enable triggered, hierarchical assembly of materials with
emergent properties.
Here, inspired by thrombin-driven aggregation of platelets, we describe a general
means by which enzyme activity may actuate the self-assembly of monodisperse
nanoparticles. Superparamagnetic, self-complementary Fe3 0 4  nanoparticles are
passivated by the attachment of inhibitory polymers that may be proteolytically removed
by matrix metalloproteinase-2 (MMP-2), a protease correlated with cancer invasion,
angiogenesis, and metastasis (196-198), to initiate self-assembly. We demonstrate that
nanoparticle assembly amplifies the transverse (T2) relaxation of nanoparticle solutions in
MRI, enables magnetic manipulation of assemblies with external fields, and allows
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Figure 2.1. Proteolytic Actuation of Self-Assembly Schematic. Neutravidin- and biotin-
functionalized superparamagnetic iron-oxide nanoparticles are passivated by the
attachment of PEG chains that are anchored by MMP-2-cleavable peptide substrates
(GPLGVRGC). Upon proteolytic removal of PEG via cleavage of the peptides, biotin and
neutravidin particles self-assemble into nanoassemblies with enhanced magnetic
susceptibility, T2 magnetic resonance relaxation, and lowered diffusivity.
magnetic resonance imaging of tumor-derived cells that produce MMP-2. In the future,
this approach may enable site-selective immobilization and enhanced image contrast in
regions of tumor invasion in vivo.
2.1 Results and Discussion
The synthesis of proteolytically-actuated, self-assembling nanoparticles involves
modifying them to be self-complementary, but passivated by protease cleavable elements
(Figure 2.1). Briefly, 50nm dextran-coated Fe3 0 4 nanoparticles, sized by analytical
ultracentrifugation (Micromod, Germany), are modified with either biotin or neutravidin
(Pierce, Rockford, IL) to generate two populations of particles. When combined in
solution, these particles self-assemble through highly stable biotin-neutravidin
interactions. To allow enzymatic control of particle assembly, the nanoparticle surfaces
of both populations are modified with the MMP-2 peptide substrate, GPLGVRGC(199),
which serves as an anchor for linear polyethylene-glycol (PEG) chains. PEG is a highly-
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Figure 2.2. Role of PEG length and Characterization of Assembly. A) Changes in light
scattering of nanoparticles over time with MMP-2 [1 lug/ml] (hollow) or without MMP-2
(solid). Shorter (2 kDa, 5 kDa) PEG chains only partially inhibit self-assembly without
MMP-2 whereas longer PEG chains (10 kDa, 20kDa) exhibit delayed aggregation
kinetics in the presence of MMP-2. B) Difference in extinction coefficients with and
without MMP-2 after 3 hours reveals optimal PEG chain length of 10 kDa C) Specificity
of triggered self-assembly demonstrated by comparing peptide sequence of 10 kDa PEG
tether. Nanoparticles with specific MMP-2 substrate aggregate in the presence of MMP-
2 [1 lug/ml] whereas particles with scrambled peptide do not. D) Atomic Force
Micrographs of particle solutions in C confirm aggregation of particles in the presence of
MMP-2. Scale bars are 500nm.
mobile, hydrophilic polymer with a large sphere of hydration that has been widely used
to deter adsorption of proteins or cells on surfaces and to extend therapeutic circulation
times in vivo(200, 201). We hypothesized that linear PEGs of appropriate lengths would
inhibit association of 50 nm nanoparticles but still allow MMP-2 proteases (< 9 nm(202))
to cleave peptide linkers. To explore this idea we conjugated varying molecular weight
PEGs (2, 5, 10, and 20 kDa) to biotin and neutravidin particles via MMP-2-cleavable
linkers and tested their ability to assemble with and without MMP-2. The rate and extent
of assembly was measured by monitoring changes in the solution extinction coefficient at
600nm due to nanoparticle assembly over time (Figure 2.2A). Assembly of PEG-coated
biotin and neutravidin particles without MMP-2 was found to be inversely related to PEG
molecular weight with almost complete inhibition of particle assembly at PEG chain
lengths of 10 kDa or higher. Nanoparticles incubated with MMP-2 also aggregated at a
rate inversely related to PEG chain length, likely due to a similar steric repulsion of
MMP-2. Comparing the change in extinction coefficient of particles incubated with
MMP-2 versus those without at 3 hours, the 5 kDa and 10 kDa PEGs allow the highest
MMP-2-catalyzed assembly enhancement (Figure 2.2B). However, because the 5 kDa
PEG cannot completely inhibit particle interaction in their native state, 10 kDa was
chosen as the optimum surface modification.
To further verify that the particle assembly was due to the sequence-specific
release of PEG by MMP-2, a scrambled linker with low cleavage-specificity by MMP-2,
GPVGLRGC(203), was generated and conjugated to particles. The nanoparticles with the
scrambled peptide exhibit markedly decreased assembly compared to the specific peptide
sequence (Figure 2.2C). At 3 hours following MMP-2 addition, assembly of
nanoparticles with specific MMP-2 substrates is detectable by a visible change in the
light scattering of the solution, appearing more turbid. The sizes of nanoparticle
assemblies, examined by atomic force microscopy (AFM), are as large as 0.5-lum after
evaporation onto freshly-cleaved mica, suggesting assembly of 10's to 100's of particles.
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Figure 2.3. MMP-2 Triggered Self-Assembly Results in Detectable Changes in T2
Relaxation Times. With a 4.7T Bruker MRI, T2 changes were detectable due to particle
aggregation over an order of magnitude variation in particle concentration, spanning
typical values used clinically [2.6mg Fe/KG body weight]. Detectable aggregation is seen
after 3 hours with the addition of 85, 170, 340, 680, and 1360 ng/ml MMP-2 for
nanoparticle concentrations of 32 pM, 10 pM, and 3.2 pM respectively.
The nanoparticles that are not incubated with MMP-2 remain disperse with diameter of
approximately 75 nm (Figure 2.2D).
Nanoassemblies of iron oxide particles that form upon proteolytic-activation
acquire emergent magnetic properties that may be remotely detected with MRI. The
coordination of superparamagnetic Fe30 4 magnetic dipoles in assembled nanoparticles
amplifies the diffusional dephasing of surrounding water molecules, causing shortening
of T2 relaxation times in MRI(190, 191). We demonstrate that measurement of T2
changes allows sensitive, remote detection of protease-triggered assembly across a ten-
fold variation in particle concentration (Figure 2.3). The concentrations used correspond
to 0.7-7 mg Fe/kg of solution, spanning the working concentrations typically utilized for
tumor and lymphatic targeting in vivo (2.6mg Fe/kg body weight)(204). Nanoparticle
solutions were incubated with varying concentrations of MMP-2 in a 384 well-plate and
their T2 relaxation times were mapped using a Carr-Purcell-Meiboom-Gill (CPMG)
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Figure 2.4. Triggered Self-Assembly of Nanoparticles by HT-1080 Tumor-Derived Cells.
A) T2 mapping of Fe304 nanoparticles incubated for 5 hrs over HT- 1080 cells that secrete
active MMP-2 in a complex medium. Nanoparticle assembly amplifies T2 relaxation
over cancer cells relative to cells incubated with the MMP inhibitor Galardin at 25uM. B)
Activated nanoparticles are drawn out of solution by a strong magnet (left) while inactive
nanoparticles (right) are not. C) Nanoparticles activated by tumor cells for 3 hrs are
targeted to the cell surface with a magnetic field and visualized by epifluorescent
microscopy using biotin-quantum dots [Em: 605 nm]. Assemblies are not targeted to cells
if an MMP inhibitor is used. Scale bar reperesents 25 pm.
sequence on a 4.7T Bruker MRI. T2 shifts of greater than 150ms are observed by MMP-2
-triggered assembly in a 3.2 pM nanoparticle solution. For 10 pM and 32 pM
concentrations, a T2 shortening approximately 50% of the starting value is observed after
incubation with MMP-2. Nanoparticles at a 10pM concentration were sensitive to at least
170ng/ml [9.4U/ml] of MMP-2, which compares favorably with levels found in tumor
tissue of MMP-2 expressing cancer cells [435 U MMP-2 per g](203).
Next, the utility of the protease-triggered nanoparticles was explored in complex
biological specimens where non-specific protein adsorption is often problematic.
Specifically, passivated nanoparticles were tested in cell culture medium above living,
tumor-derived cells. We exposed nanoparticles to the human fibrosarcoma cell line, HT-
1080, which constitutively expresses and activates MMP-2(205, 206). MMP-2 is part of
the matrix metalloproteinase family, which includes soluble and membrane bound zinc
binding proteases that play a role in regulatory protein processing and extracellular
matrix remodeling(207). MMP-2 has cleavage specificity for Type IV collagen which is
... ...........
the principal constituent of basement membranes; thus upregulation of MMP-2 activity
leads to invasive proliferation and metastases of cancer cells by breaking down tissue
barriers(196, 197). It's activity has been correlated with poor prognosis in breast,
prostate, bladder and cervical cancers 2 08 21 0 . Nanoparticles were incubated over HT-
1080 cells at a concentration of 10pM. After 5 hours, samples from the media were
transferred to a 384 well plate and T2 maps were generated with MRI. A substantial
shortening in T2 is detected in the media over HT-1080 cells versus media over HT-1080
cells incubated with the broad-spectrum MMP inhibitor Galardin (Figure 2.4A).
Triggered assembly of the nanoparticles can also be used to magnetically target
nanoassemblies to cells. Similar to the T2 relaxivity enhancement in MRI, as the
magnetic domains of coalesced nanoparticles coordinate to form an amplified cumulative
dipole, they become more susceptibile to long-range dipolar forces(211). This
phenomenon allows manipulation of the nanoassemblies with imposed magnetic fields,
while isolated particles remain unaffected. Using a high-gradient permanent magnet,
MMP-2 triggered assemblies of 1.5nM iron oxide particles can be visually drawn out of
solution, while non-activated particles remain disperse (Figure 2.4B). To demonstrate
that this can be extended towards targeting particles onto cancer cells, HT-1080 cultures
were placed over a strong permanent magnet and incubated with nanoparticles at a
150pM concentration. After 3 hours, the media was removed and the cells were washed,
fixed, and stained for aggregates using a biotinylated fluorescent probe. Bright
fluorescent staining of particle assemblies is seen over HT-1080 cells, while weak diffuse
staining, indicating little to no targeting, is seen over cells incubated with the inhibitor
Galardin (Figure 2.4C).
2.2 Conclusions
To the best of our knowledge, this represents the first demonstration of protease-
triggered nanoparticle self-assembly. Previously, our laboratories have demonstrated that
peptide-modified semiconductor quantum dots could precisely target tumors in whole
animals(145) and subcellular organelles in living cells(212). This work extends the ability
of nanoparticles not only to target sites of interest, but to interact with the processes of
disease by harnessing biological machinery to assemble nanomaterials with amplified
properties. We show that polymeric protection can temporarily shield dissimilar
complementary ligands, including both small molecules (biotin) and tetrameric proteins
(neutravidin). Accordingly, as opposed to recent reports of proteolytic activation of cell-
penetrating peptides 2l and peroxidase-initiated nanoparticle assembly29-30, our approach
can be considered entirely modular whereby key features may be altered without
significant re-engineering. Formulations with new functionalities could be easily
developed by substituting the complementary binding pairs, cleavable substrates (e.g.
glycans, lipids, oligonucleotides), or multivalent nanoparticle cores (e.g. gold, quantum
dot, dendrimer) to extend the capabilities of existing modalities.
2.3 Materials and Methods
Synthesis of Nanoparticle Probes
Protease-triggered, self-assembling nanoparticles were synthesized using 50nm
amine-functionalized, dextran-coated iron-oxide nanoparticles (6.25pmol/mg Fe), sized
by analytical ultracentrifugation (Micromod (Germany)). All peptides were obtained at
>90% purity (Synpep) and all reagents were obtained from Sigma unless otherwise
specified. A high gradient magnetic field filtration column was used between each
conjugation (Miltenyi Biotec). For biotin probes, the N-Succinimidyl 3-[2-pyridyldithio]-
propionamido (SPDP) was used to link cysteine-containing peptides [acetyl-
KGPLGVRGC-X-Biotin] to particle amines and mPEG-SMB polymers (Nektar) were
attached to peptide lysine.
Neutravidin nanoparticles were formed by modifying particles with
biotinamidohexanoyl-6-amino-hexanoic acid N-hydroxy-succinimide ester and coating
with a saturating concentration of neutravidin. The extinction coefficient of the solution
at 600nm was measured during incubation to ensure no aggregate formation.
Additionally, neutravidin coated particles were passed through a 0.lum filter to confirm
mono-dispersity. Peptide linkers and PEG were functionalized to lysines on the
neutravidin coated nanoparticles using the same methods described for biotin particle
conjugations, but with the peptide sequence (KGPLGVRGC). The scrambled sequences
used for control experiments were GVRLGPG instead of GPLGVRG.
Extinction coefficient, AFM, and Magnetic Field Migration Measurements
For all assembly experiments, equimolar ratios of particles were used. All
extinction coefficient measurements were performed in duplicate in 384 well plates using
a SpectraMax Plus spectrophotometer (Molecular Devices, Sunnyvale CA). Biotin and
neutravidin probes (0.5mg/ml) were mixed at equal ratios and 0.5ug of the recombinant
catalytic domain of MMP-2 (Biomol,) in 6ul of 50 mM Tris, 5 mM CaCl2, 0.005% Brij-
35, pH 7.5 buffer was added to 40ul probe solution at time zero. The same probe and
MMP-2 concentrations were used for AFM and solution phase magnetic precipitation
experiments. For AFM controls, 6ul of buffer without MMP-2 was added. AFM
measurements were performed using a multimode, Digital Instruments AFM (Santa
Barbara CA) operating in tapping mode using FESP Tips (Veeco Nanoprobe TM, Santa
Barbara CA). AFM reactions were incubated for 3 hours, diluted, and evaporated on
freshly-cleaved mica for analysis. In magnetic precipitation experiments, probe solutions
were incubated with or without MMP-2 overnight and placed over a strong magnet for
2.5 minutes.
MRI detection of self-assembly
MRI images were taken on a Bruker 4.7T magnet, 7cm bore. Biotin-peptide-PEG
and neutravidin-peptide-PEG nanoparticles were mixed together and serially diluted in
384 well-plate. Serial dilutions of recombinant MMP-2 in 6ul of TRIS buffer were added
to each well. After 3 hours, a CPMG sequence of sixteen images with multiples of
10.45ms echo times and a TR of 50OOms were acquired. T2 maps were obtained for each
well by fitting images on a pixel by pixel basis to the equation y=M*exp(-TE/T2) using
MATLAB.
Cell culture
HT- 1080 human fibrosarcoma cells (ATCC) were cultured in 24-well plates using
Mininum Essential Medium Eagle (Invitrogen) with 10% fetal bovine serum (Invitrogen)
and 1% penicillin/streptomycin. For MRI experiments, the media was replaced with
serum-free Dubelcco's Modified Eagle Medium (DMEM - Invitrogen) containing 10pM
nanoparticle concentration. The broad-spectrum MMP-2 inhibitor Galardin (Biomol)
was added at a concentration of 25uM in control cultures. Samples of 40ul were taken at
5 hours for MRI imaging using the same procedures for T2 mapping described above.
For fluorescent labeling experiments, media was replaced with serum-free DMEM
containing 200pM nanoparticle concentration and cells were placed over a strong magnet.
After 3 hours, the media was removed and the cells fixed with 2% paraformaldehyde.
The cells were permeabilized with 0.1% Triton-X in PBS and incubated with biotin
quantum dots (EM: 605nm - Quantum Dot Corp). Nuclear staining was performed by
incubating with 0.00 1% Hoescht for 1 min.
Chapter 3: Nanoparticle Self-Assembly Gated by Logical
Proteolytic Triggers
3.1 Introduction
Complex diseases such as cancer emerge through the dysregulation of numerous
molecular pathways. While these pathways may be inappropriately activated in cancer
cells, they typically serve important purposes in normal physiology as well. Therefore,
the single biomarker paradigm for diagnosis of diseases has largely failed to provide
definitive diagnoses for neoplastic disease. To date, nanoparticle (NP) assembly has been
exploited to probe for a host of single pathological inputs in vitro, including DNA(37,
177, 179), RNA(1 79), proteins(186, 192), viruses(180), and enzymatic activity(181, 184,
192, 213). While this methodology can be effective for in vitro applications, where
multiple assays can be performed in parallel to interrogate multiple targets, the future
development of highly diagnostic in vivo sensors may benefit from the ability to
simultaneously monitor multiple aspects of disease. In this chapter we describe a method
whereby inorganic nanocrystals may perform Boolean logic operations using two inputs
associated with cancer invasion (MMP2 and MMP7). Disperse, superparamagnetic Fe 304
NPs are designed to coalesce in response to logical AND or OR functions. In either
system, NP self-assembly amplifies the T2 relaxation rate of hydrogen protons, enabling
remote, MRI-based detection of logical operations. In the future, we believe that these
sensors may be optimized to monitor a diversity of inputs in vitro and in vivo.
Logical operations were designed to analyze inputs of two matrix-
metalloproteinases, a family of at least 26 members of secreted and membrane bound
proteases that have been studied extensively for their role in cancer(197, 214). In
particular, matrix-metalloproteinase-2 (MMP2), is over-expressed in many cancers,
including breast cancers, and is an indicator of cancer invasiveness, metastasis,
angiogenesis, and treatment efficacy(196, 198, 208-210, 215, 216). MMP7, a protease
with broader substrate specificity, is thought to facilitate early stages of mammary
carcinoma progression(217, 218). In tissues excised from breast cancer patients, both
MMP-2 and MMP-7 were expressed at statistically higher levels in carcinogenic than in
normal breast tissues(219), highlighting their potential utility as dual markers of
neoplastic inception. We demonstrate using dynamic light scattering (DLS), fluorescence,
and MRI that logical sensors can probe samples for the presence of both MMP2 and
MMP7 (AND function) or for the presence of either MMP2 or MMP7 (OR function).
3.2 Results and Discussion
To synthesize both sensor types, two kinds of NPs were initially engineered: one
with a tethered ligand (biotin) and the other with its receptor (neutravidin). These
particles were stable separately, but aggregated readily when combined. We sought to
completely mask these groups by attachment of peptide-polyethyleneglycol (PEG)
conjugates to conditionally prevent assembly. Previously, we demonstrated that two
lOkDa PEG-modified NPs could mutually deter each other's binding(184). Here, by
increasing the polymer weight to 20kDa, we demonstrate that modification of only one
NP can completely inhibit the binding of an unmodified NP (Figure S2; Figure 2).
Accordingly, we reasoned that by linking polymers to each particle via unique protease
substrates, assembly could be restricted to occur only in the presence of both enzymes
(Logical AND) (Scheme 3.1). Furthermore, by anchoring polymers to only the ligand NP
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Scheme 3.1. Schematic Representation of Logical Nanoparticle Sensors. Self-Assembly
is gated to occur in the presence of MMP2 and MMP7 (Logical AND) (Left) or in the
presence of either or both proteases (Logical OR) (Right) by attachment of protease-
removable polyethylene glycol polymers.
with a tandem peptide substrate (containing both enzyme cleavage motifs in series), we
sought to actuate assembly in the presence of either or both of the enzyme inputs
(Logical OR) (Scheme 3.1).
Peptide PEG polymers were synthesized by reacting the peptide N-terminus (or
lysine residue for OR tandem peptide) with amine-reactive 20kDa methoxy-PEG-
succimidyl a-methylbutanoate (see supplemental methods for details). Cysteine residues
were incorporated at the C-terminus of peptides to allow oriented attachment of substrate
polymers to NPs and TAMRA fluorochromes were incorporated distally to fluorescently
monitor polymer removal. To begin AND NP synthesis, ligand particles were shielded
with an MMP2 (Gly-Pro-Leu-Gly-Val-Arg-Gly)(203, 220) substrate-polymer and
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Figure 3.1. Protease activation of substrate-linked TAMRA fluorescence. A) Biotin-
MMP2-PEG NPs, Neutravidin-MMP7-PEG NPs, and Biotin-MMP2-MMP7-PEG NPs
(OR NPs) are incubated with proteases which, upon cleavage of substrates, relieve
TAMRA fluorochrome quenching by NP core and increase solution fluorescence. B-D)
NPs (40ug/ml; 50ul) were incubated with 0.2ug MMP2, 0.2 ug MMP7, purified human
enzyme controls, or 10% human serum. Thrombin and factor Xa concentrations (1 OU/ml)
were chosen to approximate lOx the activity present in human serum.
receptor particles were shielded with an MMP7 (Val-Pro-Leu-Ser-Leu-Thr-Met)(221)
substrate-polymer. Enzyme specificity for these sequences was assessed by monitoring
TAMRA fluorescence increase in the presence of various enzymes. Specific enzyme-
substrate pairs rapidly increased TAMRA fluorescence as cleaved substrate
fluorochromes diffused away from the quenching iron oxide cores (Figure 3.1). Non-
specific pairs, including human thrombin, factor Xa, and serum, showed little
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Figure 3.2. Probing nanoparticle latency and specificity using dynamic light scattering.
a) Ligand-nanoparticles were masked with MMP2-PEG to inhibit assembly with
unmodified receptor nanoparticles (40ug Fe/mil). Addition of 0.4ug MMP2 actuates
nanoparticle assembly, while 0.4ug MMP7 or no enzyme is insufficient. b) Receptor-
nanoparticles were masked with MMP7-PEG to inhibit assembly with unmodified ligand
nanoparticles (40ug Fe/ml). Here, addition of 0.4 ug MMP7 induces assembly, while
0.4ug MMP2 cannot.
fluorescence increase. We next examined each enzyme's ability to actuate assembly of
peptide-shielded particles in the presence of their unmodified cognate particles. Specific
enzyme-substrate pairs rapidly catalyzed the formation of nano- and micro-assemblies
when incubated with unmodified cognate NPs, while non-specific pairs negligibly
affected population size (Figure 3.2). To investigate the relationship between peptide
polymer removal and NP assembly, biotin-MMP2-PEG enzyme reactions were quenched
at various timepoints (Figure 3.3) and incubated with receptor NPs. Following removal
of ~50% of NP polymers, assembly begins, eventually revealing sufficient biotin to direct
NP precipitation.
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recorded over time. At various time points, reactions were quenched with addition of
20mM EDTA (quenching times indicated by arrows). B) The amount of free MMP2-PEG
released in samples from (A) was quantified by TAMRA absorbance in solution after
ultracentrifugation of NPs. Peptide-Peg removal is plotted vs MMP2 incubation time with
data colors corresponding to those in (A). Polymer removal kinetics are consistent with
the fluorescence de-quenching data in (A), suggesting that TAMRA quenching was
largely mediated by fluorochrome-NP interactions over fluorochrome-fluorochrome
interactions. C) i) Quenched ligand-MMP2-PEG samples from (A) were incubated with
unmodified receptor NPs (each at 40ug/ml) for 24 hours at which time size was measured
with DLS. The 7.5 hour MMP2 reaction precipitated during the incubation, indicating
assembly is closely controlled by the degree of polymer removal between 4-6 hrs. ii)
Assembly data is plotted vs. the polymer removal data of (B), demonstrating minimal
assembly induction prior to removal of~50% of NP polymers.
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Figure 3.4. Logical AND a) Hydrodynamic radius in dynamic light scattering is only
increased in the presence of both MMP2 and MMP7; either or none is insufficient to
actuate assembly (40ug Fe/ml). b) Assemblies express AND logic in MRI. T2 relaxation
decreases ~30% in 3 hours following addition of MMP2 and MMP7, with nominal
changes following addition of either enzyme alone (7.5ug Fe/ml). at various timepoints
(Figure S3) and incubated with receptor NPs. Following removal of -50% of NP
polymers, assembly begins, eventually revealing sufficient biotin to direct NP
precipitation.
To create a logical AND NP system, MMP2-PEG ligand particles with MMP7-
PEG receptor particles were combined. Here, in presence of either protease alone,
assembly of NPs was prohibited by the PEG polymers remaining on the cognate particle
(Figure 3.4A). In the presence of both proteases, however, NP self-assembly began and
the population hydrodynamic radius increased 5-fold over 3 hours in DLS (Figure 3.4A).
Further, nanoparticles were able to express AND logic in T2 relaxation changes, mapped
using a 4.7T Bruker MRI. In the presence of both enzymes, T2 relaxation is enhanced by
-30% as compared to samples with either enzyme alone or none (Figure 3.4B). This
enhancement is comparable to published magnetic relaxation sensors(1 79, 180, 184), and
occurs at MMP2 concentrations that mimic tumor activity levels in vivo (4ug MMP2/ml
= 221 U/ml vs. 435 U/g in vivo(203)).
A second system was constructed to actuate assembly in the presence of either of
two proteolytic inputs (Logical OR). Here, only the particles containing the ligand were
masked with peptide-linked polymers. To allow either enzyme to actuate assembly, a
tandem MMP2-MMP7 peptide substrate was synthesized, containing both cleavage
motifs in series (separated by an aminohexanioc acid spacer). Hydrodynamic radii
increased more than 5-fold in the presence of either or both enzymes, indicating proper
OR function (Figure 3.5A). Accordingly, OR NP T2 relaxation decreases -40% in the
presence of either or both enzymes, as compared to samples with no enzyme (Figure
3.5B).
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Figure 3.5 Logical OR a) Population hydrodynamic radius is increased in the presence of
either or both MMP2 and MMP7 (40ug/ml Fe). b) MRI visualization of logical function
demonstrates ~40% enhancement in T2 relaxation in the presence of either MMP2 or
MMP7 or both enzymes (1 5ug/ml Fe).
3.3 Conclusion
In conclusion, we have demonstrated the synthesis of NPs that use Boolean logic
to simultaneously monitor multiple biological processes associated with tumorigenesis. In
the future, we anticipate that logical NP switches may enable more informative imaging
of neoplastic transformation in optically opaque samples both in vitro and in vivo. The
modular design of these logical NP sensors can be applied to other enzymatic triggers,
complimentary ligand/receptor pairs, or NP cores (semiconductor, plasmonic). Looking
further, logical NP switches may enable specific localization of the processes underlying
malignant transformation in vivo, as proteolytically-assembled beacons in sites of
neoplastic inception. Such interstitial assembly may amplify the retention of particles (by
mechanical entrapment in the tumor interstitium) and allow MRI visualization of
diagnostic logic functions.
3.4 Materials and Methods:
Unless otherwise stated all reagents were purchased from Sigma-Aldrich and all
reactions were performed at room temperature.
Superparamagnetic iron oxide nanoparticles were synthesized according to the
published protocol(32). Briefly, dextran-coated iron oxide nanoparticles were
synthesized, purified, and subsequently cross-linked using epichlorohydrin. After
exhaustive dialysis, particles were aminated by adding 1:10 v/v ammonium hydroxide
(30%) and incubated on a shaker overnight. Aminated-nanoparticles were subsequently
purified from excess ammonia using a Sephadex G-50 column and concentrated using a
high-gradient magnetic-field filtration column (Miltenyi Biotec).
Peptide-Polymer synthesis: Peptides were synthesized in the MIT Biopolymers
core to sequentially contain a lysine (for the attachment of polyethylene glycol
polymers), a MMP-cleavage sequence, and a terminal cysteine (for linkage onto amines
in the dextran coat or lysines on neutravidin (Pierce) proteins. Peptide purity was verified
with HPLC and mass spectrometry. Amine-reactive 20kDa mPEG-SMB reagents
(methoxy-polyethylene glycol- succimidyl a methylbutanoate) were purchased from
Nektar Therapeutics. The following sequences were used in this investigation: (N->C)
MMP2 substrate: G-K(TAMRA)-G-P-L-G-V-R-G-C-CONH2; MMP7 substrate: G-
K(TAMRA)-G-V-P-L-S-L-T-M-G-C-CONH2; MMP7-MMP2 tandem substrate:
TAMRA-G-K-G-V-P-L-S-L-T-M-Ahx-G-P-L-G-V-R-G-C-CONH2 where K(TAMRA)
= Lys(DDE) substituted with 5(6)-TAMRA, TAMRA=5(6)-TAMRA, and Ahx=
aminohexanoic acid. Peptides were reacted with polymers in PBS + 0.005M EDTA pH
7.2 at 500uM and 400uM, respectively, for >24 hours with shaking. Free peptide was
removed by reducing with 0.1 M TCEP and filtering using a G-50 Sepahdex column. The
reduced polymer was then quantified using fluorochrome extinction and added to
nanoparticle preparations as described below.
Ligand nanoparticle synthesis: Following each conjugation, nanoparticles were
purified using a high-gradient magnetic-field filtration column (Miltenyi Biotec).
Aminated nanoparticles (1mg Fe/ml) were simultaneously reacted with
biotinamidohexanoyl-6-aminohexanoic acid N-hydroxysuccinimide ester and 4-
Maleimidobutyric acid N-hydroxysuccinimide ester (.8mM and 1.2mM, respectively) in
0.1M HEPES 0.15M NaCl pH 7.2 buffer for 30 minutes. Purified nanoparticles (1 mg
Fe/ml) were then combined with reduced peptide-polymers (1mM) in phospho-buffered
saline + 0.005M EDTA pH 7.2 and incubated for >2hrs. Particles were again purified
and used in subsequent assembly experiments.
Receptor nanoparticle synthesis: Aminated nanoparticles (1mg Fe/ml) were
reacted with biotinamidohexanoyl-6-aminohexanoic acid N-hydroxysuccinimide ester
(0.03mM) in O.1M HEPES 0.15M NaCl pH 7.2 buffer for 30 minutes. Following
filtration, nanoparticles (1 mg Fe/ml) were combined with a saturating concentration of
neutravidin protein (Pierce, 5mg/ml) and incubated for >3hrs. The extinction of
nanoparticle solutions at 600nm was monitored during neutravidin-coating to ensure
cross-linking was not occurring. After purification, neutravidin particles were passed
through a 0.2 micron filter to ensure removal of any aggregates. Neutravidin
nanoparticles (1mg Fe/ml) were then reacted with 4-Maleimidobutyric acid N-
hydroxysuccinimide ester (2mM) for 30 minutes, purified, and incubated with peptide-
polymers (1mM) for >2hrs as before. Particles were finally purified from excess peptide-
polymer and used in subsequent assembly experiments.
Dynamic light scattering studies: All dynamic light scattering experiments were
performed in 100ul solutions of 0.1M HEPES 0.15M NaCL 0.005M CaCl2 at 25"C with
nanoparticles at 40ug Fe/ml (added at equimolar concentrations). To begin experiment,
catalytic domains of MMP2 and MMP7 (Biomol) were added in 5ul to 95ul of
nanoparticles or 5ul control buffer was added. Kinetic dynamic light scattering intensity
size measurements were taken using a Malvern ZS90 and hydrodynamic radius was
plotted vs time.
Fluoresence activation experiments: NPs were incubated with various enzymes
and TAMRA fluorescence was monitored (ex: 515nm/em: 580nm; cutoff 530nm) at
30sec intervals over time. Buffer was matched to DLS studies. Purified plasma proteins
(Haematologic Technologies) were incubated with 40ug/ml NP samples in 40ul. For
partial assembly studies, reactions were quenched with addition of 10% 0.2M EDTA.
Polymer quantitation: Triplicate partial activation samples were ultracentrifuged
(50k, 30min) to precipitate nanoparticles. The supernatant was collected and TAMRA
absorbance was quantified to determine peptide-polymer concentration.
MRI detection of nanoparticle self-assembly: MRI T2 mapping was performed
using a 7 cm bore, Bruker 4.7T magnet. Nanoparticles were mixed together and serially
diluted in 384-well plate, containing 95ul total sample/well. Recombinant MMP2 or
MMP7 (Biomol) was pre-incubated at 37C for 30 minutes to activate and added in a total
of 5 uL Tris-Cl (50 mM), CaCl2 (5 mM), Brij-35 (0.005%), pH 7.5 were added to each
well. After 3 hr incubation, T2 relaxation maps were obtained. Data in each well was
displayed by fitting images on a pixel by pixel basis to the equation y=M*L10(-TE/T2)
using MATLAB.
Chapter 4: Reversible Nanoparticle Self-Assembly Under
the Control of Antagonistic Enzyme Triggers
4.1 Introduction
The ability to dynamically control both the assembly and disassembly of
biomolecular complexes is essential to higher-order biological processes, including the
control of intracellular communication(222), gene expression(223, 224), and platelet
aggregation upon injury(225). To date, assembly or disassembly of nanoparticles (NPs)
has been exploited to improve sensitivity for detection of single biomolecular targets,
including DNA(1 77, 179), small molecules, proteins(186, 192), and pH changes(193) in
vitro; however, mechanisms of sensing that allow multiple, opposing stimuli to
dynamically assemble and dis-assemble NPs have not been described. Development of
inorganic nanoparticles that respond to multiple, antagonistic biological signals could
facilitate sensing of the physiologic balance between opposing effectors of cellular and
tissue function. Herein, we introduce a nanoparticle (NP) system where self-assembly is
dynamically coupled to the balance between the classic antagonistic enzymes: tyrosine
kinase and phosphatase. In vivo, these enzymes regulate cellular communication, gene
expression, and ultimately cell life and death through the phosphorylation and
dephosphorylation of tyrosine residues on other proteins (226, 227. Their dysregulation
contributes significantly to the development of cancer and other inflammatory
diseases(228, 229). Here, kinase-induced superparamagnetic nanoassemblies enhance the
T2 relaxation of hydrogen atoms at picomolar enzyme concentrations and are shown to
be fully reversible by introducing excess phosphatase activity. In the future, these
nanomaterials may be optimized to report the balance between these cytosolic
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Scheme 4.1.: Schematic of reversible nanoparticle self-assembly. Polymer-coated,
superparamagnetic NPs were modified to polyvalently display either a tyrosine-
containing kinase substrate or an SH2 domain. NPs remain dispersed until kinases
phosphorylate substrate NPs, triggering NP assembly via phosphopepetide-SH2 binding.
Kinase-directed assembly amplifies the T2 relaxation in MRI and is fully reversible by
phosphatase
enzyme activities and may facilitate new screens for inhibitors in vitro and in vivo.
Additionally, extensions of this design logic may be synthesized to probe the dynamics of
a diversity of antagonistic biologic processes.
4.2 Results and Discussion
To construct a system of NPs that could coalesce in the presence of kinase activity
and re-disperse in the presence of phosphatase activity, two NP populations were
synthesized (Scheme 4.1). The first population was modified with peptide substrates that
.................... .......
may be phosphorylated by Abl tyrosine kinase and dephosphorylated by a phosphatase.
The second population was modified with Src Homology 2 (SH2) domains that recognize
and bind the phosphorylated Abi kinase substrate in a sequence-specific manner.(230)
Together, these NPs process kinase and phosphatase activities by assembling as peptides
become phosphorylated and disassembling as phosphates are removed. Magnetic dipoles
in NP assemblies coordinate and more efficiently dephase hydrogen protons in MRI,
allowing T2 relaxation mapping of kinase function(184, 231). Conceptually, this design
is akin to the kinase/phosphatase FRET sensors developed by Tsien et al (232-234)
among many other fluorescence-based kinase sensors,(235-238) but instead of
transducing enzyme activites into optical fluorescence changes, activity is encoded via
NMR relaxation changes.(182, 231, 239) Recently, two gold NP-based approaches have
sensed either kinase or phosphatase activity in irreversible, two-step assays.(213, 240)
These designs provide new avenues for colorimetric screening of enzyme inhibitors, yet
lack the capacity to continuously analyze both kinase and phosphatase balance. Similarly,
while NP-based sensing of single analytes and proteases has been demonstrated,(184,
231) the extension of this technology to reversibly sensing multiple enzyme activities has
not been accomplished.
We first set out to verify that phosphopeptide-SH2 domain binding could
efficiently induce NP assembly at particle concentrations relevant to MR imaging.
Dextran-coated iron oxide NPs were synthesized, cross-linked, and aminated according to
published procedures.(241-243) The Crk SH2 domain was genetically modified to
contain an (N- terminal) cysteine to allow convenient conjugation to NPs. GST-tagged
cysteine-SH2 was expressed in bacteria, purified, and the GST affinity label was removed
600 -
400
size/nm
200
0
0
I
0
*4 p so
U~
_MOO I_ 
____/ et Crk-pY peptide NPs (Mixed at 8 min)
Crk-pY peptide NPs (free Crk-pY added at 8 min)
0 Crk-Y peptide NPs
I Crk-pY peptide NPs + free Crk-pY peptide0 Non-binding pYAb substrate NPs
~ AAAAAAAL
160
t1min -
Figure 4.1. Dynamic light scattering detection of nanoparticle assembly. Phosphopeptide
(pY) NP assembly with SH2 NPs. Upon addition of SH2 NPs to pY-peptide NPs, rapid
increase in hydrodynamic radius was observed by DLS (filled circles). In the presence of
free pY-peptide, NP assembly was not observed (vertical lines). Non-phosphorylated
peptide and non-binding pY-peptide remain dispersed with SH2 NPs, demonstrating both
sequence- and phosphate- specific peptide recognition by SH2 NPs (hollow square and
hollow dot, respectively). Assembly was reversed by addition of excess free pY-peptide
to the mixture after 8 min incubation (hollow triangles).
(see methods). Reduced cysteine-SH2 were conjugated to amine-NPs (-14 SH2
domains/NP) via highly flexible heterobifunctional linkers, containing 12 polyethylene
oxide units (54.4 A), to increase conformational freedom. In parallel, a phosphotyrosine
(pY) sequence with low pM binding affinity to Crk SH2 (-QpYDHPNI-)(230, 244) was
synthesized with an N-terminal cysteine and attached to a second population of NPs
using the same linker (~15 peptides/NP). When combined, these NPs rapidly assembled
I a
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even at NP concentrations three orders of magnitude lower than the free peptide-SH2
affinity, as shown by the 10-fold hydrodynamic radius increase of 12 nM NPs within 15
minutes using dynamic light scattering (DLS) (Figure 4.1). In the presence of 200 pM
free pY peptide, assembly was inhibited. Further, SH2-NPs were able to discriminate pY-
NPs from Y-NPs (unphosphorylated tyrosine: ~13 peptides/NP) and from a
phosphopeptide not expected to bind to CRK SH2 (EAIpYAAPFAKKKC: -14
peptides/NP). 23 0 ) To test the reversibility of this system, pY NPs and SH2 NPs assembly
was interrupted with addition of 200 pM free pY-peptide or 2 ptl of buffer (Figure 4.1).
While mixing shear stress had no affect on NP assembly, particles with 200 pM free
peptide rapidly disassembled, dispersing over time.
The robust association of pY-NPs with SH2-NPs indicated that phospho-
dependent NP assembly may provide a rapid mechanism for probing kinase activity. To
begin, a kinase substrate (SRVGEEEHVYSFPNKQKSAEC) derived from paxillin was
chosen for its Crk SH2 binding and specificity to Abl.(245, 246) Three versions of this
peptide substrate were synthesized and attached to NPs: a phosphorylated substrate (pY-
Abl) (- 1 peptides/NP), an unphosphorylated substrate (Y-Abl) (~10 peptides/NP), and a
substrate where the receptor tyrosine was replaced with a phenylalanine (F-Abl) (~10
peptides/NP). Abl kinase rapidly directed assembly in solutions containing Y-Abl NPs
with SH2 NPs, while an F-Abl peptide control remained dispersed in DLS (Figure 4.2A).
We next probed the ability of NP self-assembly to transduce kinase activity into NMR T2
relaxation changes using a 4.7T Bruker MRI (Figure 2b,c). Quantifiable T2 relaxation
enhancements in solutions containing Y-Abl NPs with SH2 NPs were observed in the
presence of as little as 7 femtomoles of added kinase (110 pM kinase concentrations =
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Figure 4.2. Kinase-directed nanoparticle assembly. (A). Abl kinase (5 U/pl) (yellow
dots) was added to a mixture of SH2 NPs and tyrosine-containing, Abi substrate NPs at 2
min and NP radius was observed over time using dynamic light scattering (DLS).
Controls without kinase (red dots) with phenylalanine-Abl substrate NPs (green triangle)
did not assemble. (B) In MRI, T2 relaxation was enhanced by Abi kinase-directed
assembly (bottom two wells) and was reversed by addition of 200 pM free
phosphopeptide, but not by mixing alone. Controls lacking enzyme (top), containing
phenylalanine substrate NPs (second from top), or 200 ptM free pY substrate (third from
top) did not show enhancement. (C) Dose dependent T2 relaxation enhancement of SH2
NPs and Y-peptide NPs 3 hours following Abl kinase addition (12 nM NPs).
0.05 U/pl) (Figure 4.2C). Further, T2 enhancement was lost upon addition of free pY-
Abl substrate, demonstrating that kinase-directed NP assembly depended on
phosphopeptide-SH2 domain interactions that were reversible by competition (Figure
4.2B). As NPs coalesce, tyrosine-linked phosphates become sequestered in SH2 domain
binding pockets. Having demonstrated that addition of free pY-peptide was able to
reverse NP binding, we sought to examine whether phosphatase activity could oppose
kinase-directed self-assembly by removing phosphates from tyrosine residues as they
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Figure 4.3. Phosphatase reversal of nanoparticle assembly in DLS and MRI. (A) SH2
NPs and pY-Abl substrate NPs were allowed to assemble prior to addition of phosphatase
(2U/pl) (red) or vehicle control at 25 min (blue). (B) NPs were exposed to Abl kinase
(2.5 U/pl), followed by phosphatase (5 U/pl). (C) Kinase-directed assembly (2.5 U/pl)
and phosphatase disassembly (5 U/pl) was visualized via T2 relaxation enhancement in
MRI.
dynamically disassociate with SH2 domains. To begin, we tested YOP phosphatase's
ability to counteract the rapid association of pY-Abl NPs with SH2 NPs. Similar to the
competition test performed previously (Figure 4.1A), assembly of pY-Abi NPs with SH2
NPs was interrupted and reversed by addition of phosphatase, but not by buffer alone
(Figure 3a). Additionally, when Y-Abl NPs and SH2 NPs were first exposed to Abl
kinase and subsequently to an excess of antagonistic phosphatase, kinase-catalyzed NP
assembly was efficiently reversed by the excess phosphatase (Figure 3B,C).
Together, these results illustrate the ability of this NP system to continuously
sense cycling kinase/phophatase activities in MR. Importantly, phosphatase is able to
both halt NP assembly (by removing phosphates from free NPs) and to deconstruct
phospho-dependent nanoassemblies (by removing phosphates as they dynamically
disassociated with SH2 domains). We believe the rapid reversal of NP assembly (either
via monomer competition or substrate de-phosphorylation) and the enhancement of NP
avidity over anticipated monovalent binding (assembling at NP concentrations 1000-fold
below peptide/SH2 affinities) are indications of polyvalent NP binding.(148) Unlike
monovalent interactions, the disassociation rate of polyvalent species is accelerated by
the presence of monomeric competitor.(247) Synthetically, polyvalency has been
exploited to develop improved biological inhibitors,(148) targeting agents,(248, 249) and
affinity chromatography procedures.(247) Here, we exploit polyvalent binding to
engineer a reversible NP system that assembles into stable nanostructures, yet may also
be rapidly disassembled by competition.
4.3 Conclusions
In summary, we present the design and synthesis of a NP system that processes
two antagonistic enzymes inputs (tyrosine kinase/phosphatase) to output enhanced T2
relaxation in the presence of net kinase activity. Phosphopeptide-directed assembly
enables rapid MR visualization of kinase activity at nanomolar NP and picomolar kinase
concentrations. To the best of our knowledge, this represents the first demonstration of a
NP sensor that reversibly processes two specific, antagonistic enzyme inputs. Looking
forward, as MRI field strengths increase and methods for labeling cells with
nanomaterials advance,(212, 250, 251) optimizations of this design may enable a variety
of novel real-time assays to monitor kinase and phosphatase inhibition or to image
cytosolic enzyme activities in optically opaque media and in vivo using MRI. Further, the
modularity of our design should enable key features to be altered without requiring
significant re-engineering. For example, this technology may be extended to incorporate
new nanoparticle cores (ex. semiconductor, plasmonic) or to sense other antagonistic
biological stimuli (other kinase/phosphatase pairs, acetylase/deacetylase pairs, etc).
4.4 Materials and Methods:
All chemicals and reagents were purchased from Sigma-Aldrich unless specified.
Plasmid expressing GST-Cys-SH2 was generously supplied by Dr. Barbara Imperiali
(Department of Chemistry, MIT). Peptides were synthesized following standard Fmoc
solid phase peptide synthesis method using an ABI Model 433A peptide synthesizer in
MIT center for cancer research biopolymer laboratory. Nanoparticle size was measured
using Zetasizer (Malvern Instruments). MRI images were taken on a Bruker 4.7T magnet.
All enzyme reactions were carried out at 30 oC unless specified otherwise. Aminated
nanoparticles were synthesized according to published procedures.
Expression and purification of SH2 domain: BL21-Gold(DE3) cells harbouring GST-
Cys-Crk SH2 plasmid (pGEX4T-Cys-CrkSH2) were grown to midlog phase in LB media
containing carbenicillin (50 pig/ml) at 37 oC, 220 rpm. Protein expression was induced
with addition of 0.1 mM IPTG after cells were cooled to 16 oC and then, cells were
incubated at 16 oC for 21 hrs. The cells were centrifuged at 5000 rpm, 4 oC for 30 min,
and the cell pellet was resuspended in a lysis buffer (1xPBS, 100 mM EDTA, 1 % Triton
X-100, 10 % glycerol, 1 mg/ml lysozyme, lxprotease inhibitor cocktail set III
(CalbioChem)) and incubated for 30 min at 4oC. After sonication, the soluble fraction
was isolated from cell debris after centrifugation (14000 rpm, 30 min) and purified using
glutathione sepharose 4B affinity column (Amersham Biosciences) following
manufacture's protocol. Eluted proteins were dialyzed with 7 kD MW cutoff dialysis
cassette (Slide-a-Lyzer, Pierce) against 1xPBS and characterized by SDS-PAGE. To
remove GST tag, protein solution (1 mg/ml) was treated with TEV protease (50 units/ml,
Invitrogen) in a TEV protease buffer (50 mM Tris-HCl, 0.5 mM EDTA, pH 8.0) in the
presence of 1 mM DTT. After 4 hr incubation at 25 oC, the cleavage reaction mixture
was subject to glutathione column and then, Ni+2-NTA column to sequentially remove
cleaved GST tag and TEV protease, respectively. To ensure that cysteine thiols of cys-
SH2 domain were fully reduced, cys-SH2 domain was passed through reducing column
(Reduce-Imm Immobilized Reductant Column, Pierce) following manufacture's
instruction immediately prior to nanoparticle conjugation.
Preparation of peptide-presenting nanoparticles and SH2-conjugated
nanoparticles: First, maleimide-activated NPs were prepared by conjugating NHS-
PEO12-maleimide (succinimidyl-[(N- maleimidopropionamido)-dodecaethyleneglycol]
ester, Pierce) to aminated NPs. Typically, NPs (0.25 mg Fe) were incubated with 4 mM
of NHS-PE012-maleimide for 30 min at 25 oC and then purified using a magnetic field
filtration column (Miltenyi Biotec). SH2 conjugated particles were prepared by
incubating Cys-SH2 (1 mg/ml) with maleimide presented NPs (0.25 mg Fe) for 3 hrs at
RT. Unreacted Cys-SH2 domain was removed using a magnetic field filtration column.
Peptides were conjugated by activating amine-NPs with NHS-PEO12-maleimide as
above, followed by addition of peptide substrate. Particles were filtered 2 hours after
peptide addition. The peptides used in this investigation were synthesized as follows:
CRK SH2-binding.
TAMRA-C(Ahx)QpYDHPNI-CONH2
TAMRA-C(Ahx)QYDHPNI-CONH2
Non-Binding Abl substrate:
TAMRA-(Ahx)EAIpYAAPFAKKKC-CONH2
CRK SH2-binding Abl substrates:
TAMRA-(Ahx)SRVGEEEHVpYSFPNKQKSAEC-CONH2
TAMRA-(Ahx)SRVGEEEHVYSFPNKQKSAEC-CONH2
TAMRA-(Ahx)SRVGEEEHVFSFPNKQKSAEC-CONH2
(Ahx:aminohexanoic acid)
Quantification of peptide/SH2 numbers per NP: The yield of the SH2 domain-NP
reaction was quantified by performing a bicinchroninic acid protein assay (BCA Protein
Assay Kit, Pierce, Rockford, IL, USA) on modified vs unmodified NPs after purification.
SH2 NPs were compared with their parent PEO-NPs containing a gradient of albumin.
220ug of SH2 domain (-13kDa) were conjugated per 1mg of Fe in NPs (805,000 mg
Fe/mole NPs). Peptide attachment yields were quantified by monitoring the increase in
purified NP absorbance at 555nm following TAMRA-peptide conjugations (TAMRA
extinction: 90,000 M-1 cm-1).
SH2-binding peptide-mediated nanoparticle assembly: Nanoparticles presenting
CRK SH2-binding peptide (either phosphorylated or unphosphorylated) or non-binding
Abl substrate (phosphorylated) were incubated with CRK-SH2 NPs at 10pjg Fe/ml (12
nM NP concentration) and monitored with DLS over time.
Kinase-directed nanoparticle assembly: Nanoparticles presenting kinase substrate
peptide (10 pg Fe/ml; 12nM) and SH2-presented nanoparticles (10 gg Fe/ml; 12nM)
were mixed in a kinase reaction buffer (20 mM Tris-HCl, pH 7.5, 2 mM MgCl2, 20 mM
NaCl, 0.2 mM EGTA, 0.4 mM DTT, 0.004 % Brij 35, 0.2 mM ATP) in a total volume of
50 1tl. Kinase reaction was initiated by adding indicated amount of Abl kinase (New
England Biolabs). NP assemblies were characterized by DLS over time or MRI.
Phosphatase-directed nanoparticle disassembly: First, SH2 nanoparticles (5 pg Fe/ml;
6nM) were added to phosphorylated tyrosine containing peptide nanoparticles (5 ptg
Fe/ml; 6 nM) in a buffer solution (20 mM Tris-HCl pH 7.5, 20 mM NaCl, 0.4 mM
Na2EDTA, 2 mM DTT, 0.004 % Brij 35) to initiate nanoparticle assembly. YOP protein
tyrosine phosphatase (New England Biolabs, 2 U/pl) was added when size of assembled
nanoparticles reached to about 400 nm in radius.
Reversal of kinase induced nanoparticle assembly by phosphatase: First,
nanoparticle assembly was initiated following same protocols described above. Then,
YOP phosphatase (5 U/pl in final concentration) was directly added into a kinase reaction
mixture. Size measurement was restarted right after thoroughly mixing the reaction
mixture.
MRI imaging of nanoparticles: All nanoparticle solutions were prepared in final
concentration of 10 pg Fe/ml (12 nM) in 70 pl of kinase reaction buffer. Nanoparticle
mixtures were incubated at 30oC for 3 hrs after kinase additions (0, 0.05, 0.1, 0.2, 0.5
U/pl) and then, MRI images were taken using a 4.7T Bruker magnet (7cm bore) using
T2-mapping Carr-Purcell-Meiboom-Gill pulse sequence. To reverse the assembly, YOP
phosphatase (4 U/pl) or free pY-peptide (0.1 mM) was added to an assembled
nanoparticle solution containing 0.2 U/pl Abl kinase. The MRI image was taken after 10
min incubation at room temperature.
Section 1l: Engineering Indirect Nanoparticle Interactions
for Cancer Targeting In Vivo
A)
B)
* Signaling Nanoparticle * Receiving Nanoparticle
Scheme 11. Inspired by mechanisms of remote communication in biology, the second
section of this thesis describes nanoparticles that remotely communicate with one
another via biological intermediates to amplify tumor targeting. A) In areas of infection,
tissue resident macrophages engulf microbes and produce cytokines to remotely stimulate
the infiltration of circulating leukocytes in the blood stream (where concentrations exceed
>106 cells/ml blood). This process occurs as chemokines diffuse to the local blood
vessels and stimulate upregulation of integrins to recruit neutrophil rolling, firm
adhesion, and local transmigration into the tissue to amplify cellular assistance. B)
Inspired by this process, we set out to engineer mechanisms by which two distinct
populations of nanoparticle could communicate to improve tumor imaging and drug
delivery. Here, an initial population of 'Signaling' nanoparticles has homed to tumors
and, after arrival, remotely signals to 'Receiving' nanoparticles in circulation to
extravasate and bind.
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Chapter 5: In Vivo Nanoparticle Surface Chemistry:
'Clickable' Nanomaterials for Receptor Targeting
5.1 Introduction
The ability to target nanomaterials to precise biological locations would have
wide-ranging impact in biology and medicine. In living systems, highly controlled
transportation networks continually shuttle payloads to and from specific molecular
addresses. The efficiency of these systems provides strong motivation for the
advancement of targeted nanoparticle technologies, particularly for the diagnosis and
treatment of human diseases. Towards this goal, high throughput strategies for ligand
discovery have generated a multitude of chemical and biological motifs with the potential
to direct nanomaterials to specific biomolecular targets. However, translation of these
ligands towards in vivo nanoparticle targeting has been limited by the number of
nanoparticle attachment methods that are efficient, generalizable, aqueous-compatible,
chemically orthogonal to broad ranges of functional groups, and suitable for in vivo
applications.
Previous work has demonstrated that in vivo bacteriophage display may be used to
select for peptide sequences that mimic the ability of endogenous shuttles to target
vascular and parenchymal tissue addresses (252-256). Already, linear peptide candidates
of phage screens, as well as small molecule targeting candidates, have been translated
towards nanomaterial targeting (248, 249, 257, 258), primarily via use of exogenous or
non-essential thiols, carboxylic acids, or amines. Still, some of the most powerful
targeting motifs developed to date are those that contain essential thiol, amine, and
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Scheme 5.1. Design of a "click" nanoparticle that targets tumor cells in vitro and in
vivo. Cross-linked, fluorescent, superparamagnetic iron oxide nanoparticles are modified
to display azido-PEG groups. Conjugation of cyclic targeting peptides (purple circles)
bearing pendant alkynes to azido-PEG nanoparticles via the copper(I)-catalyzed Huisgen
1,3-dipolar cycloaddition ("click" reaction) allows specific targeting of the nanoparticles
to cells expressing the receptor (red).
carboxyl groups, thereby prohibiting their specific attachment via traditional methods. In
particular, conformationally-constrained, disulfide-cyclized targeting peptides are
desirable for their enhanced affinity to biological receptors (259, 260), and resistance to
proteolytic degradation in vivo relative to their linear counterparts (261, 262). However,
specific intramolecular cyclization makes it difficult to add exogenous cysteine residues,
while essential amines and carboxyl groups prohibit selective conjugation via exogenous
lysine, aspartic acid, or glutamic acid residues. Additionally, non-covalent methods of
ligand attachment relying on hydrophobic or electrostatic effects, although widely used in
vitro
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Figure 5.1. Native and alkyne-bearing LyP-1 peptides target p32-expressing MDA-MB-
435 cells in vitro. (A) Structures of LyP-1, propargylglycine-LyP-1, and Heptynoic acid-
LyP-1, all labeled with a TAMRA fluorophore (red). The cyclic nonapeptide is in blue.
The pendant alkyne moieties were conjugated to the N-terminus of the peptide during
standard FMOC peptide synthesis. (B) Flow cytometry shows that peptides bearing
different alkyne groups target MDA-MB-435 cancer cells similarly, while a scrambled
control (LyP-1CTL) do not target (P=propargylglycine, H=6-heptynoic acid, *p<0.01,
unpaired Student's t-test ). (C) Flow cytometry histogram shows LyP-1, P-LyP-1, and H-
LyP-1 peptides (in different shades of blue) target MDA-MB-435 cells in vitro, while
LyP-1CTL peptide (green) did not show targeting relative to peptide-free control cells
(red).
(44, 263, 264), are unlikely to remain stable in blood or to resist rapid clearance in vivo.
Recently, the copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition or "click" chemistry
has emerged as an extraordinarily selective chemistry and an attractive solution in
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Scheme 5.2. Synthesis of LyP-1 -coated nanoparticles using "click" chemistry. ( A)
Synthesis of Succinimidyl 4-azidobutyrate. (B) Synthesis of azide-PEG-thiol by linking
Succinimidyl 4-azidobutyrate to a 5kDa thiol-PEG-amine. (C) Aminated, cross-linked,
fluorochrome-labeled superparamagnetic iron-oxide nanoparticles are activated with
GMBS, filtered, and then reacted with the thiol-PEG-azide from (B) to yield azido-PEG
bearing nanoparticles. After purification, the particle solutions were reacted with alkyne-
bearing LyP-1 peptides with CuSO4 / Na Ascorbate as catalysts to yield LyP-1-coated
nanoparticles for in vitro and in vivo use.
applications where commonly used thiol-reactive (maleimide, 2-pyridyldithio,
iodoacetyl) or amine-reactive (NHS, epoxy, aldehyde, EDC) chemistries are not suitable
(265). In vitro, "click" chemistry has been utilized to generate functionalized polymers
(266-268), surfaces(269-271), and nanoparticles (272-280), and meets the criteria for
broad utility in nanoparticle functionalization (chemical orthogonality, aqueous
efficiency, applicability for diverse substrates). However the use of "click" nanoparticles
for in vivo applications has not been investigated. Particularly, as opposed to small
molecule reagents with circulation times on the order of minutes (258), ligand
attachments on long circulating nanomaterials must remain stable against in vivo
degradation for hours while nanoparticles circulate systemically and identify molecular
targets.
Here, we find that alkyne-azide "click" chemistry provides a facile, single-step
method for specifically linking the cyclic tumor-targeting peptide LyP-l (CGNKRTRGC;
(252, 281)), which contains essential thiol and amine groups, to polymer-coated magneto-
fluorescent nanoparticles. LyP-1 binds to p32, a mitochondrial proteins that is both
overexpressed and aberrantly localized at the cell surface of tumor cells, macrophages
and lymphatic endothelial cells in certain experimental tumors and in human cancers
(282, 283). We find that "click" LyP-l nanoparticles are able stably traverse the systemic
circulation, extravasate into tumors, and penetrate the tumor interstitium to specifically
bind to receptors on p32-expressing cells in the tumors. Together, these results provide
strong motivation for future use of "click" functionalization as a strategy for developing
nanoparticles for in vivo biomedical applications.
5.2 Results and Discussion
In order for "click" chemistry to be applied to the development of peptide-
targeted nanomaterials, peptides must be able to harbor pendant alkyne or azide moieties
without abating peptide activity. To investigate the efficacy of targeting peptides
harboring pendant alkyne moieties, LyP-1 peptide (CGNKRTRGC) and untargeted cyclic
control peptide, LyP-1CTL (CRVRTRSGC) in which the essential NKRTR motif is
replaced with RVRTR to maintain net charge but abate p32 targeting(281), were
synthesized to incorporate either of two alkyne moieties (the unnatural amino acid
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Figure 5.2: Fluorophore-labeled LyP-1 Peptide Spectra. UV-Vis spectra for LyP-1 and
LyP- 1 CTL peptides synthesized with varying pendant alkyne groups (prop=
propargyiglycine; Hep=heptynoic acid)
propargyiglycine or 6-heptynoic acid) and a 5,6-carboxytetramethylrhodamine
fluorophore (TAMRA) (Figure 5.1A; Figure 5.2). Because the alkyne moieties provide
molecularly small chemical handles that may be incorporated in FMOC synthesis to
either the N- or C-terminal of essential peptide sequences, we hypothesized their
presence could be tailored to allow chemical attachment to azido-nanomaterials without
interfering with LyP-1 peptide activity. In previous investigations, we found that N-
terminal addition of visible and near-infrared fluorophores do not disrupt peptide binding
to its receptors (252, 281). Accordingly, we reasoned alkyne moieties located near the N-
.............
terminus would be well-tolerated by the peptide (Figure 5.1A). To verify the specificity
and efficacy of alkyne-LyP- 1 targeting, 10 pM of LyP-1, bearing either propargylglycine,
heptynoic, or no alkyne group were incubated for 45 minutes on monolayers of MDA-
MB-435 human tumor cells, which have been shown to bind and internalize LyP-1 and
express p32 at the cell surface (281, 282), LyP-1 CTL peptides were included as a control
sequence to verify targeted enhancement of uptake over non-specific cyclic peptide
structures. Cellular uptake of LyP-1 peptide was quantified via flow cytometry (Figure
5.1B) and plotted as the populational fluorescent intensity, relative to cells incubated with
vehicle alone. In vitro targeting of LyP-1 peptides bearing either propargylglycine or 6-
heptyoic acid was similar to that of native LyP-1 and control peptides (Figure 1C),
indicating that alkyne modifications N-terminal to targeting sequences were innocuously
chaperoned by peptides and did not affect cell binding.
We next probed the effect of three variables on "click" reaction conditions
between our peptides and an azido-PEG-amine (catalyst, catalyst concentration, and
reaction time). Azido-PEG-amine was chosen to emulate the azido-PEG surface of the
nanoparticles to be used subsequently and to provide a model reaction amenable to HPLC
quantitation of product formation. Copper(I) catalyst was added either directly as an
iodinated salt (Cu(I)I), or indirectly as soluble copper sulfate (Cu(II)S0 4) and reduced by
sodium ascorbate in situ. The degree of product formation was measured via HPLC with
mass spectrometric verification of product identity. The addition of the azido-PEO-amine
rendered peptides more hydrophilic and decreased retention times compared to
unconjugated peptides. As shown in Table 5.1, product formation proceeded more
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Figure 5.3. LyP-1 -conjugated nanoparticles target p32-expressing MDA-MB-435 cells in
vitro, while nanoparticles conjugated to control cyclic peptides (LyP-JCTL) do not
target. (A) The amount of peptide bound per particle was quantified
spectrophotometrically by measuring the absorbance of the TAMRA dyes added
following the click reaction. With the addition of catalyst CuSO4/Na ascorbate (dark
circles), the TAMRA absorbance at 555nm was quantified to equal approximately 30
peptides per particle, whereas no TAMRA signal was observed without catalyst (light
circles). (B) LyP-1-nanoparticles or control LyP-lCTL-nanoparticles (both at -30
peptides per particle), or parent azido-bearing particles (N3), were added to MDA-435-
MB cancer cells in normal 10% serum (dark green) and 0.1% serum-starved (light green)
conditions. Flow cytometry histogram shows marked increase in uptake of LyP-1-
nanoparticles (blue) vs. LyP-1CTL-nanoparticles (green) and particle-free control cells
(red). Each error bar represents 6 parallel experiments. (C) Addition of free LyP-1
peptides at concentrations from 10 to 100 uM inhibited cellular uptake of LyP-1-coated
nanoparticles, suggesting that the LyP-1 peptide and LyP-1-labeled particles target the
same receptor.
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completely in the tested reaction conditions for the heptynoic acid-LyP-1, likely due to
reduced steric hindrance provided by the extended hydrocarbon chain. Optimal reaction
conditions were found to be either: 1 mM CuSO 4 / 5 mM Na ascorbate or 1 mM -100
mM Cul for 72 h. Notably, the reaction yields with 10 mM CuSO 4 levels were
dramatically lower than 1mM, likely due to global precipitation of reduced Cu(I) in
solution. Nevertheless, we found 1mM CuSO4 reactions to yield more reliable
conjugations than 1 to100 mM Cul reactions, possibly because the insolubility of Cul in
aqueous solutions produced variations in the amount of available catalyst delivered to the
reactions. Therefore, the optimal conditions for subsequent nanoparticle modification
were determined to be 1 mM CuSO 4 and 5 mM Na ascorbate. Under these conditions we
did not observe any reduction of peptide disulfide bonds due to copper catalyst or Na
ascorbate reduction as determined by MALDI mass spectrometry and HPLC analysis.
Having verified that alkyne-bearing LyP-1 peptides could effectively target p32-
expressing MDA-MB-435 cancer cells and become linked to azido-bearing PEG
polymers, we next developed a protocol for linking these peptides onto azido-PEG
bearing, near-infrared fluorochrome-labeled (VivoTag 680) iron oxide nanoparticles.
Dextran-caged iron oxide nanoparticles were used as the parent formulation to provide a
highly stable, relatively non-cytotoxic, and in vivo-tested nanoparticle scaffold. Briefly, a
heterobifunctional linker bearing an azide on one end an N-hydroxysuccinimide leaving
group on the other was synthesized and attached to an amine-PEG-thiol polymer (MW
50000 Da) via its terminal amine (Schematic 5.2A, 5.2B). Azido-PEG-thiol polymers
LyP-1CTL-Nanoparticles
Figure 5.4. Tumor cell targeting with LyP-] nanoparticles. LyP-1-nanoparticles target
MDA-MB-435 cancer cells (right). Fluorescence imaging of cells incubated with LyP-1-
nanoparticles showed increased near-infrared fluorescence (red). Uptake of azido-bearing
or scrambled control peptide (LyP-1CTL)-bearing nanoparticles are not visible or show
minor background (left and middle).
were subsequently linked to surface of cross-linked, aminated, and fluorochrome-labeled
dextran-coated iron oxide nanoparticles via the linker N-[y-maleimidobutyryloxy]
succinimide ester (GMBS) (Schematic 5.2C). Long PEG polymers were utilized to carry
pendant azide groups in order to enhance particle circulation time in vivo and to provide a
generalizable nanoparticle surface, whereby optimized "click" attachment conditions
might be applicable to other PEG-coated organic and inorganic nanomaterials in the
future. Azido-PEG particles were purified from excess polymer and linked to alkyne-
bearing peptides in 1 mM CuSO4 , 5 mM Na ascorbate. Finally, the conjugated
nanoparticles were purified and sterile filtered for in vitro and in vivo applications.
N3-Nanoparticles LyP-1 -Nanoparticles
PEG-LyP-1 NPs
Figure 5.5: LyP-1-nanoparticles target MDA-MB-435 cancer cells and become localized
in endosome-like compartments over 24hrs in vitro. Cells were incubated with LyP-1-
nanoparticles for 30min, washed, and incubated for 24hrs before nuclear staining and
imaging. PEG-LyP-1 nanoparticles no longer show diffuse membranous staining, but
have become localized into punctuate compartments, implying endosomal sequestration
away from cell surface
Peptide valency on nanoparticles was assessed spectrophotometrically by quantifying the
number of TAMRA dyes added onto nanoparticles following "click" reaction (Figure
5.3A). In the presence of catalyst, approximately 30 peptides were added per nanoparticle
for both LyP-1 and LyP-lCTL peptides, whereas no addition was observed in the absence
of catalyst (Figure 5.3A). LyP-l nanoparticles, LyP-lCTL nanoparticles, or azide
nanoparticles were incubated over MDA-MB-435 tumor cells for 2 hours and
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Figure 5.6: Probing "Click" Nanoparticle Cytotoxicity to Human Cell Cultures. Human
HeLa cervical cancer cells were incubated with parent NH2-PEG-NPs, PEG-N3-NPs, or
PEG-LyP-lCTL-NPs at varying concentrations for 24 hrs, rinsed, and incubated with
media containing thiazolyl blue tetrazolium bromide (MTT reagent) at 0.5mg/ml. After
3hr, blue precipitates begin to form within cells as a result of mitochondrial activity.
Quantitaion of cellular viability via absorbance of DMSO:isopropanol-solubilized MTT
reagent showed that all three NP peparations have TC50 values of greater than 7mM,
which is over 35-times that used in vitro here (1OOnM NPs used in cell culture and FACS
expts = 0.2mM Fe) and greater than sixteen times the maximum blood concentrations
during in vivo experiments (200nM NP concentration in blood immediately after
injection = 0.4mM Fe).
nanoparticle accumulation was quantified using flow cytometry (Figure 5.3B). LyP-1-
nanoparticles showed significant tumor cell accumulation, while LyP-1CTL-
nanoparticles or azide-nanoparticles displayed minimal cell uptake (Figure 5.3B). The
effect of serum on nanoparticle uptake was also studied, as low serum levels enhance the
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Figure 5.7: Near-Infrared Fluorescence Analysis of LyP-1- and Azido-Nanoparticle
Tumor Accumulation. Near-infrared fluorochrome-labeled nanoparticles bearing terminal
azide groups (red) or LyP-1 peptides (blue) were injected intravenously via the tail vein
into mice bearing human MDA-MB-435 cancer xenografts (4 mice). After particles had
cleared the systemic circulation (24hrs), mice were sacrificed and tumor, liver, spleen,
and kidneys were fluorescently imaged for nanoparticle accumulation (LI-COR
Odyssey). As expected for nanoparticles above the renal filtration limit, clearance was
predominately via reticuloendothelial system uptake (liver and spleen). Nanoparticle
accumulation in tumors was slightly decreased for peptide-modified nanoparticles, likely
due to a decrease in the particle circulation time following cationic peptide attachment
and concomitant decrease in the passive targeting.
stress-induced expression of the p32 receptor (281). The slight increase in LyP-1-
nanoparticle targeting in lower serum levels provided further validation of receptor-
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specific targeting, as decreased serum protein concentrations lowers the likelihood of
non-specific serum protein mediated uptake. To further confirm the uptake specificity of
LyP-1-nanoparticles, free LyP-1 peptide was added to cells along with LyP-1-particles
(Figure 5.3C). Dose-dependent inhibition of uptake was observed with LyP-1 peptide
concentrations from 10 to 100 pM, suggesting the free LyP- 1 and LyP- 1-labeled particles
share common cellular receptors. We attribute the large excess of free peptide required
for inhibition compared to the concentration of nanoparticles used (1 OOnM) to the
presence of multiple copies of the LyP- 1 peptide on each nanoparticle, thus improving
nanoparticle avidity to receptors through polyvalent binding (284). In order to visualize
LyP-1 peptide-mediated cell uptake, nanoparticles bearing pendant LyP-1 peptides,
control LyP-1CTL peptides, or azides were incubated over MDA-MB-435 cells for 30
minutes, washed, incubated with a nuclear stain, and imaged via epifluorescence
microscopy (Figure 5.4). LyP-1-nanoparticles were seen associated with cells, while
markedly less binding of azide-bearing or control peptide-bearing nanoparticles was not
observed. If the same staining procedure was instead performed at 24 hrs post incubation,
LyP-1-nanoparticles were seen in punctate locations consistent with sequestration in
endosome-like compartments (Figure 5.5). To assess the cytotoxicity of "click"
nanoparticles, NH2-PEG-, azido-PEG- and peptide-conjugated nanoparticles were
incubated for 24hrs of incubation above HeLa cell cultures (Figure 5.6). In all three
formulations, the TC50 is >7mM Fe, or over 16 times higher than maximal blood
concentrations during in vivo experiments performed here and 32 times higher than
concentrations used in vitro here.
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Having found that "click" attachment of homing peptides could mediate the
targeting nanoparticles in vitro, we evaluated the ability of "click" chemistry to direct
nanoparticle targeting to specific tumor cells in vivo. Again, near-infrared fluorochrome-
labeled (VivoTag 680) nanoparticles were "clicked" to LyP-1 peptides, resulting on
average of -30 LyP-1 peptides per particle, while the parent azido-PEG nanoparticles
were used as a negative control. Each population of nanoparticles was injected
intravenously into mice bearing human MDA-MB-435 cancer xenografts. Nanoparticles
were allowed to circulate and distribute in mice for 24hrs, after which the mice were
sacrificed and organs collected for immunohistochemical or whole organ fluorescence
analysis. Vascular staining with anti-CD31 antibodies showed that azide nanoparticles in
tumors remained localized within the immediate periphery of blood vessels (Figure
5.8B). This perivascular distribution of untargeted nanomaterials is in agreement with
previous histological and intravital observations of passive liposomal accumulation in
tumors(285, 286). By contrast, LyP-1 "click" nanoparticles appeared to have extravasated
from the tumor vasculature, penetrated into the interstitial space of the tumor, and bound
to p32-expressing cells (Figure 5.8B, 5.8C). As a result, the fraction of LyP-1
nanoparticles that get sequestered beyond the perivascular space was significantly higher
than that of azido-nanoparticles (Figure 5.8D) (P<0.005). This pattern was observed in
all injected mice and is characteristic of LyP-1 peptide and phage homing observed
previously(252). Interestingly, previous LyP-1 bacteriophage experiments showed that
the LyP-1-expressing phage concentrate in non-vascularized sites of tumors within
minutes after injection while insertless phage do not reach these regions(252). Thus, there
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Figure 5.8: "Click" LyP-1-nanoparticle targeting to tumor cells in vivo. Nanoparticles
bearing only azide groups (top) or labeled with LyP-1 peptides (bottom) that are matched
in circulation time were injected intravenously via the tail vein into mice bearing human
MDA-MB-435 cancer xenografts. Histological sections were obtained 24 hours post
injection. (A) Light reflectance images of mice bearing the tumor xenografts. (B)
Fluorescent LyP-1-nanoparticles (VT680 fluorescence pseudocolored as green) did not
colocalize with CD31, a blood vessel marker (red) while untargeted azide-PEG
nanoparticles remained localized to the blood vessels or their immediate periphery. (C)
LyP-1-nanoparticles (green) accumulated in regions of high p32 expression (red),
whereas untargeted, azido-bearing nanoparticles did not accumulate in these areas. D)
Histological quantitation using CD31 stain to assess nanoparticle localization to
immediate periphery of blood vessels. The fraction of LyP-1 nanoparticles outside of the
perivascular space of CD31-stained blood vessels is significantly higher than azido-
nanoparticles (P<0.005) as assessed from 3 randomly chosen views in each set of mice
(n=-3). Together, LyP-1-coated nanoparticles penetrate into the tumor interstitium to
target p32-expressing cells.
may be unique transportation pathways within tumors that are exploited by this ligand
after extravasation that are not available to untargeted materials. In the future, the
localization of LyP-1 nanoparticles in avascular tumor regions may be of use for
directing therapeutics into hypoxic regions of tumors, where most nanoparticle therapies
do not reach. Whole organ assessment of near-infrared tumor fluorescence demonstrated
that, despite the distinct microscopic behavior of LyP-1 nanoparticles, the macroscopic
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tumor accumulation of LyP-1 nanoparticles and PEG-azide nanoparticles was similar
(Figure 5.7), indicating that the targeted accumulation of LyP- 1 -nanoparticles was on par
with passive delivery, whereby long-circulating materials accumulate in tumors via their
hyper-porous vasculature over time(287, 288). These results are in accordance with data
showing that the development of targeted nanoparticle formulations that amplify the
macroscopic accumulation in tumors requires systematic in vivo optimization of multiple
material parameters, including target avidity, circulation time, and particle size(150, 289).
Experiments of this kind are ongoing in order to probe the power of the LyP-1 targeting
ligand for amplifying the accumulation and efficacy of nanoparticle-based imaging and
therapeutic agents.
5.3 Conclusions:
In this work, we have demonstrated that "click" chemistry may be used to develop
nanoparticles that seek out specific cells in vivo based on their surface expression of
protein markers. Ultimately, these findings suggest that "click" chemistry meets the
criteria of being applicable under aqueous conditions, efficient, orthogonal to thiol- and
amine-containing targeting motifs, and stable in the complex in vivo environments of the
blood and tumor milieu. In the future, this work may empower the development of
"click" nanomaterials that seek out specific tumor cell types, including tumor stem cells
and angiogenic endothelial cells, or amplify the macroscopic accumulation of imaging
agents or therapeutics in tumors. Further, the modularity of this "click" attachment
strategy should allow it to be adapted to a diversity of in vivo nanoparticle platforms and
both biological and synthetic ligands, potentially empowering novel on-nanoparticle
screen approaches to targeted nanomaterial development.
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5.4 Materials and Methods:
Unless otherwise stated all reagents were purchased from Sigma-Aldrich and all
reactions were performed at room temperature.
Iron Oxide Nanoparticle Synthesis. Cross-linked, amininated, fluorescent,
superparamagnetic iron oxide nanoparticles were synthesized according to the published
protocol (241, 243). Briefly, dextran-coated iron oxide nanoparticles were synthesized,
purified, and subsequently cross-linked using epichlorohydrin. After exhaustive dialysis,
particles were aminated by adding 1:10 v/v ammonium hydroxide (30%) and incubated
on a shaker overnight. Aminated-nanoparticles were subsequently purified from excess
ammonia using a Sephadex G-50 column and concentrated using a high-gradient
magnetic-field filtration column (Miltenyi Biotec). The near infrared-fluorochrome
VivoTag 680 was added to remotely detect particle accumulation in vitro and in vivo by
reacting in 0.1M HEPES buffer with 0.15M NaCl at pH 7.2. DMSO-solubilized
fluorochromes were added into particle solutions at 4'C under mixing and allowed to
warm to room temperature to react for 2 hours. The yield was approximately 10
fluorochromes per nanoparticle for all experiments.
Succinimidyl 4-azidobutyrate synthesis (Schematic 5.2). Ethyl 4-azidobutyrate
(1). To a solution of ethyl 4-bromobutyrate (5.85 g, 30 mmol) in dimethyl sulfoxide
(DMSO, 20 ml), sodium azide (2.925 g, 45 mmol) was added with stirring. The reaction
mixture was stirred for 22 hrs at 55 'C, and cooled to room temperature. Water was added
to the reaction mixture and extracted with ethyl ether (3 x 30 ml). Combined organic
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layer was washed with water and brine, and reduced in vacuuo to afford 3.80 g of the
azido compound 1.
4-Azidobutyric acid (2). Ethyl 4-azidobutyrate 1 (3.14 g, 20 mmol) was dissolved
in aqueous sodium hydroxide solution (1 N, 24 ml) with minimum amount of methanol to
make the solution homogeneous. The reaction mixture was stirred for 3 hrs at room
temperature. After removal of methanol in vacuo, the aqueous solution was acidified to
pH 0 with HCI and extracted with ethyl ether (3 x 50 ml). The ether layer was then dried
over sodium sulfate and filtered. Removal of solvent gave the acid 2 (2.25 g).
Succinimidyl 4-azidobutyrate (3). To a solution of N-hydroxyl succinimide (1.65
g, 14.3 mmol) in methylene chloride (100 ml) was added acid 2 (1.68 g, 13 mmol)
followed by 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDAC,
2.74 g, 14.3 mmol). After stirring for 4 hrs at room temperature, the reaction mixture was
washed with water and brine, dried over sodium sulfate, and filtered. Solvent was
removed under reduced pressure to yield 1.15 g of the succinimidyl 4-azidobutyrate 3.
Peptide Synthesis. Peptides were synthesized in the MIT Biopolymers Lab and
their composition was confirmed via HPLC and mass spectrometry. The LyP-1 and LyP-
1 CTL peptides were synthesized with either heptynoic acid or propargylglycine at the N-
terminus for conjugation. Each peptide is also labeled with a TAMRA fluorophore
(Anaspec) via a lysine residue separated by an aminohexanoic acid (Ahx) spacer. (final
sequence for LyP-1: Heptynoic acid or propargylglycine - K(Tamra)[Ahx] -
CGNKRTRGC; for LyP-1CTL: Heptynoic acid or propargylglycine - K(Tamra)[Ahx] -
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CRVRTRSGC). Peptides were cyclized by bubbling air into 10 pM aqueous peptide
solutions overnight. Finally, peptide solutions were lyophilized for subsequent use.
"Click" attachment of peptides to nanoparticles. Succinimidyl 4-azidobutyrate
was linked to 5kDa thiol-PEG-amine polymers in 0.1 M HEPES 0.15M NaCl pH 7.2 for 1
hour at a 2:1 molar ratio between linker and polymer. Simultaneously, amino-modified,
fluorochrome-labeled nanoparticles were activated with N-[y-maleimidobutyryloxy]
succinimide ester (GMBS) (dissolved in DMSO) cross-linker under similar conditions at
a 200:1 molar ratio between cross-linker and nanoparticles. To remove excess GMBS,
nanoparticle samples were filtered on a G50 column into 50mM Na Phosphate buffer at
pH 7.2 supplemented with 10mM EDTA. Purified nanoparticles were then combined
with the polymer reaction mixture and allowed to react at room temperature overnight.
Azido-PEG-nanoparticles were then purified from excess polymer and succinimidyl 4-
azidobutyrate on a size exclusion column (ACA-44 media: Pall) into 0.1 M HEPES pH
7.2 buffer. Finally, the azide-PEG-bearing particles were concentrated using Amicon
Ultra-4 (Millipore) filters and stored at 4'C.
To optimize catalyst concentrations for the "click" reaction by HPLC, a 10-fold
excess of azido-PEG-NH 2 or 0-(2-Aminoethyl)-O'-(2-azidoethyl)pentaethylene glycol
(Polypure) was added to a 100 pM peptide solution. CuSO 4 and Na ascorbate were
dissolved in H20 and added to the reaction mixture to final concentrations of 1 mM/5
mM and 10 mM/50 mM CuSO4/Na Ascorbate. This mixture was shaken at 370 C for
various times (1 day to 3 days), after which it was characterized via HPLC.
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Alkyne-bearing peptides (35:1 peptide:nanoparticle molar ratio), CuSO4 (1 mM),
and sodium ascorbate (5 mM) in H2 0 were added to a solution of particles and the
mixture was shaken at 37'C for 48 h. Following the reaction, nanoparticles were purified
from copper catalyst and excess peptides by filtration in ACA-44 size exclusion media
into 0.1M HEPES 0.15M NaCl pH 7.2 buffer.
Cell Culture. Cell uptake experiments were performed using a human MDA-MB-
435 cancer cell line. Grow media was minimum essential medium eagle (Invitrogen) with
fetal bovine serum (10%; Invitrogen). Cells were passaged into 96-well plates and used at
60-80% confluency.
For peptide uptake experiments, LyP- 1 or LyP- 1 CTL peptides were added to cell
monolayers in serum-containing media at a final concentration of 10 pM. After 45
minutes of incubation at 37 'C, cells were washed with media, PBS, treated with trypsin
(0.25%) and EDTA, and resuspended in 1% BSA (in PBS) for flow cytometry (BD
LSRII). Fluorescence data on 10,000 cells was collected for each sample.
For nanoparticle uptake experiments, particles bearing an LyP-1, LyP-1CTL, or
terminal azides were added to the cells in serum media at a final concentration of 100
nM. After 2 h of incubation, cells were trypsinized and assayed for particle fluorescence
by flow cytometry. For peptide inhibition experiments, free LyP-1 peptides (10 pM to
100 pM) were first incubated with the cells for 1 h. The cells were then washed with
media and 100 nM of LyP-1-coated nanoparticles were added to the cell culture. For
imaging, cells were washed with PBS and observed using a 20x objective. Images were
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captured with a CCD camera mounted on a Nikon TE200 inverted epifluorescence
microscope.
In vivo Studies of Nanoparticle Targeting. Nude athymic mice were inoculated
subcutaneously with human cancer cells (MDA-MB-435). After tumors had reached ~.5
cm3 in size, LyP-1- and azide-bearing nanoparticles were injected intravenously in the
tail vein (lmgFe/kg). Twenty-four hours after the injection, tumor tissues were excised,
snap frozen, and cut into 15 pm histological sections. Rat anti-mouse CD-31 (1:50, BD
Pharmingen) and polyclonal anti-p32 antibody (1:200; (282)) were used for
immunohistochemical staining of frozen tissue sections. The corresponding secondary
antibodies were added and incubated for 1 hour at room temperature: Alexa Fluor 594
goat anti-rat IgG (1:500, Invitrogen) for CD-31 and Alexa Fluor 594 goat anti-rabbit IgG
(1:500, Invitrogen) for p32 antibody. The slides were washed three times with PBS and
mounted in Vectashield Mounting Medium with DAPI (Vector Labs). The stained tumor
sections were observed with a fluorescence microscope (Nikon, Tokyo, Japan).
Histological quantitation of nanoparticles localization was done using ImageJ software.
Stacks of CD31-stained sections and nanoparticle fluorescence images were utilized for
intra- and extravascular particle distribution quantitation. Regions with CD31-staining
were selected to denote intravascular accumulation of nanoparticles and surrounding
areas were classified as extravascular. The net nanoparticle fluorescence signal above
background was quantified for each of these regions to determine the approximate
percent of nanoparticle fluorescence localized to the vasculature vs the extravascular
space. Three sections from each set of mice were randomly chosen for analysis.
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Chapter 6: Development of a Novel Building Block for In
Vivo Nanosystem Construction: Gold Nanorod Antennas
for Ultra-Sensitive Photothermal Tumor Therapy
6.1 Introduction:
The electromagnetic properties of plasmonic nanomaterials have been harnessed
to develop ultra-sensitive diagnostic(37, 38), spectroscopic(39, 40), and, recently,
therapeutic technologies(41-44). In particular, tunable plasmonic nanomaterials have
attracted attention for their immense optical absorption coefficients and potential as
injectable nanoantennas that target tumors and locally convert otherwise benign
electromagnetic energy to thermal energy for ablation. Currently, tumor ablation
approaches in clinical practice, including radio frequency, laser, and focused ultrasound
methods, lack intrinsic tumor specificity to energy absorption. The inability to selectivity
heat tumor tissues over surrounding compartments necessitates efforts to externally direct
applied energy towards tumor tissues, making effective treatment of tumor margins and
complex tumor geometries very challenging. By providing a tumor-specific heat source,
nanoantennas could considerably broaden the clinical applicability of thermal therapies
by simplifying their integration with current therapeutic practices (including improving
margin clearance in surgery and synergizing with regional radiation therapies) and
reducing morbidity due to off-target heating. Further, by pulsing the external energy
source used, tumor-targeted nanoantennas can theoretically ablate with single-cell
precision, thereby providing improved accuracy over standard surgical methods and
opening the possibility of precisely treating complex tumor margins in sensitive tissues.
To date, preparations of gold nanoshells and nanorods have shown considerable efficacy
for tumor ablation using NIR-light(41, 42, 48, 107), with the most recent data showing
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complete resorption of -55% and -25% of irradiated tumors, respectively(108, 109).
These results highlight the clinical promise of these technologies and also motivate the
further development of superior nanomaterials and improved methods for optimizing
irradiation regimens, which could synergistically improve photothermal therapies. From a
material perspective, the development of nanoantennas with enhanced circulation times
in vivo, increased absorption coefficients per weight, and narrower absorption spectra
would more efficiently permeate into tumors after intravenous administration, amplify
the photothermal contrast between antennas and normal tissue, and allow improved tumor
treatment at lower laser intensities or at greater depths in vivo. From a procedural
perspective, despite a rich history of heat transfer modeling in the hyperthermia field, the
use of quantitative modeling to predict the in vivo function of plasmonic nanomaterials
has widely remained absent from their testing(41, 42, 48, 108, 109). Because the efficacy
of photothermal therapy is driven by both the potency of nanoantenna absorption in
tumors and the dose of near-infrared irradiation, translation of plasmonic materials to
effective clinical use will benefit from cohesive integration of biodistribution data with
photothermal modeling to predict and customize the 4D irradiated temperature profiles in
tumors.
Recently, rod-shaped gold nanoparticles have emerged as precisely-tunable
plasmonic nanomaterials that may be synthesized in bulk, have narrow size distributions,
optical absorption coefficients 104-10 6-fold higher than conventional organic
fluorochromes, and theoretical per micron absorption coefficients exceeding those of
NIR-absorbing gold nanoshells(6, 46, 290). The long precedence of gold nanoparticles in
clinical rheumatoid arthritis therapies, make gold nanorods (NRs) appealing new
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candidates for nano-antenna-based photothermal ablation and a wide array of other
biomedical applications. Already, gold NRs have been utilized for a diversity of
biological purposes, including multiplexed in vitro detection(291), two-photon
fluorescence imaging(292), and photothermal heating of tumor and bacterial cell
targets(43, 44, 109, 293-295). In addition to their plasmon resonance, the superior atomic
number and high material density of gold nanomaterials (z=79, p=19.3 g/cm 3) compared
to clinical formulations of iodine-based reagents (z=53) have attracted interest for x-ray
CT angiography and a few spherical nanoparticle reagents have been developed for in
vivo use(29, 65).
Here, we describe the development of PEG-coated gold NRs as highly-absorbing
nanoantennas for photothermal tumor destruction under the guidance of biodistribution-
based photothermal modeling. We chose a PEG polymer coating, due to the widespread
clinical use of variable length PEG polymers for extending the circulation time of protein
therapeutics(296, 297) and for nanoparticle formulations, such as the drug-loaded
liposomes: DoxilTM. We find that PEG-NRs are highly stable, relatively non-cytotoxic in
vitro, superior photothermal antennas compared to a gold nanoshell preparation in vitro,
and are improved x-ray absorbing agents compared to a clinical iodine standard.
Following intravenous administration, we find PEG-NRs to be among the longest
circulating inorganic nanomaterials described to date (t 12 '~17 hrs) allowing passive
accumulation into xenograft tumors. Using 4D biodistribution-based heat-transfer
simulations, we designed a therapeutic irradiation regimen that was able to fully destroy
all irradiated tumors on mice injected with PEG-NRs, using half the light intensity of
previous nanoshell therapies.
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Figure 6.1: Structure and synthesis of highly absorbing, polyethylene glycol (PEG)-
protected gold nanorods. A) Near-infrared absorbing (810 nm longitudinal plasmon
resonance peak) gold nanorods were imaged via transmission electron microscopy
(TEM). B) Schematic of process to drive CTAB-nanorod conversion to PEG-nanorods
under dialysis with rendering and molecular schematic of PEG coating on nanorod
surface C) PEG-nanorods show prolonged stability in biological media (>1000 hrs) while
CTAB-coated nanorods precipitated over time.
6.2 Results and Discussion:
In principle, gold nanoparticles are attractive for medical applications because various
formulations have been approved by the Food and Drug Administration (FDA) and in
clinical use for decades. However, one barrier facing the widespread biological use of
gold nanorods has been the need to replace the cationic cetyl trimethylammonium
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Figure 6.2: PEG-Nanorod Synthesis and Stability In vitro. A) The plasmon resonance of
gold nanomaterials is highly sensitive to aggregation-mediated red-shifting. By
monitoring plasmon resonance peak over >1000 hrs in biological solutions, we find that
PEG-nanorods show prolonged stability in biological media while CTAB-coated
nanorods aggregated over time in PBS (0.15 M NaCl 0.1 M Na Phosphate, pH 7.2) or
10% human serum monitored for over 1000 hrs in vitro. B) PEG-NRs were readily
dispersed in a variety of solvents, including acetone, acetonitrile, dimethyl sulfoxide
(DMSO), dimethylformamide (DMF), ethanol, methanol, or PBS.
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Figure 6.3: Probing Nanorod Cytotoxicity to Primary Rat Hepatocyte cocultures. A)
Primary rat hepatocyte: 3T3-J2 human fibroblast co-cultures were incubated with PEG-
NRs at varying concentrations for 24 hrs (left column), rinsed, and incubated with media
containing thiazolyl blue tetrazolium bromide (MTT reagent) at 0.5 mg/ml. After lhr,
blue precipitates begin to form within hepatocytes as a result of mitochondrial activity
(right column). B) Microscopy shows cultures incubated with PEG-NRs at maximal
concentrations to show similar morphology to controls. C) Quantitaion of cellular
viability via absorbance of DMSO:isopropanol-solubilized MTT reagent shows no
cytotoxicity of PEG-NRs, even at concentrations of 20-times that used in vitro here and
approximately equal to maximum blood concentrations during in vivo experiments.
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Figure 6.4: Spectral and photothermal properties of highly-absorbing gold nanorods
compared to gold nanoshells. A) Schematic of photothermal heating of gold nanorods.
The dimensions of gold nanorods are tuned to have a near-infrared plasmon resonance, at
which point nanoparticle electrons resonantly oscillate and dissipate energy as heat. B)
Spectra for PEG-gold nanorods (red) and PEG-gold nanoshells (blue), a benchmark for
tunable plasmonic nanomaterials, at equal gold concentrations. C) Rate of temperature
increase for triplicate PEG-nanorod and PEG-gold nanoshell solutions (7 pig Au/mL, 810
nm laser, 2 W/cm2, n=3 each) (top). Infrared thermographic image of PEG-nanorods vs
PEG-gold nanoshells following 2 minutes of irradiation (scale bar=5 mm) (bottom). D) In
vitro photothermal toxicity of PEG-nanorods over human cancer cells in culture (MDA-
MB-435). Tumor cells were incubated with PEG-nanorods (14 pg/mL; above), PEG-
nanoshells (14 pg/mL; middle), or media alone (below) and treated with laser irradiation
(2 W/cm2 , 810 nm, 5 min) Calcein AM staining indicates destruction of cells with PEG-
nanorods, while cells irradiated in the presence of nanoshells or media remained viable.
Phase region of calcein staining inset (all scale bars=10 pm).
bromide (CTAB) surfactants used to drive their anisotropic growth with hydrophilic,
biocompatible coatings. We found that NRs, with axial sizes of 12.7 nm (+/- 3.4) and 47
n (+/- 9.3) (Figure 6.1A), coated in CTAB are cytotoxic and colloidally unstable in 0.15
M NaCl or 10% human serum (Figure 6.1 B, 6.1 C). After PEGylation (Figure 1 B), gold
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NRs contained -20,000 polymers per particle by the SPDP assay(298) and were rendered
highly stable in vitro, showing minimal spectral shifting, which would indicate particle
destabilization and aggregation, even after >1000 hours in 0.15 M NaCl or 10% human
serum (Figure 6.1C, 6.2). Additionally, PEG-NRs could be dispersed in a variety of
solvents, including acetone, acetonitrile, DMSO, DMF, ethanol, and methanol, further
highlighting the stability of their coating and their amenability to future chemical
processing and functionalization (Fig. 6.2). After 24 hrs of incubation above primary rat
hepatocyte co-cultures, an in vitro liver model that was previously used to elucidate
semiconductor quantum dot toxicity(59) and has shown utility for rank-ordering
pharmacological toxicities(299), PEG-NRs displayed no significant alterations in
mitochondrial activity compared to saline alone, even at doses 20 times above that used
over cells in vitro here and equal to maximal blood concentrations during in vivo therapy
experiments (Figure 6.3), highlighting their potential biocompatibility for medical
applications.
In light of the prior utility of gold nanoshells for photothermal tumor therapy, they
were used as a benchmark here to evaluate the photothermal performance of PEG-NRs
(Figure 6.4A, 6.4B). PEGylated Nanoshell preparations with similar composition and
spectra to those used for photothermal in vivo applications (41, 42, 48) (~120 nm silica
cores and ~15 nm gold shells, 810 nm peak plasmon resonance; Figure 6.4B). PEG-NRs
exhibited <1/3 the spectral bandwidth and -3 times higher extinction coefficient per gram
gold than PEG-nanoshells (FWHM of PEG-NRs: 130 nm; PEG-nanoshells: 490 nm)
(Figure 6.4B). Additionally, under identical experimental conditions, irradiated PEG-NR
solutions generated heat >6 times more rapidly than PEG-nanoshells per gram gold
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(Figure 6.4C). These findings are consistent with theoretical calculations indicating that
gold nanorods of this size exhibit superior per micron absorption coefficients to gold
nanoshells(290). Accordingly, incubation of PEG-NRs with MDA-MB-435 human tumor
cells in vitro enabled their widespread destruction with levels of NIR-light that were
insufficient for nanoshell-mediated toxicity (Figure 6.4D). Exposure to individual
stimuli: NRs, nanoshells, or laser; did not affect cell viability.
In order to translate the photothermal efficacy of PEG-NRs to in vivo therapy, we
next developed a method through which PEG-NRs could be heated under the guidance of
biodistribution-based computational photothermal modeling. To model and customize
patient irradiation regimens, we sought to acquire nanoparticle distributions remotely
using x-ray CT, a desirable imaging modality due to its high 3D anatomical resolution,
rapid imaging speed, quantitative dynamic range of detection, full body penetration, and
ubiquitous clinical use. To investigate the ability of PEG-NRs to act as dense x-ray
absorbing agents for x-ray CT, solutions of PEG-NRs were serially diluted and imaged
using a GE microCT scanner (Figure 6.5A). The resulting relationship between PEG-NR
concentration and x-ray contrast was highly linear and exhibited -2-fold amplified x-ray
contrast compared to a clinical iodine standard per mole (Figure 6.5B, Figure 6.6A),
analogous to that found previously for spherical gold nanoparticle reagents(29, 65). In
addition to providing enhanced x-ray absorption, PEG-NRs allow NIR photothermal
heating, while iodine reagents show no heating above water alone (Figure 6.6B,C).
To assess the utility of the high x-ray absorption of PEG-NRs for remote
detection in vivo, -3 pmoles of PEG-NRs (-4 pmole Au) were directly injected into the
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Figure 6.5: X-ray computed tomography, quantitative photothermal modeling, and near-
infrared photothermal heating of gold nanorods in vivo. A) Schematic of x-ray
absorption by gold nanorods in x-ray CT. B) X-ray CT number of PEG-nanorods
compared to an iodine standard (Isovue-370) C) PEG-nanorods were intratumorally
administered to mice bearing bilateral MDA-MB-435 tumors and imaged using x-ray CT
to visualize 3D PEG-nanorod distribution in tumors (left). A 3D solid model of the
complete geometry was rapidly reconstructed by image processing for use with
computational photothermal modeling (middle, red=PEG-nanorods). Experimental
thermographic surveillance of NIR-irradiation after x-ray CT (-.75 W/cm2, 1 min) (right)
D) Meshed geometry of the left tumor chosen as the computational domain (left). Plot of
theoretical heat flux propagation inside the tumor upon irradiation (middle-left).
Predicted internal temperature distribution at 3 different planes inside the tumor (middle-
right) along with surface temperature map (right) matching the left tumor in C)
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Figure 6.6: X-ray Absorption, Optical Spectra, and Photothermal Comparison between
PEG-Nanorods and Clinical Iodine X-ray Computed Tomography Reagent. A) X-ray
computed tomography number of PEG-nanorods compared to an iodine standard (Isovue-
370). Linear x-axis plot of the same data presented in Figure 2B, clarifying linearity of
PEG-gold nanorod detection via x-ray CT B) Optical extinction spectra of PEG-
Nanorods (0.045 mg/ml Au) vs solution of an iodine-based clinical regent (350 mg/ml
iodine) and saline. Notably, iodine reagents lack absorbance in the near-infrared that
could allow remote photothermal heating. B) Photothermal heating comparison between
PEG-Nanorods, iodine, and saline monitored using infrared thermography (810 nm NIR
light, 2 W/cm2).
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Figure 6.7: Linking PEG-Nanorod X-ray Tomography with Computational Modeling. A)
Transverse and sagittal slices showing PEG-Nanorod distributions following intratumoral
administration into bilateral breast tumors B) 3D reconstructions depicting geometry of
PEG-NR injections C) hnportation of 3D x-ray CT data into geometries for 4D
photothermal modeling (red= PEG-nanorods, white=skeletal structure).
tumors of mice bearing bilateral human MDA-MB-435 tumors, implanted either in the
mammary fat pad or the rear flank. We found that x-ray CT rapidly detailed the 3D
distribution of PEG-NRs in tumors, showing clear distinction between NRs and soft
tissues (Figure 6.5C, 6.7, 6.8). To understand the relationship between the nanoparticle
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Figure 6.8: X-ray CT-Fused Computational Modeling of Photothermal Tumor Heating.
A) X-ray CT image of PEG-Nanorod distribution in tumor B) A 3D solid model of the
complete geometry was reconstructed by image processing for use with computational
photothermal modeling. C) Meshed geometry of the injected tumor chosen as the
computational domain with laser orientation and intensity matching that used (1 W/cm2)
(laser direction signified by curved arrows) D) Plot of theoretical surface temperature
distribution (left) and the internal predicted temperature profiles inside the computational
geometry of the tumor (right) 240 sec following the onset of irradiation. E) Graphical
comparison between simulated and thermographically measured maximum surface
temperatures over time after the onset of irradiation.
distribution in tumors and the associated processes of thermal deposition and flux during
irradiation, a finite element model of PEG-NR heating was developed based on the
Pennes bioheat transfer equation, including: 1) 3D skeletal, soft tissue, and PEG-NR
geometries transferred from x-ray CT imaging; 2) Temperature-dependent optical
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absorption and scattering 3) Heat transfer, including surface thermal flux, internal
diffusive flux, and temperature-dependent perfusive thermal flux in tissues; and 4) an
extracorporeal NIR-laser of variable intensity, beam diameter, and orientation matching
that used (see Materials and Methods). X-ray CT data was exported into ScanIP and
ScanFE image processing softwares for skeletal, nanorod, and soft tissue geometry
construction and subsequently into COMSOL Multiphysics modeling software for
photothermal simulations. Exported geometries enabled rapid delineation PEG-NRs
along with skeletal structures and surrounding soft tissues for spatially defining model
parameters (Figure 6.5C, 6.7, 6.8). Computational, finite element heat transfer
simulations were performed using PEG-NRs and tumor geometries as computational
domains to evaluate the feasibility of applying 4D modeling to the process of
photothermal heating under irradiation (Figure 6.5D, 6.8). Simulations revealed the
intratumoral vectors of thermal flux extending from regions of PEG-NRs as well as the
internal and surface temperature history expected for irradiation at varying laser
intensities (Figure 6.5D, 6.8). At matched computational and experimental laser
intensities, simulated surface heating behavior qualitatively and quantitatively matched
the observed surface temperature values and distributions acquired using infrared
thermographic observation (Figure 6.5D, 6.8). We believe this establishes the potential
of fusing quantitative imaging with computational modeling to provide insight into the
unintuitive, highly complex phenomena of in vivo photothermal heating. Next, we
proceeded to explore the power of this modeling to quantitatively predict in vivo heating
following intravenous tumor targeting.
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Figure 6.9: Long circulation time, passive tumor targeting, and photothermal heating of
passively-targeted gold nanorod antennas in tumors. A) PEG-nanorods were
intravenously administered (20 mg/kg) to 3 mice bearing MDA-MB-435 tumors and
blood was withdrawn over time to monitor clearance from circulation. B) PEG-nanorod
biodistribution and targeting to MDA-MB-435 tumors 72hrs following intravenous
administration, quantified via ICP-MS (3 mice). (T--tumor, Br=brain, Bl=bladder,
M=muscle, H=heart, Lu=lung, K=kidney, Li=liver, Sp=spleen) (Data is tabulated in STI)
C) PEG-nanorods or saline were intravenously administered (20 mg/kg) to mice bearing
MDA-MB-435 tumors on opposing flanks. After nanorods had cleared from circulation
(72 hrs after injection) the right flank was irradiated using an 810nm diode laser (2
W/cm 2 ; beam size indicated by dotted circle). D) Thermographic surveillance of
photothermal heating in PEG-NR-injected (top) and saline-injected (bottom) mice.
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Figure 6.10: Assessing PEG-NR concentration in plasma via plasmon resonance peak
height. A) PEG-NRs at various concentration were diluted into plasma and
spectrophotometrically analyzed to assess NR concentration via the NIR plasmon
resonance peak. NRs could be rapidly quantified between ~0.2 mg/ml (the approximate
concentration in plasma immediately following injection in mice) and -0.02 mg/ml. B)
Following injection, this method could be applied to rapidly detect PEG-NRs in the
plasma of injected mice over time, showing that PEG-NRs maintain their plasmon
resonance throughout their blood circulation in vivo.
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Figure 6.11: Assessing PEG-NR concentration in organs via ICP-MS Au quantitiation.
PEG-NRs at various concentration were diluted into buffer or into glass vials containing
200 mg sections of liver. Samples were all prepared for ICP-MS quantitation to assess
the linearity of Au detection and whether the presence of organs affected quantitation.
The samples were made to approximate a range of -2% to 70% ID/g for 200 mg tissues.
Results are plotted for triplicate samples and plotted against the ideal relationship of y=x.
We next investigated the behavior of PEG-NRs following intravenous
administration in mice in order to systemically target tumors through the enhanced
permeability and retention (EPR) effect(14). For PEG-NRs to passively target tumors via
the EPR effect and act as nanoantennas for photothermal therapy, they must be able to
traverse the systemic circulation, deter protein opsonization and reticuloendothelial
system (RES) clearance, permeate through transendothelial pores in tumor blood vessels,
and be retained in the tumor interstitium. Following intravenous administration to tumor-
bearing mice (20 mg Au/kg), our PEG-NRs were found to exhibit blood half-lives of-17
hrs (Figure 6.9A) and to maintain their 810 nm longitudinal plasmon resonance
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throughout this time, allowing spectrophotometric detection in serum over time (Figure
6.10).
To quantitatively assess tumor accumulation of PEG-NRs, nude mice bearing
MDA-MB-435 human tumors were intravenously administered with PEG-NRs and, once
NRs had cleared from circulation (72 hrs), organs were removed for gold quantitation.
Here, inductively-coupled plasma mass spectrometry (ICP-MS) was used to quantify the
accumulation of exogenously-administered gold in tissues. ICP-MS Au NR detection was
found to be highly sensitive and linear across a relevant range for gold NR detection
(Figure 6.11). As expected for nanomaterials above the renal filtration limit, PEG-NRs
were found to clear via RES uptake with splenic clearance dominating hepatic (Figure
6.9B), a pattern analogous to that observed previously for PEG-protected 10 nm diameter
spherical gold nanoparticles(65). Importantly, passive tumor accumulation of PEG-NRs
after injection was found to be highly efficient, even at 72 hrs post injection,
accumulating at -7% ID/g (Figure 6.9B), allowing PEG-NRs to amplify the tumor
absorption coefficient of 810 nm light by -7 fold. Based on empirical studies of passive
tumor targeting, the enhancement of the PEG-NR circulation time over reported PEG-
nanoshell formulations should amplify their passive tumor accumulation in tumors,
which, in concert with their enhanced photothermal heat generation in vitro, would be
expected to provide overall enhanced photothermal contrast between tumors and normal
tissue. However, as PEG-nanoshells are not commercially available, a side-by-side in
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Figure 6.11: PEG-NR biodistribution in tumor-free mice at 2 months following
intravenous injection. PEG-nanorod biodistribution 2 months following intravenous
administration, quantified via ICP-MS (3 mice). Percent values indicate the clearance (or
decrease in %ID/g) that occurred during this time period compared to values of organs
collected 72 hrs after particle injection (Br=brain, Bl=bladder, M=muscle, H=heart,
Lu=lung, K=kidney, Li=liver, Sp=spleen).
Figure 6.12: Compuatational domain for modeling photothermal therapy following
intravenous administration of PEG-Nanorods. For intravenous photothermal modeling, a
cylindrical domain of 20 mm diameter around the tumor with a depth of 12 mm for the
muscle domain was considered for computation. The outer shell of the tumor was
considered to be of 0.5 mm thickness.
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Figure 6.12: Quantitative photothermal modeling of gold nanorod tumor heating A) 3D
finite element modeling of PEG-nanorod heating in vivo. Simulated 3D temperature
distributions matching thermographic time points in 4D) are shown for PEG-nanorod
(top) and control tumor irradiation (bottom). B) Thermographically measured and
simulated tumor surface temperatures over time for irradiation of PEG-nanorod or saline
mice. C) Simulated temperature increases various depths for PEG-nanorod- and saline-
injected mice. By 5 minutes following the onset of irradiation, the entire PEG-nanorod
tumor is predicted tumor to have reached ablative temperatures of >60 C, motivating the
choice of this irradiation regimen for subsequent therapeutic trials.
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vivo comparison could not be pursued. Separately, to study the long-term clearance of
PEG-NRs from RES organs, tumor-free mice were injected with PEG-NRs and sacrificed
two months after injection. During these two months, injected mice showed no signs
overt NR toxicity such as weakness, belabored breathing, or failure to thrive. Organ
analysis demonstrated that the %ID/g values for tissues decreased by >50% in all organs
and by >80% in muscle, heart, lungs, and kidneys (Figure 6.11), indicating the existence
of routes for gold nanorod clearance after uptake in tissues.
Having observed their efficient passive homing to human tumors via the EPR
effect, the ability of PEG-NRs to remain active as optical nanoantennas for photothermal
tumor heating after clearance from the systemic circulation (~72 hrs) was subsequently
investigated. Either PEG-NRs (20 mg Au/kg) or a saline solution was administered
intravenously into mice bearing two MDA-MB-435 tumors on opposite flanks. Once
PEG-NRs had cleared from circulation (72 hrs), irradiated tumors on PEG-NR-injected
mice rapidly heated to temperatures of over 70'C (Figure 6.9C, 6.9D), whereas saline-
injected mice displayed less focal temperature increases with maximum surface
temperatures of approximately 40"C (Figure 6.9D). To inform the development of near-
infrared radiation doses that would fully destroy tumors, photothermal heating
simulations were again conducted using the intravenous biodistribution data and
computational domains containing ellipsoidal tumor geometries matching those used in
experiments (Figure 6.11). Photothermal heating simulations closely matched
experimental surface temperature data (Figure 6.9D, Figure 6.12A, Figure 6.12B),
suggesting that tumor-targeted nanoantennas substantially retained their photothermal
efficacy during the 72 hrs after injection in vivo. Further, the simulations predicted that
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the entire tumor volume, including the deepest tumor:tissue interface, would be heated to
ablative temperatures (>60'C) by 5 minutes following the onset of laser irradiation
(Figure 6.12C). Thus, a 5 minute, 2 W/cm 2 irradiation regimen was utilized for
subsequent therapeutic experiments in an effort to provide fully destructive photothermal
tumor treatment.
To test the prediction that a single dose of PEG-NRs could destroy tumors under
the computationally-designed protocol of NIR irradiation, nude mice bearing bilateral
human MDA-MB-435 tumors were injected with either PEG-NRs or saline. Following
intravenous clearance of PEG-NRs, the right flank of each mouse was irradiated for 5
min (810 nm, 2 W/cm2) and all tumors were measured at regular intervals over time.
Within 10 days all the irradiated, PEG-NR-targeted tumors completely disappeared by
external observation, while all other tumors, including those exposed to laser after saline
injection, continued to grow uninhibited (Figure 6.13A). To assess the survival benefit of
PEG-NR-directed tumor ablation, mice bearing a single MDA-MB-435 tumor were
divided between 4 cohorts: PEG-NRs + laser, PEG-NRs - laser, saline + laser, saline -
laser; and all tumors were measured over time (Figure 6.13B). By twenty days following
treatment, all irradiated, PEG-NR-injected mice displayed only a minor scar with no
evidence of tumor regrowth, while all other surviving mice harbored thriving tumors
(Figure 6.13B, Figure 6.13C). Over the course of >50 days of observation, no irradiated,
PEG-NR-injected mice showed evidence of recurrence, while all mice in controls had to
be euthanized by day 33. Body weights of PEG-NR-treated mice were monitored over
time and showed no obvious losses due to tumor ablation and resorption (Figure 6.14). In
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Figure 6.13: Photothermal destruction of human tumors in mice using long-circulating
gold nanorods. A) Mice harboring two MDA-MB-435 human tumors on opposite flanks
were injected with either saline or PEG-nanorods. After PEG-nanorods had cleared from
circulation (72 hrs after injection), the right flank of each mouse was exposed to the
computationally-designed irradiation regimen (810 nm, 2 W/cm2, 5 min). Volumetric
changes in tumor sizes are plotted over time following irradiation. B) Mice harboring one
MDA-MB-435 human tumor were injected with either saline or PEG-nanorods and
irradiated as in A). Survival of mice following irradiation is plotted versus time after
irradiation. C) At 20 days following irradiation, NIR-irradiated, all PEG-nanorod-injected
mice showed only a minor scar and no evidence of tumor regrowth, while all other
treatment groups harbored thriving tumors.
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Figure 6.14: Weight of irradiated, PEG-NR-injected mice during tumor resorption
following treatment. A) Body weight curve of mice bearing unilateral MDA-MB-435
tumors from the survival study (Figure 5C). No obvious body weight loss was observed
following PEG-NR-mediated tumor therapy. C) Close view of site of tumor resportion
showing only evidence of minor scar.
a separate experiment to assess the acute hematological effects of NR-directed tumor
ablation, the only statistically-significant change observed in response to NR-mediated
tumor ablation was a slight increase in the percent of band neutrophils in NR + Laser sets
(p<0.05 for NR+ Laser vs. NR, Saline + Laser, and Saline) (Figure 6.15) likely due to an
acute inflammatory response to tumor ablation.
Here we present the development of an integrated system for nanoantenna-based
photothermal tumor therapy involving: the synthesis of long-circulating gold NRs as
efficient NIR-nanoantennas, biodistribution data acquisition via x-ray CT nanomaterial
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Figure 6.15: Hematological effects of PEG-NR irradiation in mice. To explore the
effects of NR administration and near-infrared ablation, mice bearing bilateral MDA-
MB-435 tumors were injected with either saline or PEG-NRs and, 72 hrs later, either
exposed to the therapeutic tumor irradiation protocol under anaesthetic (-2 W/cm2, 5
min, 810 nm) or anaesthetized without irradiation (n=3 each set). Following irradiation or
comparable time under anaesthetic, blood was collected for hematology and mice were
sacrificed. The only statistically-significant change observed in response to NR-mediated
tumor ablation was a slight increase in the percent of band neutrophils (p<0.05 for NR+
Laser vs NR, Saline + Laser, and Saline), likely due to an acute inflammatory response to
tumor ablation.
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imaging or ex vivo spectrometry, and photothermal computational modeling to guide
surgical irradiation planning. Broadly, the efficacy of a nanoantenna for photothermal
therapy depends both on intrinsic (optical absorption coefficient, material cytotoxicity)
and extrinsic (polymer coating, macrophage affinity, and circulation time) material
characteristics, as well as external parameters, such as the use of optimized dosing and
irradiation protocols for effective treatment.
We show that PEG-nanorods exhibit superior intrinsic absorption and
photothermal efficacy compared with gold nanoshells (-6 times greater heat generation
per weight gold), as well as substantially improved circulation times in vivo (17 hrs vs
~4 hrs), extrinsically imparted by their polymer coating(41, 42). Surveying literature on
inorganic nanoparticle circulation times in vivo, the circulation half-life of PEG-NRs is
among the longest achieved to date. Previously, polymer-stabilized inorganic
nanomaterials have been described with circulation half-lives of a few hours in vivo(28,
300), including a variety of other gold nanoparticle preparations(29, 301-303), and on
occasion with circulation times of ~10-15 hrs in mice(14, 65, 116). Elsewhere, another
PEG-nanorod formulation was developed for in vivo applications, but showed a 30 min
half-life without investigation into their ability to passively target tumors or mediate in
vivo photothermal heating(302). Because nanoparticle circulation time has been shown to
determine the efficiency of nanoparticle accumulation in tumors via the EPR effect, in
mouse cancer models and in clinical cancer treatment(14), the long circulation time
reported here has potential to directly translate to improved clinical tumor accumulation
over previous nanoantennas.
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Beyond the material determinants of nanoantenna efficacy, the irradiation
protocol utilized (ie. beam intensity, shape, cross-section, duration, direction, etc.) and
nanoantenna dosing regimen directly control the rates of energy capture and dissipation
to surrounding tissues in vivo. While nanoantennas have the potential to increase the
selectivity of tumor ablation, unoptimized irradiation of tissues carries the risks of either
unnecessary morbidity due to collateral damage or ineffective therapy due to incomplete
treatment of tumor margins. Here, we show that quantitative biodistribution data
incorporated into computational modeling can help anticipate the photothermal heating in
tumors and surrounding tissues during irradiation. Future developments of the
quantitative model presented here could enable rapid quantitative modeling of
photothermal temperature gradients in arbitrarily complex 3D tissues and provide a route
towards a priori personalization of irradiation regimens. As a proof-of-principle, we
establish a means of integrating whole subject x-ray CT data with quantitative heat
transfer modeling, offering a new route towards merging the clinical paradigms of
imaging and therapy for personalized 4D radiation planning and optimization. Further,
using a computationally planned therapeutic method, we show that intravenous
administration of PEG-NR nanoantennas enabled complete destruction of all irradiated
tumors, under otherwise benign near-infrared light.
6.3 Conclusions:
We believe our findings motivate future investigation into the long-term
biodistribution of PEG-NRs, more extensive analysis of their potential toxicity in vivo,
and the development of methods for detecting low concentrations of PEG-NRs in whole
animals to remotely quantify intravenous tumor targeting. Methods for actively targeting
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nanorods to tumors, particularly to vascular epitopes, could potentially enhance their
specificity for tumors or direct their additional accumulation in premalignant lesions and
metastatic lymphatics. Finally, we provide evidence that the application of quantitative
biodistribution-based modeling to the in vivo testing of nanomaterials can provide insight
into their function and direct procedural optimization.
6.4 Materials and Methods:
Preparation of PEG-coated gold nanorods: Highly stable, ~13 nm x 47 nm (Figure 1A)
CTAB-coated gold nanorods with longitudinal plasmon resonance at 810 nm (Nanopartz,
a division of Concurrent Analytical Inc., Salt Lake City, UT) were centrifuged at 16,000
rcf to concentrate and gently resuspended in 250 pM 5 kDa methyl-PEG-thiol (Laysan
Bio, U.S., Arab, AL). Thiol activity of polymers was quantified spectraphotometrically
using 5,5'-Dithiobis(2-nitrobenzoic acid) (Sigma, St. Louis, MO) against a dithiothreitol
(Sigma) gradient to verify that polymer stocks were fully reduced. The solution of 5 kDa
methyl-PEG-thiol and CTAB-coated gold nanorods was gently mixed at room
temperature for 1 hr and dialyzed exhaustively against ultrapure water (18 MQ cm') via
cellulose ester membrane dialysis to drive PEG addition (Spectrapor, Rancho
Dominguez, CA). Dialyzed samples were filtered through 100 kDa filters (Millipore,
Billerica, MA) to remove excess polymer and stored at 4'C. To quantify the number of
polymers per particle, NRs were coated as described with an amino-PEG-thiol polymer.
After dialysis and extensive filtration on 100 kDa centrifugal filters, amino NRs were
harvested and an SPDP assay was performed to quantify the number of amines(298).
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Stability and cytotoxicity: Solutions of PEG-NRs or CTAB-NRs (-60 gg Au/ml) were
normalized and incubated in PBS or 10% human serum for extended periods of time. At
regular intervals, samples were spectrophotometrically analyzed for plasmon resonance
peak shifts, which would indicate particle aggregation. To assess material toxicity,
micropatterned primary hepatocyte:human fibroblast co-cultures were prepared as
described previously(59). 24 hrs following liver co-culture seeding, coculture wells were
exposed in triplicate to a gradient of PEG-NRs (from 0 to 280 pg Au/ml) and allowed to
incubate for 24 hrs. At this point, PEG-NRs were removed, cells were washed repeatedly,
and viability was assessed via an MTT viability assay (Sigma), a colorimetric viability
assay for mitochondrial dehydrogenase enzyme activity read using a spectrophotometer
(SpectraMax, Molecular Devices, Sunnyvale, CA).
Photothermal comparison between PEG-nanorods and PEG-nanoshells: Gold nanoshells
(Nanocomposix, San Deigo, CA) with 120 nm silica core and ~15 nm gold shell were
mixed with methyl-PEG-thiol as described(41, 42, 48). Both PEG-nanoshells and PEG-
NRs were brought to 7 pg Au/mL, as determined by inductively coupled plasma mass
spectrometry (ICP-MS). Tubes containing 200 pl of these solutions were broadly
irradiated, under identical conditions, by an 810 nm diode laser (RPMC Lasers Inc) at 2
W/cm2 . During irradiation, an infrared thermographic camera (FLIR, Goleta, CA
Thermacam S60) was used to measure peak sample surface temperature. To assess
photothermal cell toxicity, MDA-MB-435 human cancer cells (ATCC) were cultured in a
96-well microplate and grown to 80% confluency using ATCC-recommended media.
Cells were incubated with either PEG-NRs (14 pg/mL), PEG-nanoshells (14 pg/mL), or
media alone. For each, triplicate wells were exposed to the diode laser light (5 min, 2
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W/cm 2) or no laser. After treatment, cells were incubated with Calcein AM (5 jig/mL in
culture medium; 1hr incubation, Invitrogen Carlsbad, CA), a fluorescent indicator of
esterase activity in viable cells, and imaged using phase and fluorescence microscopy.
X-ray Computed Tomography of PEG-nanorods. PEG-NRs were suspended in PBS after
concentration via membrane centrifugation and serially diluted over a 1000-fold
concentration gradient. A clinical iodine standard was similarly diluted for comparison
(Isovue-370). X-ray computed tomography was performed in a GE eXplore Locus
microCT scanner (80 kV, 450 pA, 45 pm resolution). For in vivo imaging, mice were
imaged prior to NR injection to reveal the baseline level of soft tissue x-ray contrast. 10
pl of PEG-NRs (~3pmol) were injected with a 30 gauge needle directly into the center of
the tumor and the needle was maintained in place for ~10 seconds to allow the tumor to
accommodate the additional fluid. Following intratumoral administration, mice were
imaged and irradiated (-.75 W/cm 2 , 810 nm). X-ray CT images were exported as
DICOM files for exportation into modeling software (See supporting methods).
Inductively coupled plasma mass spectrometry (ICP-MS). Samples for ICP-MS (Thermo-
Scientific Finnigan ELEMENT2) analysis were frozen, lyophilized, and dissolved in aqua
regia, prepared by adding 100 pl of nitric acid + 300 pl of 37% hydrochloric acid for 72
hrs to dissolve gold particles. Then, samples were brought up into 10 mLs of 9.6 mL 2%
HNO 3 and analyzed via ICP-MS against standards. Control saline and organ samples
with exogenously added PEG-NRs were utilized to calibrate the linearity of this method.
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In vivo circulation time and biodistribution of PEG-nanorods. Nude mice were bilaterally
injected subcutaneously in the hind flank with ~2x106 MDA-MB-435 cells. After 2-3
weeks animals were anaesthetized with isoflurane and injected through the tail vein with
PEG-NRs in 0.15 M NaCl, 0.1 M Na Phosphate buffer, pH 7.2 (20 mg Au/kg). 10 pl
blood samples were withdrawn periodically from the sub-orbital space, diluted with PBS
containing 10 mM EDTA, centrifuged to remove RBCs, and read on a spectrophotometer
to assess PEG-NR plasmon peak height. For biodistribution experiments, following
vascular clearance of PEG-NRs (72 hrs), injected animals were euthanized and organs
were collected, weighed, and lyophilized for ICP-MS quantification of PEG-NR
biodistribution.
In vivo photothermal heating of gold nanorods and photothermal therapy. For both initial
modeling and growth curve assessments following photothermal treatment, nude mice
were bilaterally injected in the hind flank with -2x10 6 MDA-MB-435 cells. After 2-3
weeks animals were anaesthetized with isoflurane and injected through the tail vein with
PEG-NRs in PBS (20 mg Au/kg) or PBS alone. Following vascular clearance of PEG-
NRs (72 hrs), the right flank of mice was irradiated (2 W/cm 2 , 810 nm, 1 cm beam
diameter). Thermographic imaging of photothermal heating was utilized to facilitate
modeling of 3D temperature distributions in tumors (n=3 mice for each set). To explore
the hematological effects of NR administration and near-infrared ablation, mice bearing
bilateral MDA-MB-435 tumors were injected with saline or PEG-NRs and, 72 hrs later,
either exposed to the therapeutic tumor irradiation protocol under anesthesia (~2 W/cm 2,
5 min, 810 nm) or anesthesia without irradiation (n=3 each set). Following exposure,
blood was collected for hematology and mice were sacrificed. Therapeutic assessment
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of the affect of PEG-NR heating on tumor growth was conducted similarly (n=4 mice in
each treatment set). Both irradiated and unirradiated tumors of each mouse in the
therapeutic assessment trial were measured at regular intervals using digital calipers.
Survival studies were conducted using mice that were unilaterally injected in the hind
flank with -2x106 MDA-MB-435 cells (n= 5 mice in each treatment set). Tumor sizes
were measured over time and mice were considered dead once tumors exceeded 500
3mm.
Finite Element Modeling of Photothermal Tumor Heating
To reveal the magnitude and kinetics of in vivo photothermal heat generation by the
nanorods and native tissue, the temporal and spatial propagation of thermal gradients, and
to assess the timescale within which the entire tumor volume would reach ablative
temperatures, a finite element computer simulation of the photothermal ablation process
was developed and carried out. The tumor was approximated as a paraboloid, resting
above the muscle and covered by skin of 300 pim thickness. The bio-heat transfer
equation of Pennes (1948) was applied to the computational domain in the form(304):
pc (aT/8t) + V. (-k V T) = pbcbwb(Tb-T) +Qmet + Qiaser
Where, pc is the heat capacity of the muscle, tumor periphery, tumor core or skin as
appropriate in the respective regions. The heat capacity of blood is pbcb and its perfusion
rate in the respective domain is wb. Qmet and Qiaser are the metabolic and laser heat
generation in the tissues respectively. For intravenous photothermal modeling, a
cylindrical domain of 20 mm diameter around the tumor with a depth of 12 mm for the
muscle domain was considered for computation. The shell of the tumor was considered to
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be of 0.5 mm thickness having higher rate of blood perfusion than the tumor core. A cut
view of the computational domain is shown in Fig S 10.
The blood perfusion rate is known to be different in tumor periphery, tumor core,
healthy tissues and skin. Hence, they have been taken accordingly from literature (Fujita
et al., 1998) as follows
wb = F [1]
= F[1+ (p-1) (T-39)/(45-39)]
= F[p- (p-1) (T-45)/(51-45)]
= F [1]
for T < 390C
for 390C <T < 450C
for 450C <T < 510C
for T >510C
The maximum perfusion rate and the parameter p for different region are given as
Tissue
Tumor core
Tumor periphery
Muscle
Skin
F (m3/kg/s)
5 X 10-
1.67 X 10-6
8.3 X 10-6
8.3 X 10-6
The thermophysical properties of various regions were taken from accepted values as
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Tissue
Tumor core
Tumor periphery
Muscle
Skin
Blood
Density
m3/kg
1050
1050
1050
1200
1000
Specific heat
J/(kgK)
3700
3700
3700
3700
4200
Thermal conductivity
W/(mK)
0.5
0.5
0.5
0.2
The metabolic heat generation rate is taken to be 400 W/m3 .
Laser heat generation in tissues is a widely studied area. Welch (1984) gave a good
overview of the various models available in this area(305). Seeing various possibilities,
the following equation for heat generation, which is a modification of his equation (12)
for the present geometry, was chosen:
Qiaser = Io exp[-r 2/[2c-(0) exp($ze)]]exp[-(a+p)zc]
Where Io is the laser irradiation intensity in W/m 2, r is the radial distance from the center,
and ze is the depth of the location from the skin. The parameters a and p are the
absorption and scattering coefficient (in m-1) of the tissues respectively. To incorporate
the curvature of the tumor's surface and the internal multi-layer tissue structure (skin,
tumor), the following modification was made:
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Qiaser = a Io exp[-r2/[2T(0) exp(pze)]]exp[-(a+p)(zc-c-d)] exp[-(as+ps)(zs)] exp[-(at+pt)zt]
Here, c is the depth of the skin surface from the tumor vertex at a given radial position, d
is the depth of the normal tissue above a location, zs is the depth of the skin above a
location and zt is the depth of the tumor tissue above a location. The suffixes: s and t
indicate skin and tumor absorption and scattering coefficients, respectively; the values of
which were taken to be 0.4 and 5.3 cm' in absence of nanorods(306). For the
experiments with nanorods, the absorption coefficient of the tumor was predicted to be
3.07 cm' based on the Nrod biodistribution data (-7% ID/g; 20 mg/kg injected dose; 0.1
cm3 tumor volume) and in vitro absorption measurements. Jain et al (2006) showed that
the extinction coefficient of -13 nm x 47 nm nanorods is dominated by absorption and
hence we assumed that nanorods only enhance the tumor absorption coefficient, with
insignificant alteration of large endogenous scattering coefficients(307). The surface heat
loss coefficient to the environment was taken as 15 W/m 2K, which is a typical value for
natural convection on planar surfaces.
Finite element method (FEM) using the multiphysics enabled software COMSOL was
used for modeling. After careful grid variation, a total of 4436 triangular elements per
half symmetry plane was chosen to represent tumor heating. The temperature tolerance
was at the default value of 0.000 1 and a direct matrix inversion technique was used.
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Simulation of localized injected nanorod geometry using X-Ray tomography data
For the purpose of simulating the 3D geometry of injected nanorods and the resulting
thermal flux upon irradiation, a multi-step procedure was performed to translate 3D X-
ray CT images into a form amenable to computational modeling of photothermal heating.
For the present cases, 406 DICOM slices were exported, including the tumor, muscle,
and the internal skeletal details, as well as the distribution of injected nanorod solutions
as shown in Fig. 3 and supplementary Figs. 5 and 6. Subsequently these data were
imported in the image processing software Scan IP and reconstructed based on the grey
scale values of the scan to form volumetric geometries for nanorods, skeletal structures,
and soft tissues as shown in Fig. 3D supplementary Figs.5C and 6B. Next, the solid
model was imported to the meshing software Scan FE and proper surface meshing was
carried out. Finally, the 3D meshed geometries were imported to COMSOL Multiplysiscs
and the thermal analysis was carried in an identical fashion to the previous description in
the ellipsoidal geometry.
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Chapter 7: Nanoparticles that Communicate to Amplify
Tumor Targeting In Vivo
7.1 Introduction:
Advances in nanotechnology have produced an expansive toolkit of nanodevices
with unique electromagnetic properties(4, 32, 54) and the capacity to encapsulate and
programmably release a diversity of therapeutics, ranging from small molecules(1 7, 93,
308, 309) to oligonucleotides(310, 311). Over the past three decades, approaches to
targeting these materials in vivo have predominantly focused on tuning the properties of
individual particles including geometry, surface chemistry, ligand type and ligand density
(14, 16, 90, 141, 142, 145, 169-172). These materials are typically administered as
populations of >1 trillion nanoparticles in vivo to carry out identical, often competitive
functions. While these approaches have resulted in some improvements in targeted
nanoparticle delivery, the overall tissue accumulation remains low, typically due to inter-
nanoparticle competition and microenvironmental challenges such as restricted
transvascular transport and receptor availability.
In contrast to such systems composed of near-identical constituents, natural
systems frequently generate complex behaviors through collective interactions between
multiple system components-enabling emergent processes such as computation,
amplification, and dynamic communication. For example, the recruitment of
inflammatory cells to regions of infection is coordinated by resident tissue macrophages
that emit chemokines which diffuse through the interstitium to enhance endothelial
adhesion molecule expression and enable the recruitment of circulating neutrophils. This
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Schematic 7.0. Architecture and information flow in nanoparticle signaling networks. A)
Generic architecture for nanoparticle signaling networks. Extravascular nanoparticles that
have targeted tumors signal remotely to recruit intravascular nanoparticles. B)
Information flow in nanoparticle signaling networks. Extravascular Signaling
nanoparticles convert an electromagnetic signal into a local physical signal that is
biologically-transduced into a local biochemical signal for circulating therapeutic or
diagnostic Receiving nanoparticles. C) Signaling pathway between Signaling and
Receiving nanoparticles. Tumor-targeted, extravascular plasmonic gold nanorods
(Signaling nanoparticle (NP)) initiate coagulation cascade activation by photothermally
disrupting tumor vessels and activating the extrinsic and intrinsic coagulation pathways,
respectively. The resulting biomolecular amplification of the coagulation cascade is
channeled to recruit organic (drug-loaded liposomes) or inorganic (iron oxide
nanoworms) via activity of the coagulation transglutaminase FXIII (solid path on right)
or via targeting of polymerized fibrin (dotted path on left).
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signaling pathway transmits spatial information to circulating immune cells and
ultimately results in an amplified local response. Inspired by this process, we considered
the design of nanoparticle systems that interact to produce emergent behaviours with the
capacity to enhance in vivo diagnostics, regenerative medicines, and other therapeutics
(Scheme 7.1A).
We devised a two-component nanoparticle signaling network to amplify tumor
targeting in vivo. In this system, interstitial Signaling nanoparticles provide a physical
stimulus that is biologically transduced into an abundant biochemical signal for
Receiving nanoparticles in circulation (Scheme 7.1B). Specifically, the Signaling
nanoparticles consist of intravenously-injected, polymer-protected gold nanorods (NRs)
that passively-target xenograft tumors in mice. Remote, photothermal heating of tumor-
targeted NRs locally increases vascular permeability, exposing circulating plasma to the
tumor interstitium and activating the coagulation cascade to generate an abundant
biochemical signal for coagulation-targeted Receiving nanoparticles (Scheme 7.1C). To
explore the modularity of this technique, two types of nanoparticles were explored: a
model imaging agent (magnetofluorescent iron oxide nanoworms) and a model
therapeutic agent (doxorubicin-loaded liposomes). Furthermore, to investigate whether
information could be channeled to Receiving nanoparticles through multiple molecular
pathways in coagulation, two types of targeting strategies were explored: peptide coatings
that recognize fibrin directly and peptides that target coagulation enzyme activity by
acting as a substrate for the coagulation transglutaminase Factor XIII (FXIII) (Scheme
7.1C).
147
7.2 Results and Discussion:
We first set out to examine the transduction of tumor heating into localized
coagulation by evaluating fibrin deposition in tumors as a function of temperature
(Figure 7.1A). Purified fibrinogen (the precursor to fibrin) and albumin (an abundant
blood protein unrelated to coagulation) were labelled with unique near-infrared
fluorochromes to allow simultaneous assessment of coagulation-dependent and
independent protein tropism to heated tumors. Mixtures of fibrinogen and albumin were
intravenously injected into athymic (nu/nu) mice bearing bilateral human MDA-MB-435
tumors, after which one tumor was heated using a temperature-controlled water bath. At
24 hours, mice were sacrificed and the relative levels of tumor fibrin(ogen) and albumin
were assessed fluorescently. We observed a marked induction of fibrin(ogen)
accumulation in tumors between 45C and 530C, with little accompanying increase in
albumin accumulation, indicating that heat specifically directed coagulation cascade
activation in tumors(Figure 7.1C, 7.2). Immunohistochemical staining for fibrin(ogen) in
tumors from uninjected mice corroborated these findings, demonstrating that exogenous
fibrinogen administration did not artificially drive accumulation in heated tumors (Figure
7.3).
Having probed the thermal sensitivity of coagulation in tumors, we next
investigated whether tumor-targeted gold NRs could localize coagulation to. Rod-shaped
gold nanoparticles are precisely-tunable plasmonic nanomaterials that may be
synthesized in bulk, have narrow size distributions, optical absorption coefficients 104-
106-fold higher than conventional organic fluorochromes (6, 46, 290). Previously, we
demonstrated that polyethyleneglycol-coated gold NRs (PEG-NRs) have >17 hr
circulation half-lives in mice, enabling passive targeting to tumors via their fenestrated,
angiogenic blood vessels(312, 313) and precise tumor heating using otherwise benign
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Figure 7.1. 'Signaling nanoparticle' characterization. A) Schematic of nanorod-directed
stimulation of the coagulation cascade. Gold nanorods (NRs) are passively targeted to
tumors to photothermally specify coagulation cascade activation in tumors. B)
Transmission electron microscopy of near-infrared absorbing NRs. C) Probing the
coagulation-dependent and -independent protein tropism to heated tumors. Fibrinogen
and albumin were labelled with unique near-infrared fluorochromes and injected into
mice bearing bi-lateral MDA-MB-435 tumors. Immediately following injection, one
tumor on each mouse was heated using a temperature-controlled water bath. At 24 hrs
post-injection, mice were dissected and both tumors imaged for the relative abundance of
fibrinogen (green) and albumin (red). Both heated (+ row) and unheated (- row) tumors
are displayed across the temperatures tested. D) Experimental timeline for exploring
fibrinogen deposition in PEG-NR heated tumors. E) Thermographic imaging of PEG-
NR- and saline-injected mice under broad NIR irradiation of the right flank. F) Visible
light image of mice 24 hrs after NIR-irradiation. G) Fluorescence reflectance imaging of
mice to visualize fibrinogen tropism to PEG-NR-heated tumors.
near-infrared (NIR) energy. Here, PEG-NRs (10 mg Au/kg) or saline were intravenously
administered to mice bearing bilateral MDA-MB-435 tumors (Figure 7.1D). After PEG-
NR clearance from circulation (72 hrs post-injection), fluorescent fibrinogen was
intravenously injected and the right flanks of mice were irradiated with near-infrared light
(~1 W/cm2), generating focal tumor surface temperatures of ~49 C in PEG-NR-injected
mice, while saline-injected tumor surface temperatures remained below -37*C (Figure
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Figure 7.2. Specific fibrinogen tropism to heated tumors. A) Probing the coagulation-
dependent and -independent protein tropism to heated tumors. Fibrinogen and albumin
were labelled with unique near-infrared fluorochromes in the opposite channels as in
Figure 1A (VT680 and VT750, respectively) and injected in mice under identical
conditions. Reversing the fluorophore labelling on fibrinogen and albumin enables
quantitation of protein tropism to heated tumors independent of any potential optical or
molecular fluorophore bias. At 24 hrs post-injection, mice were dissected and both
tumors imaged for the relative abundance of fibrinogen (red) and albumin (green). Both
heated (+ row) and unheated (- row) tumors are displayed across the temperatures tested.
B) Quantitation of fibrinogen: albumin fluorescence ratio across tested tumor
temperatures. Data taken under conditions of lA and SlA were utilized to quantify the
relative abundance of fibrinogen and albumin in heated tumors vs unheated. At 45-53"C,
fibrinogen abundance in tumors was significantly enhanced over albumin (P<0.05; 1-
sided t-test; 4-mice per temperature).
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Figure 7.3. Histopathological analysis of anti-fibrin(ogen) binding to unheated and
heated tumors. Quantitation of anti-fibrin(ogen) binding to sections from unheated and
externally-heated tumors. As an independent measure of fibrin(ogen) deposition in heated
tumors, uninjected mice bearing bilateral MDA-MB-435 tumors had one tumor immersed
in a temperature-controlled water bath for 20 minutes and were sacrificed 24 hrs later for
histological sectioning. Fluorescent quantification showed significantly enhanced
abundance of antibody binding at both 45 and 53*C (P<0.0001, 1-sided t-test, 6 separate
regions analyzed in each condition).
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Figure 7.4. Histopathological analysis of NR-directed fibrinogen deposition in tumors.
Mice bearing bilateral MDA-MB-435 tumors were injected with PEG-NRs (10 mg
Au/kg) or saline and, 72 hrs later, injected with fluorescently-labeled fibrinogen (VT750)
and broadly irradiated on their right side (~1 W/cm2 , 810 nm, 20 min). At 24 hrs post-
injection, mice were sacrificed and tumors isolated for histological analysis of fibrinogen
distribution (Red=CD31 antibody stain, Blue= DAPI nuclear stain, Green=fibrinogen
distribution).
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Figure 7.5. 'Receiving nanoparticle' synthesis and testing. A) Schematic of Receiving
NP homing to regions of coagulation cascade activity. Multimodal nanoworm (NW)
imaging agents and drug-loaded liposomes (Lps) (top and bottom, respetively) were
derivatized with coagulation-targeting peptides to form Receiving NPs that accumulate in
regions of fibrin deposition (fibrin in grey). Receiving NP characterization utilized
temperature-controlled water baths to initially probe the thermal sensitivity of Receiving
NP homing to tumors. B) Nanostructure and biological activity of Receiving NPs.
Transmission electron microscopy images of the two classes of nanomaterials utilized in
Receiving NP synthesis: iron oxide nanoworms (NWs; scale bar=50 nm) and
doxorubicin-loaded liposomes (Lps; scale bar=400 nm). Two peptides were utilized to
direct Receiving NPs with targeting specificity for coagulation: a fibrin-binding peptide
and a glutamine-containing substrate for the coagulation transglutaminase FXIII to
respectively direct particle binding and covalent attachment in regions of coagulation. C)
Fluoresence reflectance imaging of Receiving NP homing to externally-heated tumors.
Mixtures of targeted (green) and untargeted (red) NWs, labelled with the unique NIR-
fluorochromes VT750 and VT680, respectively, were intravenously injected into mice
bearing bilateral MDA-MB-435 tumors. Immediately following injection, one tumor was
submerged in a temperature-controlled water bath for 20 min and mice were dissected at
24 hrs for fluorescent organ imaging. Overlaid fluorescence images are shown for
targeted (green) and untargeted (red) Receiving NP accumulation in both heated (+, 45*C
heating) and naive (-) tumors from the same mouse. D) Histopathological analysis of
Receiving NP homing to heated tumors. Histological sections from naive (top) and
heated (bottom, 45*C) tumors in FXIII-NW-injected mice were stained for CD31 (red)
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and nuclei (blue) and imaged to reveal Receiving NP distribution (green). E) Quantifying
the amplification of FXIII-Substrate and Control NW Receiving NP homing to heated
over unheated tumors. The fold enhancement of NW targeting is plotted across the range
of temperatures tested (n=4, p<0.05 for the difference between FXIII-substrate-NWs and
Control substrate NWs at 45*C, 49"C, and 53*C; paired, one-sided t-test). F) Quantifying
the amplification of FXIII-Substrate and Control Drug-loaded Liposome Receiving NP
homing to heated over unheated tumors. The fold enhancement of doxorubicin
accumulation in tumors is plotted across the range of temperatures tested for FXIII-
substrate Lps and Control-substrate Lps (n=3, p<0.05 for the difference between FXIII-
substrate-NWs and Control substrate NWs at 45*C and 49"C, respectively; unpaired, one-
sided t-test).
7.1E). At 24 hrs post-injection, irradiated tumors on NR-injected mice displayed
macroscopic evidence of injury (Figure 7.1F) and localized accumulation of fibrinogen
(Figure 7.1G); while tumors with PEG-NRs or near-infrared energy alone lacked these
features. Histopathological analysis revealed that fibrin(ogen) deposition formed a broad
interstitial mesh in heated tumors, indicating that NR heating could compromise tumor
blood vessels to initiate extravascular coagulation (Figure 7.4).
We next set out to develop Receiving nanoparticles that could efficiently target
regions of heat-induced coagulation to deliver therapeutics or act as imaging agents
(Figure 7.5A). Initially, magnetofluorescent iron oxide nanoworm imaging agents (NWs)
(Figure 7.5B top) were derivatized with a peptide substrate for the coagulation
transglutaminase Factor XIII (G-N-Q-E-Q-V-S-P-L-T-L-L-K-X-C-Fluorescein)(314-
316) to enable incorporation into regions of active coagulation (Figure 7.5B bottom,
7.6). To test the ability of Receiving NWs to home to heated tumors, mixtures of targeted
and untargeted NWs, labelled with unique near-infrared fluorochromes, were
intravenously injected into mice bearing two MDA-MB-435 tumors. Immediately
following injection, one tumor was submerged in a temperature-controlled water bath for
20 min and mice were dissected at 24 hrs for fluorescent organ imaging. We found that
the accumulation of FXIII-substrate Receiving NWs was sharply amplified at 45*C
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Figure 7.6. Spectrophotometric, fluorescent, and size characterization of Receiving
modules. A) Spectrophotometric characterization of NW Receiving module
functionalization. Aminated NWs were conjugated with NHS-activated NIR
fluorochromes (VT680 or VT750) to allow fluorescent imaging and subsequently linked
to thiol-containing FXIII-substrate peptides or control-peptides. The spectra NWs were
utilized to quantify the number of peptides and NIR-fluorochromes per particle (-600
FXIII- or control-peptides/NW and -12-15 fluorochromes/NW, respectively).
Conjugation conditions were optimized to produce populations with approximately equal
numbers of peptides in the FXIII-NWs and control-NWs. B) Dynamic light scattering
characterization of FXIII-NW and control-NW Receiving modules. After peptide
functionalization with NIR-fluorochromes and peptides, samples were analyzed via DLS
to probe the hydrodynamic size of each conjugate. C) Fluorescent characterization of
FXIII-Lps and control-Lps. The fluorescence emission spectra of Fluorescein-conataining
FXIII- and control- peptides was utilized to ensure similar surface density on Lp
conjugates (excitation: 444 nm; cutoff: 455 nm; emission 480 nm-700 nm). D) Dynamic
light scattering characterization of FXIII-Lp and control-Lp Receiving modules. After
peptide functionalization, Lp Receiving modules were analyzed via DLS to probe the
hydrodynamic size of each conjugate.
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Figure 7.7. Fluoresence reflectance imaging of Receiving module homing to externally-
heated tumors. Mixtures of targeted (red) and untargeted (green) NWs (labelled with the
opposite orientation of NIR-fluorochromes used in Figure 2C to control against potential
optical or molecular fluorochrome bias to Receiving module detection in heated vs
unheated tumors) VT680 and VT750, respectively, were intravenously injected into mice
bearing bilateral MDA-MB-435 tumors. Immediately following injection, one tumor was
submerged in a temperature-controlled water bath for 20 min and mice were dissected at
24 hrs for fluorescent organ imaging. Overlaid fluorescence images are shown for
targeted (green) and untargeted (red) Receiving module accumulation in both heated
("+", 450C heating) and naive ("-") tumors are shown from the same mouse.
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Figure 7.8. Fluorescent quantification of fibrin-binding and untargeted-NW Receiving
module homing to heated over unheated tumors. The fold enhancement of NW targeting
is plotted across the range of temperatures tested (n=4 mice in each set, p<0.05 for the
difference between fibrin-binding-NWs and untargeted-NWs at 45"C, 490C, and 530C,
respectively).
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Figure 7.9. Histopathological analysis of control-substrate NWs. Mice bearing bilateral
MDA-MB-435 tumors were injected with control-substrate NWs and one tumor was
heated to 45*C for 20 min. At 24 hrs post-injection, mice were sacrificed and tumors were
analyzed for NW distribution in histology using the same exposure conditions for NW
imaging as Figure S8, S10, and Figure 2D. (Red=CD31 antibody stain, Blue= DAPI
nuclear stain, Green=control-substrate NW distribution)
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Figure 7.10. Histopathological analysis of FXIII-substrate localization to areas of anti-
fibrin(ogen) staining. Mice bearing bilateral MDA-MB-435 tumors were injected with
FXIII-substrate NWs and one tumor was heated to 45*C for 20 min. At 24 hrs post-
injection, mice were sacrificed and tumors were analyzed for NW distribution in
histology using the same exposure conditions for NW imaging as Figure S8, S9, and
Figure 2D. (Red=anti-fibrin(ogen) antibody stain, Blue= DAPI nuclear stain,
Green=FXIII-substrate NW distribution)
159
A) B)
C) D)
Figure 7.11. Histopathological analysis offibrin-targeted NWs in heated and unheated
tumors. Mice bearing bilateral MDA-MB-435 tumors were injected with fibrin-binding
NWs and one tumor was heated to 45'C for 20 min. At 24 hrs post-injection, mice were
sacrificed and tumors were analyzed for fibrin-NW distribution in histology. A)
Distribution of fibrin-targeted NWs in unheated tumors. (Red=CD31 antibody stain,
Blue= DAPI nuclear stain, Green-fibrin-targeted NW distribution) B) Co-localization of
fibrin-targeted NWs with anti-fibrin(ogen) antibody staining in heated tumors.
(Red=CD31 antibody stain, Blue= DAPI nuclear stain, Green=fibrin-targeted NW
distribution)
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compared to Control-NWs bearing peptides without the essential glutamine for FXIII
cross-linking (Figure 7.5C, 7.5D, 7.6), enabling nearly an order of magnitude increase in
tumor targeting compared to unheated tumors. The specificity of heat-induced targeting
to coagulation persisted up to 53'C, although the magnitude of accumulation decreased
(Figure 7.5E), likely indicating that higher temperatures accelerated intravascular
coagulation and occlusion, diminishing the perfusion required for delivery of Receiving
NWs into tumors. Histopathologically, FXIII-substrate NWs showed marked
extravasation and interstitial spreading in heated tumors compared with controls (Figure
7.5D, 7.9, 7.10), illustrating the capacity of thermal energy to dismantle tumor vascular
barriers and enable abundant interstitial penetration.
To explore a separate mechanism for targeting coagulation, NWs were separately
derivatized with a fibrin-binding peptide (Ac-d-d-d-G-Y-e-C-hyP-cY-G-L-C-Y-I-Q-K-
Fluorescein) (Figure 2B) and tested in a similar assay. Fibrin-binding Receiving NWs
also exhibited nearly a 10-fold amplification of targeting to water-bath heated tumors
(Figure 2C, 7.7, 7.8), with prominent extravascular accumulation histopathologically
(Figure 7.11).
Therapeutic Receiving nanoparticles were constructed by modifying doxorubicin-
loaded liposomes (Lps) with FXIII substrates(Figure 7.6, 7.12). Here, tumor heating to
45*C directed the accumulation of over 40-times higher doses of doxorubicin in tumors
compared with unheated controls and significantly enhanced targeting over control
substrate-modified Lps (Figure 7.5F).
After probing each component of the system independently, we studied the ability
of the fully integrated signaling network to amplify tumor targeting in vivo (Figure
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Figure 7.12. Cytotoxicity experiments to assess intrinsic toxicity of Au nanorods and
doxorobicin-loaded liposomes. Cytotoxicity assessments were conducted using Human
HeLa cervical cancer cultures (ATTC) in 96well plates grown to -70% confluency. Cells
were incubated with various dilutions of either PEG-NR or Lp formulations assessed for
viability after 24hrs of incubation using the fluorogenic intracellular esterase sensor
Calcein acetoxymethylester (each point represents the average of 4 wells in a 96-well
plate).
7.13A). Signaling NRs (or saline) were intravenously-injected into mice bearing bilateral
MDA-MB-435 tumors. After NR clearance from circulation (72 hrs), mixtures of active
and inactive Receiving nanoparticles (FXIII-NWs and Control-NWs) labelled with
distinct near-infrared fluorochromes were co-injected intravenously, followed by laser
irradiation of the entire right flank of the mouse (-0.75 W/cm2, 810 nm, 20 min) under
infrared thermographic observation. At 96 hrs, the entire mouse and then the individual
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Figure 7.13. Integrated function of nanoparticle signaling networks. A) Schematic of
integrated nanoparticle signaling networks. B) Experimental timeline for testing
nanoparticle signaling networks. C) Thermographic imaging of photothermal PEG-
nanorod heating. At 72 hrs post NR- or saline-injection (10 mg Au/kg), mice were co-
injected with targeted (FXIII-NWs) and untargeted (Control-NWs) and their right flanks
were broadly irradiated (810 nm, -0.75 W/cm2 , 20 min) while under infrared
thermographic surveillance. D) Overlaid fluorescence reflectance image of targeted and
untargeted Receiving NP homing. At 24 hrs post-irradiation, whole-animal fluorescence
imaging revealed the distributions of targeted (FXIII-NWs, green) and untargeted
(Control-NWs, red) Receiving NPs. E) Quantification of NW Receiving NP homing in
irradiated vs contralateral unirradiated tumors. After whole-animal imaging, mice were
dissected and the fluorescence of each tumor was measured to quantify the homing of
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Receiving NPs. F) Quantification of doxorubicin-loaded Lp Receiving NP homing in
irradiated vs contralateral unirradiated tumors. After whole-animal imaging, mice were
dissected and the fluorescence of each tumor was measured to quantify the homing of
Receiving NPs. G) Histopathological analysis of NR-directed FXIII-Substrate Lp
targeting and doxorubicin delivery. Histopathological sections from the integrated NP
signaling experiments in F). At 24 hrs post-NW injection, mice were sacrificed and
tumors were analyzed for FXIII-Lp and doxorubicin distributions in histology. (Red=
doxorubicin, Blue= DAPI nuclear stain, Green=FXIII-targeted Lp distribution).
explanted organs were fluorescently imaged (Figure 7.13B). Thermographic surveillance
of photothermal heating showed focal tumor heating only in NR-injected mice (Figure
7.13C) and whole-animal imaging at 96 hrs revealed pronounced homing of FXIII-
targeted NWs to NR-heated tumors, with over an order of magnitude increase in
accumulation above both unirradiated contralateral tumors and tumors on saline-injected
mice (Figure 7.13D, 7.13E, 7.14). Histologically, integrated signaling networks
produced intense regions of FXIII-NW fluorescence relative to controls, particularly in
tumor boundaries where blood vessels were well perfused (Figure 7.15). Nanoparticle
signaling networks were found to be effective in xenograft cervical tumor models as well,
directing several fold amplification in homing of targeted Receiving nanoparticles over
untargeted controls (Figure 7.16).
When therapeutic FXIII-targeted Receiving liposomes (Lps) were incorporated into
the integrated system, the accumulation of doxorubicin in tumors was amplified by over
40-fold (-8% ID/g) as compared to the Lps alone (Figure 7.13E). This amplification of
drug delivery likely has at least two components: heat-dependent increases in passive
accumulation due to improved tumor transport (as indicated by control-Lps and
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Figure 7.14. Active NP signaling network experiments from Figure 3D, but with inverted
fluorophore-targeting ligand relationships to control against bias and ex-vivo imaging of
excised tumors. A) Simultaneous near-infrared imaging of co-injected: VT750-labeled,
FXIII-substrate-NWs (green, left mouse) and VT680-labeled, control-substrate NWs
(red, left mouse); or VT680-labeled, FXIII-NW (red, right mouse) and VT750-labeled,
control-substrate NWs (green, right mouse). Inversion of fluorochrome-NW relationships
prevents optical or molecular bias from fluorophores in homing visualization. + indicates
broad laser irradiation (810 nm, 0.75 W/cm 2, 20 min). B) Imaging of NW homing in
excised tumors from experiments in Figures 3D and S12A. Each box was imaged using
the same acquisition parameters for both VT750 (green) and VT680 (red) and contains
the left and right tumors from MDA-MB-435-bearing mice.
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Figure 7.15. Histopathological analysis of FXIJI-targeted NWs with integrated and
disconnected NP signaling networks. Histopathological sections from the integrated NP
signaling experiments in Figures 3C, 3D, 3E and S12. At 24 hrs post-NW injection, mice
were sacrificed and tumors were analyzed for FXIII-NW distribution in histology.
(Red=CD31 antibody stain, Blue= DAPI nuclear stain, Green=FXIII-targeted NW
distribution).
consistent with previous observations (105) and specific biochemical recognition of the
coagulation process by the peptide coating. (Figure 7.13F) Histologically, FXIII-Lps
formed a broad interstitial mesh in NR-heated tumors, with released doxorubicin
fluorescence emanating from the nuclei of surrounded tumor cells (Figure 7.13G).
The efficacy of therapeutic nanoparticle signaling networks was evaluated in mice
bearing single MDA-MB-435 human carcinoma tumors. PEG-NRs (10 mg/kg) or saline
were injected into mice and, once NRs had cleared from circulation (72 hrs), we
administered a single intravenous dose of FXIII-substrate-Lps, Control-substrate-Lps, or
saline (2 mg/kg doxorubicin), followed immediately by irradiation with near-infrared
light (-0.75 W/cm2 , 810 nm, 20 min). We found that the integrated system significantly-
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Figure 7.16. Portability of NP signaling networks across xenograft tumor types. Athymic
(nu/nu) mice bearing bilateral Hela human cervical cancer tumors were injected with
PEG-NRs and, 72 hrs later, a mixture of FXIII-substrate-NWs and control-substrate-
NWs, labelled with unique NIR-fluorophores, as described for MDA-MB-435 tumor-
bearing mice in Figure 3. Immediately following injection of NW mixtures, the right
flanks of mice were broadly irradiated with a diode laser source. At 24 hrs post-injection,
the homing of FXIII-NWs and control-NWs was visualized using NIR fluorescent organ
imaging. ("Tumor +" indicates the irradiated tumor; "Tumor -" was not exposed to diode
irradiation)
enhanced tumor therapy, directing a prolonged inhibition in tumor growth compared with
its isolated components (FXIII-Lps, Control-Lps, NRs) and control systems (NRs
+Control-Lps) (Figure 7.17A, 7.17B) (P<0.02 for NR + FXIII-Lps compared to all other
treatment groups at each day from 5-24 after treatment; one-sided t-test) without
detectable weight loss due to systemic toxicity (Figure 7.18).
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Figure 7.17. Tumor therapy using nanoparticle signaling networks. A) Tumor volumes
for active NP signaling networks and controls. Tumors in all treatment groups except
Saline (-laser) were exposed to near-infrared irradiation for 20 min (~0.75 W/cm 2, -810
nm) (P<0.02 for NR + FXIII-Lps and all other treatment sets between days 5 and 24; one-
sided t-test, n=6 or 7 mice in each set). B) Representative images of active signaling
network treatment results (NRs + FXIII-Lps, below) compared with untreated controls
(Saline, above) (20 days post-treatment).
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Figure 7.18. Animal weights for mice treated with therapeutic signaling networks
compared with those administered saline only.
7.3 Conclusions:
This chapter describes the design, construction, and testing of a nanoparticle
signaling network that amplifies the delivery of imaging or therapeutic agents to tumors.
The network architecture incorporates two synthetic components that co-opt a biological
cascade to transduce a physical signal (local heating) into a spatially-localized, amplified
biochemical signal (fibrin/FXIII activity). Given the generality of vessel damage-induced
coagulation across tumor types and organisms, this framework provides a robust platform
on which to further customize the signal generation by molecular targeting of the
Signaling nanoparticles to other tissue or disease types. In addition, strategies to locally
activate the clotting cascade without an external trigger have the potential to produce a
fully autonomous system (317). In contrast to the current paradigm of engineering
complex nanoparticle functions into a population of near-identical components, we
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believe the strategy of building interactive, higher-order nanosystems with emergent,
system-scale properties provides new avenues for developing next-generation diagnostics
and therapeutics.
7.4 Materials and Methods:
PEG-NR Signaling Module Synthesis. PEG-NRs were synthesized as described
previously (von Maltzahn et al., Cancer Research (In Review)). Briefly, highly stable,
~13 nm x 47 nm (Figure 1A) CTAB-coated gold nanorods with longitudinal plasmon
resonance at 810 nm (Nanopartz, a division of Concurrent Analytical Inc., Salt Lake City,
UT) coated in 250 pM 5 kDa methyl-PEG-thiol (Laysan Bio, U.S., Arab, AL). The
solution of 5 kDa methyl-PEG-thiol and CTAB-coated gold nanorods was gently mixed
at room temperature for 1 hr and dialyzed exhaustively against ultrapure water (18 MK
cm1) via cellulose ester membrane dialysis (Spectrapor, Rancho Dominguez, CA) to
drive PEG addition. Dialyzed samples were filtered through 100 kDa filters (Millipore,
Billerica, MA) to remove excess polymer and stored at 4'C.
Fibrinogen deposition in heated tumors. Bovine fibrinogen (Sigma) and albumin (Sigma)
were reacted with near-infrared fluorochromes (VT750-NHS or VT680-NHS) at a 2:1
fluorophore: protein molar ratio in PBS for -2 hrs and dialyzed extensively at 4C against
PBS to remove unreacted fluorophores. The product of the dialysis was passed through a
0.1 ptm filter, quantified using a BCA protein assay (Pierce), and assessed for fluorophore
labelling via the absorption at the peak fluorphore absorbance (max=750 and 680 nm,
respectively, for VT750 and VT680). This reaction generated fibrinogen and albumin
protein stocks carrying ~1 fluorophore/protein. To assess whether fibrinogen and albumin
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home to heated tumors, - nanomole of both proteins (bearing distinct NIR-fluorophores)
was injected intravenously into mice bearing bi-lateral MDA-MB-435 carcinoma tumors.
Immediately following injection, one tumor on each mouse was externally heated using a
temperature-controlled water bath set to between 41-53'C for 20 min. At 24 hrs post-
injection, mice were dissected and both tumors fluorescently imaged for the relative
abundance of fibrinogen and albumin (LI-COR Odyssey Infrared Imaging System). To
ensure that fluorophores did not optically or molecularly skew homing results, all
fluorescent experiments were performed with equal numbers of mice allocated to VT750-
fibrinogen/VT680-ablumin and VT680-fibrinogen/VT750-albumin administration at each
temperature tested. Increases in protein tropism to heated tumors were analyzed by
combining the fold increase in targeting observed for both fluorophore orientations (n=4
mice at each temperature tested).
Photothermal heating of passively-targeted nanorod Signaling modules in vivo. Nude
mice were injected subcutaneously in the hind flank with -2x106 MDA-MB-435 cells.
After 2-3 weeks animals were anaesthetized with isoflurane and injected through the tail
vein with PEG-NRs in 0.15 M NaCl, 0.1 M Na Phosphate buffer, pH 7.2 (10 mg Au/kg,
-150ul bolus). All photothermal heating of NRs was conducted at 72 hrs post
administration (a time point after which they had completely cleared circulation) under
the guidance of infrared thermography to continually illuminate the surface temperature
of irradiated regions (FLIR Thermacam S60). A custom diode laser (RPMC Lasers Inc,
810nm, 30 W) was utilized to broadly irradiate the right flank of tumor-bearing mice at
-0.75 W/cm2 and -1 W/cm 2 to maintain desired peak tumor temperatures in NR-injected
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mice (~46'C for initial fibrinogen-homing experiments and integrated signaling network
implementation; 20 min exposure).
Immunohistochemical analysis in tumors. For histologic analysis, frozen sections of
tumors were prepared. The sections were first fixed with acetone. Rat anti-mouse CD-31
(1:50, BD PharMingen) and biotinylated mouse fibrin(ogen) antiserum (1:50, Nordic)
were used for immunochemical staining of tumor tissue sections. The corresponding
secondary antibodies were added and incubated for 1 hour at room temperature:
AlexaFluor-594 goat anti-rat or rabbit IgG (1:1,000; Molecular Probes), streptavidin
Alexa Fluor 594 (1:1000; Molecular Probes). The slides were washed three times with
PBS and mounted in Vectashield Mounting Medium with DAPI. At least three images
from representative microscopic fields were analyzed for each tumor sample.
Peptide Synthesis. The three peptides used in this work: a fibrin-binding peptide (Ac-d-d-
d-G-Y-e-C-hyP-cY-G-L-C-Y-I-Q-K-(K-Fluorescein)) (binding sequence in bold), a
peptide substrate for the transglutaminase Factor XIII (G-N-Q-E-Q-V-S-P-L-T-L-L-K-X-
C-(K-Fluorescein)) (active glutamine in bold; X=6-aminohexanoic acid linker), and a
control substrate for FXIII (G-N-A-E-Q-V-S-P-L-T-L-L-K-X-C-(K-Fluorescein)) (single
amino acid substitution in bold) were synthesized via standard FMOC solid-phase
peptide synthesis (MIT Biopolymers Core or Tufts University Core Facility). Products
were HPLC-purified to >90% purity and characterized via mass spectrometry. Fibrin-
binding peptides were cyclized by bubbling air into 10 pM aqueous peptide solutions
overnight, followed by lyophilization for subsequent use.
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Receiving Module NP Syntheses. Superparamagnetic, dextran-caged iron oxide
nanoworms (NWs) with a longitudinal size of -55 nm were synthesized, aminated using
20% v/v ammonium hydroxide, and derivatized with near-infrared fluorophores as
described previously2 7 . Fibrin-binding peptides were attached to NWs via their
exogenous lysine by first reacting fluorophore-labelled NWs with the bifunctional linker
NHS-PEO 5-NHS (Pierce) in phosphate buffered saline pH 7.2 (PBS) at a 5000:1
linker:NW molar ratio to prevent cross-linking. Following activation with linker, NWs
were filtered using a gel filtration column (G50 media) and incubated overnight with
cyclized fibrin-binding peptides at -1000:1 peptide:NW ratio with shaking. After -12
hrs, NWs were purified from extra peptides by repeated filtration on centrifugal
membrane filters (100 kDa size cutoff, Centricon, Millipore) and finally dispersed in PBS
for spectrophotometric analysis of peptide labelling. Factor XIII-substrates were attached
to NWs via their exogenous cysteine similarly, but with the linker NHS-PE0 12 -
Maleimide (Pierce) in place of the bifunctional NHS-PEO5 -NHS linker. All peptide-
functionalized NWs were characterized via dynamic light scattering (DLS) and
intravenously injected in vivo to ensure targeted NWs and control NWs exhibited similar
circulation times.
Doxorubicin-loaded liposome synthesis. Hydrogenated soy sn-glycero-3-phosphocholine
(HSPC), cholesterol, and 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-
polyethylene glycol 2000 [DSPE-PEG(2k)], 1,2-Distearoyl-sn-Glycero-3-
Phosphoethanolamine-N-[Maleimide(Polyethylene Glycol 2000)] [DSPE-PEG(2k)-
MAL] were purchased from Avanti Polar Lipids (Alabaster, AL). Doxorubicin was
purchased from Sigma Chemical Co. (St.Louis, MO). For peptide conjugation, liposomes
173
with maleimide groups were prepared from HSPC, cholesterol, DSPE-PEG(2k), and
DSPE-PEG(2k)-MAL in the molar ratio of 75:50:3:3 by lipid film hydration and
membrane (100 nm) extrusion method(318). Encapsulation of doxorubicin (DOX) into
the liposomes was then carried out using the pH gradient-driven loading protocol(319).
Free doxorubicin was removed by gel filtration on Sephadex G-50. After doxorubicin
loading, the maleimide-terminated liposomes were reacted with thiols on peptides (FXIII
and control) for 2 hrs and then purified by by gel filtration on Sephadex G-50. The
peptide-conjugated doxorubicin liposomes were stored in PBS at 4 'C before use.
In vitro cytotoxicity: Cytotoxicity assessments were conducted by the MIT Nanomaterials
Toxicity Core using Human HeLa cervical cancer cultures (ATTC) in 96-well plates
grown to ~70% confluency. Cells were incubated in quadruplicate with various dilutions
of either PEG-NR or Lp formulations assessed for viability after 24hrs of incubation
using the fluorogenic intracellular esterase sensor Calcein acetoxymethylester
(Invitrogen).
Quantifying NW homing to tumors. Mixtures of NIR-fluorophore-labelled, targeted and
control NWs (bearing VT750 and VT680 or VT680 and VT750, respectively) were co-
adminstered intravenously in PBS (2 mg Fe/kg) to tumor-bearing nu/nu mice as described
in the Results and Discussion to provide an internal control reference for coagulation-
specific NW homing. At 24 hrs post-NW injection, mice were sacrificed and organs were
analyzed for both NIR-fluorophores (LI-COR Odyssey Infrared Imaging System). For
integrated signaling network characterization, mice were additionally imaged under
isofluorane anaesthetic before euthanization using a whole animal fluorescence
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reflectance imaging system (Xenogen, IVIS Imaging System) to visualize the specificity
of NW homing to tumors. Images from both organ scanning and whole animal imaging
are displayed as overlaid fluorescent images from both channels (VT750=green and
VT680=red). As with fibrinogen/albumin characterization earlier, all experiments were
conducted with VT750-labeled targeted particles alongside VT680-labeled control
particles and with VT680-labelled targeted particles alongside VT750-labeled control
particles to ensure that fluorophore bias did not perturb results. For initial Receiving
module characterization, levels of targeted and control NW homing were plotted by
comparing the average NW fluorescence in heated tumors versus unheated tumors (n=4
mice at each temperature). For integrated network evaluation, levels were plotted by
comparing the average targeted and untargeted NW fluorescence in irradiated tumors
versus un-irradiated tumors (n=4 mice for all conditions).
Quantification of doxorubicin in tissues. MDA-MB-435 xenografts were established in
nu/nu mice and administered with FXIII-substrate or control-substrate Lps as described
in the Results and Discussion. At 24 hrs post-irradiation or external heating, doxorubicin
in tissues was fluorescently quantified in organ homogenates. Briefly, organs were
removed, weighed, incubated with 500 p.l of 70% EtOH, 0.3 N HCl, and homogenized
(Tissue Tearor, Biospec Products) to release doxorubicin from tissues. Following
homogenization, another 1 ml of 70% EtOH, 0.3 N HCl, was added to samples and they
were centrifuged. Supernatants of samples were analyzed for doxorubicin fluorescence
using a fluorescence microplate reader (Molecular Devices, SpectraMax GeminiEM) and
compared to standard curves.
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Therapeutic assessment of nanoparticle signaling networks. Therapeutic studies were
conducted by first intravenously administering PEG-NRs or saline into nu/nu mice
bearing a single MDA-MB-435 tumor. At 72 hrs post-injection, mice were intravenously
administered FXIII-substrate Lps, control-substrate Lps, or saline (in ~150 pl bolus) and
broadly irradiated in the vicinity of the tumor with NIR light to supply the input to the
inter-nanoparticle signaling network (810 nm, ~1 W/cm 2 , 20 min). An additional cohort
of mice was administered saline at 0 and 72 hrs and not exposed to NIR light in order to
isolate any therapeutic efficacy of this input in isolation. Each therapeutic cohort included
7 mice, except for the unirradiated saline-only control, which had 6 mice. At regular
intervals after treatment, tumors were measured and mice were weighed. Mice were
sacrificed when tumors exceeded 500 mm .
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Chapter 8: Autonomous Signaling Networks for
Amplified Nanoparticle Tumor Targeting In Vivo
8.1 Introduction:
Technologies with the ability to precisely and abundantly target imaging agents
and therapeutics to regions of neoplastic disease could have a dramatic impact on cancer
therapy(22). Rapid progress in cancer nanotechnology has generated a diverse ensemble
of nanomaterials with unique electromagnetic and therapeutic properties(] 7, 22, 32, 308).
However, our capacity to home these devices to tumors remains very limited. Over the
past three decades, targeted nanomaterials have been predominantly been developed as
single-component formulations, wherein specificity to regions of disease is conferred via
carrier size and shape or via surface display of various ligand types, including antibodies,
peptides, aptamers, and small molecules(142, 145, 169, 172).
Evolution has produced more complex targeting strategies that couple the
specificity of molecular interactions with potent signaling and amplification mechanisms
to enable precise and abundant targeting to regions of nascent injury or infection. Blood
coagulation, for example, utilizes parallel inter-component communication to sense
injuries, amplify initial signals, and orchestrate the deposition of a new tissue. Synthetic
biology aims to capture such higher-order biological behaviours and has already
produced artificial biosensors, metabolic processes, molecular automata, and genetic
circuits(320, 321). At the confluence of nanotechnology and synthetic biology lies the
potential to build hybrid systems that leverage the strengths of each field (eg. unique
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Schematic 8.1. Signaling network architecture and information flow. Structure and
information flow in signaling networks. Sensors are ligand-targeted, truncated human
tissue factor proteins (tTF) proteins that are latent in circulation, but gain coagulation-
inducing activity upon binding to target receptors in tumor blood vessels (avp3 and
CD13/aminopeptidase N for tTF-RGD and tTF-NGR Sensors, respectively). Signaling
networks exploit the hardware of the extrinsic coagulation pathway to locally amplify and
transmit Sensor output to FXIII-sensing Receiver nanoparticles.
electromagnetic/therapeutic properties vs signal processing/self-replication) to more
effectively solve biomedical problems.
Here, inspired by natural signaling mechanisms, we construct autonomous, hybrid
biological/nanotechnological signaling networks for amplifying nanoparticle tumor
targeting. We sought to build upon the nanoparticle signaling networks in Chapter 7 by
constructing a system that functions independently of any exogenous electromagnetic
inputs and, therefore, would have the potential to systemically survey host vessels for
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tumor processes. Our hybrid network is comprised of two synthetic components that
harness the extrinsic coagulation cascade to communicate: tumor-homing truncated
human tissue factor (TF) 'Sensors' and coagulation-targeted, magneto-fluorescent
'Receiver' nanoworms (NW) (Schematic 1).
To engineer an autonomous signaling network, we utilized a synthetic biological
Sensor module that could function as a switch by initiating coagulation signaling in
response to molecular interactions in tumor blood vessels. Tissue factor is expressed
ubiquitously outside of the vasculature and is the dominant initiating factor for the
coagulation cascade. When the extracellular domain of TF is truncated (tTF) and
expressed as a soluble protein, its activity towards factor X activation diminishes by 5
orders of magnitude due to separation from cell surface phosphatidylserine co-
factors(322). This cell surface requirement for TF activity allows synthetic ligand-
targeted tTF constructs to specify TF activity to receptors in tumor vessels, where
endothelial cell surfaces display increased phosphatidylserine(323, 324). Previously
Mesters, Berdel and coworkers demonstrated that synthetic tTF proteins expressing the
ligands RGD- and NGR- (which target ayp3 and CD13/aminopeptidase N, respectively)
provide receptor-specific tumor coagulation in mouse models and, very recently, that
synthetic tTF-NGR constructs were well tolerated and diminished tumor perfusion in
terminal cancer patients(323, 324) (Blood, in press). Here, we utilize ligand-targeted
synthetic tTF constructs as Sensors to survey host vasculature for receptors associated
with angiogenesis and, upon binding, engage the extrinsic coagulation cascade as a signal
amplifier to recruit coagulation-targeted Receiver nanoparticles (Schematic 1).
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Figure 8.1. Characterizing fluorophore-labeled fibrinogen and albumin as coagulation-
specific and non-specific probes. Fibrinogen and albumin proteins were labeled with
unique near-infrared fluorochromes (VT750 and VT680, respectively) and mixed
together into vials of human plasma. Upon addition of thrombin and CaCl 2, fibrinogen
(green) was rapidly sequestered into the fibrin plug, while albumin fluorescence (red)
remained dispersed.
8.2 Results and Discussion:
We initially characterized the function of Sensor and Receiver modules
independently. To remotely visualize coagulation-specific and non-specific protein
tropism to tumors in response to Sensor administration, we labeled fibrinogen (the
precursor for fibrin polymers in coagulation) and albumin (a common serum protein
unrelated to coagulation) with unique near-infrared (NIR) fluorophores (VT750 and
VT680) (Figure 8.1). Purified fluorescent conjugates were co-injected (-1 nanomole
each, -1 fluorophore/protein) alongside varying amounts of targeted (tTF-RGD or tTF-
NGR) Sensors into nu/nu mice bearing single MDA-MB-435 breast xenograft tumors. At
24 hrs post-injection, Sensor-injected mice harboured tumors with a distinct
hemmorhagic appearance (Figure 8.2). Fluorescent fibrinogen was found to accumulate
within vessel-like tumor structures in Sensor-injected mice, without accompanying
albumin accumulation. Such fibrinogen accumulation was not observed in control organs
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of Sensor-injected mice and was not significantly evoked by untargeted tTF constructs,
even at high doses (Figure 8.3A, 8.4A). Histopathologically, fibrinogen deposition in
tumors of Sensor-injected mice formed broad intravascular networks (Figure 8.3B,
8.4B), illustrating the potential for targeted tTF Sensors to orchestrate intravascular
recruitment of circulating agents to tumor vessels.
Receiver nanoworms were synthesized as described previously(32) and derivatized with
near-infrared (NIR) fluorophores for optical imaging (Figure 8.3C). Receivers were
designed to attach to regions of coagulation by harnessing the activity of the coagulation
transglutaminase Factor XIII. Factor XIII-specific (G-N-Q-E-Q-V-S-P-L-T-L-L-K-X-C-
Fluorescein) or control (Control) (G-N-A-E-Q-V-S-P-L-T-L-L-K-X-C-Fluorescein)
peptides, where the single substitution of an alanine for the integrated glutamine nearly
abolishes FXIII activity for the Control peptide, were linked to NWs to create FXIII- and
Control- Receivers (Figure 8.5)(315). To probe for coagulation targeting, human plasma
clots were formed in the presence of FXIII- or Control-NWs. We found that FXIII-
substrate NWs strongly concentrated in human plasma clots in vitro, while Control-
substrate NWs did not (Figure 8.3D).
We next explored the ability of tTF-RGD Sensors to amplify FXIII-NW homing
following their simultaneous intravenous injection into nu/nu mice bearing MDA-MB-
435 tumor xenografts. Integrated signaling networks (tTF-RGD + FXIII-NWs) were
compared to control networks (tTF-RGD + Control-NWs), FXIII-NWs in isolation, and
to the homing capacity of NW populations bearing RGD targeting ligands. At 24 hrs
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Figure 8.2. Intraoperative images at 24-hrs post-Sensor injection. Nu/nu mice bearing a
single MDA-MB-435 tumor were intravenously injected with saline, tTF-RGD, or tTF-
NGR (1 mg of tTF-RGD or tTF-NGR/kg) and dissected 24 hrs later. Administration of
both Sensors led to the macroscopic appearance of tumoral hemorrhage and RBC stasis,
while saline-injected mice harbored ivory-hued tumors.
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Figure 8.3 Signaling network component characterization A) Sensor characterization.
tTF-RGD Sensors were injected intravenously at varying doses alongside mixtures of
fluorescent fibrinogen (green, VT750) and albumin (red, VT680) (~1 nmole of each
protein) to monitor for Sensor-mediated fibrinogen deposition in tumors. Untargeted tTF
proteins were similarly injected at the highest dose used with targeted Sensors. B)
Histopathologic analysis of tumor fibrinogen distribution without (left panel) and with
Sensor co-injection (right panel) (Red = CD31 blood vessel stain; Green = injected
fibrinogen fluorescence; Blue = nuclear stain) C) Model Receiver nanoparticles were
synthesized by tethering FXIII peptide substrates to fluorescent, polymer-caged iron
oxide nanoworms (NWs). D) Fluorescent FXIII- (GNQEQVSPLTLLK) and Control-
substrate (GNAEQVSPLTLLK) NWs were tested for coagulation targeting in vitro by
adding thrombin/CaCl2 to solutions of NWs in citrate-stabilized human plasma (3 pg
Fe/ml; 25 nM NW).
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Figure 8.4. Macroscopic and histopathological distribution of fluorescent fibrinogen in
tTF-RGD Sensor-injected mice. A) Information flow between Sensor and coagulation
cascade and macroscopic distribution of fluorophore-labeled fibrinogen at 24 hrs
following co-injection with tTF-RGD Sensor (1 mg tTF-RGD/kg) (~1 nmole fibrinogen;
VT750 fluorophore). B) Anti-fibrinogen antibody stain co-localizes with injected
fibrinogen fluorescence (Red = Anti-fibrinogen; Green = injected fibrinogen
fluorescence; Blue = nuclear stain), top = VT750-labeled fibrinogen without tTF-RGD
Sensor injection; bottom = VT750-labeled fibrinogen with tTF-RGD Sensor injection (1
mg tTF-RGD/kg);
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Figure 8.5. Characterization of superparamag-netic iron oxide nanoworm Receiver
nanoparticles. A) Structure of the Factor XIII substrate peptide used to confer
coagulation specificity to NWs (substrate sequence in blue, exogenous cysteine in red
and fluoroscein in black). For Control-NW synthesis, an identical peptide was used with
the essential glutamine replaced by an alanine residue. This enabled development of two
NW Receiver populations with high and low specificity for coagulation via a single
amino acid difference in their surface properties. B) UV-visible spectra of FXIII-NWs
before and after NIR-fluorophore and peptide conjugation. Changes in the visible spectra
of NW conjugates facilitates the quantitative characterization of the number of peptides
and fluorophores chaperoned on each particle scaffold (-600 FXIII-substrates/NW and
-25 VT750 fluorophores/NW). C) Dynamic light scattering characterization of FXIII-
substrate and Control-substrate NWs. Following modification with FXIII and Control
peptide substrates (both at -600 peptides/NW), NWs retain similar size by light
scattering.
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Figure 8.6. Amplification of nanoparticle targeting in vivo using hybrid signaling
network. A) Intraoperative imaging of NW targeting in hybrid signaling networks. Nu/nu
mice bearing a single MDA-MB-435 tumor were intravenously injected with integrated
(tTF-RGD + FXIII-NWs) or control (tTF-RGD + Control-NWs) signaling networks,
FXIII-NWs alone, or NWs targeted by the peptide used to direct Sensor tumor homing (1
mg/kg tTF-RGD; 1.5 mg Fe/kg). At 24 hrs post-injection, tumors were surgically
exposed under anaesthetic for fluorescent intraoperative imaging of NW homing to
tumors. B) Fluorescent quantitation of NW homing in integrated signaling networks and
controls (*p<0.05 versus all other sets, n=3 or 4 mice for each set)
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Figure 8.7. NIR-imaging of NWs from excised tumors in integrated and control signaling
networks. Nu/nu mice bearing a single MDA-MB-435 tumor were intravenously injected
with integrated (tTF-RGD + FXIII-NWs) or control (tTF-RGD + Control-NWs) signaling
networks, FXIII-NWs alone, or NWs targeted by the peptide used to direct Sensor tumor
homing (1 mg/kg tTF-RGD; 1.5 mg Fe/kg). At 24 hrs post-injection, mice were sacrificed
and tumors were surgically removed for fluorescent imaging of NW localization to
tumors. Integrated networks show dramatic accumulation in characteristically branching
vascular pattern, while this effect is absent in all controls.
A)
Sensor: tTF-RGD tTF-RGD
Receiver: FXIII-NWs CTL-NWs FXIII-NWs RGD-NWs
B)
Figure 8.8. Microscopic and macroscopic characterization of nanoparticle targeting in
vivo using hybrid signaling network C) Histopathologic analysis of NW homing in
integrated signaling networks and controls. Green = NW fluorescence; Red = CD31
blood vessel stain; Blue = nuclear stain. D) Tumor specificity of hybrid signaling
networks. Excised organs from mice injected with integrated signaling networks (tTF-
RGD + FXIII-NWs) were imaged for NW fluorescence at 24 hrs post-injection (1 mg/kg
tTF-RGD; 1.5 mg Fe/kg).
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post-injection, mice were anaesthetized and tumors were surgically revealed for intra-
surgical NIR fluorescent imaging of NW homing (Figure 8.6A). Intra-operative imaging
revealed marked enhancement of vascular homing of FXIII-NWs in the integrated
network (tTF-RGD + FXIII-NWs), with substantially diminished NW accumulation for a
control network (tTF-RGD + Control-NWs) and FXIII-NWs in isolation (Figure 8.6A,
8.6B). Importantly, integrated networks also generated superior tumor homing compared
to the traditional strategy for directly targeting nanoparticles to receptors: RGD-NWs
(Figure 8.6A, 8.6B, 8.7), demonstrating the central role of signal amplification in
communicating the presence of Ayp3 integrins to NWs. Histopathological analysis of
tumors demonstrated abundant intravascular Receiver homing that filled the lumen of
tumor vessels in the case of integrated networks, an effect that was absent in all controls
(Figure 8.8A). RGD-NWs could be observed in endothelial cells lining some tumor
vessels, but at considerably lower concentrations and without the amplified luminal
accumulation of FXIII-NWs in integrated networks. As was observed during isolated
characterization of Sensors, we found the vascular targeting of FXIII-NWs in integrated
signaling networks to be highly specific to tumors, with negligible homing to control
tissues, including lungs, heart, fat, brain, skin, muscle (Figure 8.8B). To further verify
that our signaling networks channel information via the coagulation cascade, we
administered integrated networks alongside a strong coagulation inhibitor, heparin, to
disrupt thrombin-mediated FXIII activation. Indeed, heparin administration eliminated
characteristic vascular homing pattern of FXIII-NWs in integrated networks (Figure 8.9).
In order to assess the modularity of receptor-targeted Sensor components, we
finally tested tTF-NGR Sensors, which seek out CD1 3/aminopeptidase N receptors in
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Figure 8.9. Heparin-mediated disruption of signaling network communication. A)
Schematic of heparin's disruption of communication in hybrid signaling networks. B)
Nu/nu mice bearing a single MDA-MB-435 tumor were intravenously injected with
integrated signaling networks (tTF-RGD + FXIII-NWs; 1 mg/kg tTF-RGD; 1.5 mg
Fe/kg) alongside heparin to prohibit thrombin activation (intravenous bolus of 800
units/kg + intraperitoneal bolus of 500 units/kg 30 minutes later). At 24 hrs post-
injection, mice were sacrificed and tumors were surgically removed for fluorescent
imaging of NW localization to tumors. Tumors on heparin-injected mice lack
characteristic vascular pattern of integrated signaling between Sensors and Receivers.
tumor vessels, alongside FXIII-targeted NWs. We found that tTF-NGR Sensors were
similarly able to amplify NW targeting to tumors (Figure 8.10A, 8.10B), highlighting the
capacity for our signaling network architecture to be customized for specific cancer types
and stages.
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Figure 8.10. Modularity of hybrid signaling networks: Signaling networks composed
using a distinct ligand-targeted tTF enzyme Sensor. tTF-NGR Sensors survey host
vasculature for CD13/aminopeptidase N receptors associated with tumor angiogenesis.
Upon binding, tTF-NGR sensors gain activity and transmit their signal to Receiver
nanoparticles through the extrinsic coagulation cascade. Nu/nu mice bearing a single
MDA-MB-435 tumor were intravenously injected with integrated (tTF-NGR + FXIII-
NWs) or control (tTF-RGD + Control-NWs) signaling networks, FXIII-NWs alone, or
NWs targeted by the peptide used to direct Sensor tumor homing (1 mg/kg tTF-NGR; 1.5
mg Fe/kg). At 24 hrs post-injection, mice were sacrificed and tumors were surgically
removed for fluorescent imaging of NW localization to tumors. B) Quantification of
average fluorescence from tumor cohorts above (n = 4 mice in each set; * denotes P<0.05
between tTF-NGR -> FXIII-NWs and all other tumor sets).
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8.3 Conclusions:
The hybrid signaling networks developed here demonstrate the potential for
ensembles of biological (engineered proteins, viruses, phage) and nanotechnological
components (nanoparticles, nanowires, etc) to cooperate to perform complex operations
in vivo. A fundamental advantage of the strategy presented here over traditional NP
targeting approaches is the amplification produced coupling molecular interactions with a
biological cascade amplification system. In contradistinction to pre-targeting approaches
that require sequential administration of system constituents(325), our signaling network
components are simultaneously administered and autonomously perform their functions.
Finally, because we utilize a human tissue factor Sensor that has been tested in patients,
this network architecture may translate to improved clinical cancer imaging and
therapeutic systems.
8.4 Materials and Methods:
tTF, tTF-RGD, tTF-NGR Sensor expression and purification
The cDNAs coding for the tTF-containing amino acids 1 - 218 and the respective C -
terminal peptide extension were amplified by polymerase chain reaction (PCR) using the
primers:
5'-CATGCCATGGGATCAGGCACTACAAATACTGTGGCAGCATATAAT-3'(5'-
Primer), 5'-CGGGATCCTATTATCTGAATTCCCCTTTCTCCTGGCCCAT-3' (3'-
Primer) for tTF,
5'-CGGGATCCTATTATGGAGAATCACCTCTTCCTCTGAATTCCCC-3' (3'-Primer)
for tTF-RGD and
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5'-CGGGATCCTATTATGCATGTGCTCTTCCGTTACCTCTGAATTCCCC-3' (3'-
Primer) for tTF-NGR. With the DNA-Ligation Kit (Novagen, Schwalbach am Taunus,
Germany) the cDNA was cloned into the expression vector pET-30(+)a (Novagen) using
the BamHI and NcoI sites of the vector. The vectors were introduced in competent
Escherichia coli cells (BL21 DE3) according to the manufacturer's protocol (Novagen).
The bacteria were cultivated in Luria broth medium supplemented with kanamycin (30
pig/ml) at 370 C. When the bacteria cell suspensions reached an OD of ~ 0.6, over-
expression of the fusion proteins was initiated by adding 1 mM IPTG (Novagen). After
-16 h, the cells were harvested and 5-7 ml lysis buffer (10 mM Tris-HCl, pH 7.5; 150
mM NaCl; 1 mM MgCl 2; 10 ig/ml aprotinin; 20 Il benzonase; 2 mg/ml lysozyme) per
gram wet weight were added. The lysed cells were incubated for 90 minutes at room
temperature (RT) and centrifuged at 12,000 g for 20 min at 4'C. The pellet was
resuspended and homogenized by sonicating in washing buffer (10 mM Tris/HCl, pH 7.5;
1 mM EDTA, 3% Triton X-100). To solubilize the inclusion bodies, 2-4 ml guanidinium
buffer (6 M GuCl, 0.5 M NaCl, 20 mM Tris/HCl, pH 7.5; 1 mM DTT) per gram wet
weight was added. After incubation overnight at RT, the suspension was centrifuged at
10,000 g for 20 min at 4'C and the supernatant was filtered through a 0.22 pm filter.
The solubilized tTF fusion proteins were refolded and purified by using a multi-
step HPLC-based purification process (HPLC unit: AKTA purifier 100 System, GE
healthcare, Uppsala, Sweden). It consists of an immobilized metal-(copper-)affinity
chromatography (IMAC; IMAC Sepharose 6 FF, GE healthcare). The histidine-tagged
tTF fusion proteins bind to the immobilized copper ions so that the complete refolding
(gradient from 6 M to 0 M urea buffer within 60 min) and washing processes are
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performed on the column, from which the tTF Sensor proteins are eluted by applying 300
mM imidazole. During the subsequent gel filtration the IMAC eluate is conditioned by a
buffer exchanging step (20 mM Tris/HCl, pH 8; 20 % glycerol) using Sephadex G-25
(GE healthcare) in order to prepare for the following intermediate anion-exchange
chromatography step (AlEX; Q Sepharose HP, GE healthcare; used buffers: 20 mM
Tris/HCl, pH 8; 20 % glycerol +/- 300 mM NaCl). The concluding polishing step again
comprises a gel filtration using Sephadex G25 in order to remove any remaining trace
impurities and to exchange the puffer to PBS. The final protein solutions (> 95% purity)
are stored at -80*C. Each sample produced was tested for purity (SDS-PAGE, Western
Blot, endotoxins, HPLC) and activity (Factor-X coagulation test).
Factor-X activation by tTF Sensor proteins
The ability of the tTF Sensor proteins to enhance the specific proteolytic activation of
Factor (F) X by FVIIa was assessed as described by Ruf et al.'. Briefly, to each well in a
microtiter plate was added 20 ptl of: (a) 50 nM recombinant FVIIa (Novo-Nordisc,
Bagsvord, Denmark) in TBS-BSA; (b) 0.16 nM - 1.6 pM tTF/tTF-NGR in TBS
containing 0.1 % bovine serum albumine (BSA); (c) 25 nM CaCl 2 and 500 pLM
phospholipids (phosphatidylcholine/phosphatidylserine, 70/30, MM; Sigma, Mnnchen,
Germany). After 10 min at RT, 20 ptl of the substrate FX (Enzyme Research
Laboratories, Swansea, UK) was added in a concentration of 5 pM. Aliquots were
removed from the reaction mixture every minute and stopped in 100 nM EDTA.
Spectrozyme FXa (American Diagnostica, Greenwich, CT, USA) was added and rates of
FXa generation were monitored by the development of color at 405 nm with a microplate
reader (Bio-Rad, Hercules, California, USA).
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Probing Sensor-mediated tumor coagulation via fibrin(ogen) deposition in tumors.
Bovine fibrinogen (Sigma) and albumin (Sigma) were reacted with near-infrared
fluorophores (VT750-NHS and VT680-NHS, respectively; Visen Medical) at a 2:1
fluorophore: protein molar ratio in PBS for ~2 hrs and dialyzed exhaustively at 4'C
against PBS to remove unreacted fluorophore. The product of the dialysis was passed
through a 0.1 pm filter, quantified using a BCA protein assay (Pierce), and assessed for
fluorophore labeling via the peak fluorophore absorption (ax=750 and 680 nm,
respectively, for VT750 and VT680). After labeling/purification fibrinogen and albumin
protein stocks harbored -1 fluorophore/protein. To assess Sensor-mediated coagulation in
mice, -1 nanomole of both proteins (bearing distinct NIR-fluorophores) were injected
intravenously alongside varying amounts of tTF, tTF-RGD, or tTF-NGR into mice
bearing a flank MDA-MB-435 carcinoma tumor. At 24 hrs post-injection, mice were
dissected and tumors were fluorescently imaged for the relative abundance of fibrinogen
and albumin (LI-COR Odyssey Infrared Imaging System). Increases in protein tropism to
tumors were analyzed by assessing mean tumor fluorescence (n=4 mice with each type of
tTF tested).
Peptide Synthesis. The four peptides used in this work: a peptide substrate for the
transglutaminase Factor XIII (G-N-Q-E-Q-V-S-P-L-T-L-L-K-X-C-(K-Fluorescein))
(active glutamine in bold), a control substrate for FXIII (G-N-A-E-Q-V-S-P-L-T-L-L-K-
X-C-(K-Fluorescein)) (single amino acid substitution in bold), the a3 3 targeting ligand
(Fluorescein-X-C-G-R-G-D-S-P-COO-), and the CD13/aminopeptidase N targeting
ligand (Fluorescein-X-C-G-N-G-R-A-H-A-COO-) were synthesized via standard FMOC
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solid-phase peptide synthesis (X=6-aminohexanoic acid linker) (Tufts University Core
Facility). Products were HPLC-purified to >90% purity and characterized via mass
spectrometry.
Receiver Synthesis. Superparamagnetic, dextran-caged iron oxide nanoworms (NWs)
with a longitudinal size of -60 nm were synthesized, aminated using 20% v/v ammonium
hydroxide, and derivatized with near-infrared fluorophores as described previously'.
FXIII-substrate and Control peptides were attached to NWs via their exogenous cysteine
by first reacting fluorophore-labelled NWs with the hetero bifunctional linker NHS-
PEO12-Maleimide (Pierce) in phosphate buffered saline pH 7.2 (PBS) at a 5000:1
linker:NW molar ratio. Following activation with linker, NWs were filtered using a gel
filtration column (G50 media) and incubated overnight with peptides at ~1000:1
peptide:NW ratio with shaking. After ~12 hrs, NWs were purified from extra peptides by
repeated filtration on centrifugal membrane filters (100 kDa size cutoff, Centricon,
Millipore) and finally dispersed in PBS for spectrophotometric analysis of peptide
labelling. All peptide-functionalized NWs were characterized via dynamic light scattering
(DLS) and intravenously injected in vivo to ensure targeted NWs and control NWs
exhibited similar circulation times.
Quantifying NW homing to tumors in vivo. NIR-fluorophore-labeled peptide-bearing
NWs (bearing VT750 fluorophores) were intravenously (2 mg Fe/kg) in PBS to MDA-
MB-435 tumor-bearing nu/nu mice alone or alongside tTF Sensors (25 ptg). At 24 hrs
post-NW injection, mice were sacrificed and organs were analyzed for NIR Receiver
fluorescence (LI-COR Odyssey Infrared Imaging System). For intraoperative fluorescent
195
tumor imaging, mice were anaesthesized and tumors were surgically exposed to reveal
detailed tumor fluorescence (LI-COR). Levels of NW homing to tumors were plotted by
comparing the average NW fluorescence in fully-excised tumors (n=4 mice at each
condition).
Immunohistochemical analysis of tumors. For all histologic analysis, tumors were frozen
in Optimal Cutting Temperature embedding media and sections of tumors were prepared
in the MIT Koch Institute Histology Core. The sections were first fixed with acetone. Rat
anti-mouse CD-31 (1:50, BD PharMingen) and biotinylated mouse fibrin(ogen)
antiserum (1:50, Nordic) were used for immunochemical staining of tumor tissue
sections. The corresponding secondary antibodies were added and incubated for 1 hour
at room temperature, namely AlexaFluor-594 goat anti-rat or rabbit IgG (1:1000 dilution;
Molecular Probes), streptavidin Alexa Fluor 594 (1:1000 dilution; Molecular Probes).
The slides were washed three times with PBS and mounted in Vectashield Mounting
Medium with DAPI. At least three images from representative microscopic fields were
analyzed for each tumor sample.
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9.0 Perspective and Future Directions
In the past, engineering disciplines have emerged after a significant foundation of
quantitative, experimental, and experiential knowledge had been established in a field-
e.g. mechanical and civil engineering leveraged thousands of years of experience with
construction materials and tools; electrical engineering required the foundational
discoveries of Ohm, Faraday, and Maxwell; chemical engineering was built upon the 1 9 h
century's developments in the field of chemistry; and biological engineering leveraged
the rapid advances in molecular biology during the 2 0 th century. Building upon the
immense progress in nanoparticle synthesis over the past twenty years, the field of
bionanotechnology is now ripe to begin its own engineering discipline, focused, in part,
on incorporating multiple individual nanodevices into cohesive systems that exhibit novel
and predictable functions. The primary goal of this thesis was engineer reliable, higher-
order nanoparticle systems where mechanisms of inter-nanoparticle interaction and
communication produce emergent system behaviors for biomedicine.
In contrast to systems in electrical engineering, biological systems store
information via chemical identity and complementarity and process it through largely
amorphous molecular pathways that rely on biochemical specificity, local concentration
gradients, and dynamic regulation of component activity to propagate and process
information. The nanoparticle systems presented here operate in this wet and wireless
arena of biology and their function takes inspiration from information processing in both
electrical circuits and biological processes.
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The first section of this thesis describes mechanisms of nanoparticle interaction
and communication that exploit biological recognition elements to promote nanoparticle
interactions. Specifically, nanoparticles are modified to harness the high-affinity binding
interaction of streptavidin and biotin or to polyvalently utilize the phospho-specific
interactions between phospho-tyrosine peptides and SH2 domains. These biological
domains provide nanoparticles the opportunity to precisely interact with one another even
within complex biological environments, due to the borrowed specificity of these
biochemical 'addresses.' Looking forward, because such recognition elements underlie
the specificity of virtually all biological information processing, they provide an immense
landscape of other addresses through which future populations of nanoparticles could
interact with single or multiple partners in a programmatic fashion. Beyond the sensing
applications developed herein, these strategies could be used in combination with disease
targeting ligands to enable receptor binding to be followed by an elongation phase where
nanomaterials locally polymerize upon receptor-bound 'initiators.' Such a process could
harness either disease-specific or ubiquitous enzymatic machinery as 'nanoparticle
polymerases' to catalyze elongation. For example, tumor proteases could perform this
function by removing inhibitory domains on latent nanoparticles in circulation similar to
those developed in Chapters 2-3, enabling tumor-programmed nanoparticle assembly
onto receptors. Alternatively, soluble factors in the vicinity of diseases could be
sequestered by nanoparticles as bridging moieties to link otherwise dispersed
nanoparticles into elongated assemblies. Further, nanoparticle systems could be
engineered to exploit disease markers as kinetic triggers to initiate otherwise very slow
inter-nanoparticle binding events.
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Generally, these systems were designed such that biology inputs (enzymes) would
direct inter-nanoparticle interactions by revealing or modifying surface moieties that are
distinct from inputs themselves. The rate of these processes is driven by Michaelis-
Menten kinetics and particle activation proceeds in a linear fashion. In more advanced
embodiments, biological inputs could stimulate the release or activation of additional
input from particles to produce autocatalytic, exponential behaviours. This could provide
initial events to initiate chain-reactions analogous to the amplification networks present
in the coagulation cascade and those used in polymerase chain reactions (PCR) that could
facilitate enhanced sensing and targeting of disease processes. Further, negative feedback
processes could also be engineered into such networks through production of inactivating
stimuli in response to peripheral, non-disease related inputs.
In the second section of this thesis, nanoparticles remotely communicate through
endogenous biological information pathways in plasma (blood coagulation). Specifically,
we describe a system wherein Signaling nanoparticles specifically engage the coagulation
cascade in tumors and Receiving nanoparticles sense the abundant downstream products
of this process. The information flow in this system is complex: external near infrared
energy is locally transduced to heat by tumor-targeted gold nanorods (Signaling
nanoparticles), which locally increases microvascular permeability in tumors, which
exposes plasma to the tumor parenchyma, which activates the intrinsic and extrinsic
coagulation pathways, which generate abundant activity of the protease thrombin, which
produces an abundant fibrin network and activates the transglutaminase Factor XIII,
which together recruit the amplified accumulation of circulating diagnostic or therapeutic
Receiving nanoparticles. Despite its apparent complexity, this network is founded upon
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the robust evolutionary processes of injury repair to propagate a message of tumor's
location between two nanoparticles with high fidelity. Stated another way, in this process,
the biological system is simply performing the function it was evolutionarily selected to
(i.e. If (injury) Then (repair)), without the 'knowledge' that it is delivering a message
between two populations of synthetic devices. A second system comprised of a
nanotechnological and a synthetic biological component was also engineered to hijack
the coagulation cascade to transmit and amplify communication between synthetic
devices. However, as opposed to the first system that utilizes a class of Signaling
nanoparticles capable of generating local vascular injuries in tumors, this second system
utilizes a synthetic biological Sensor that provides a new program for the coagulation
cascade, causing it to respond to endothelial receptors associated with tumor formation.
In the former system, the coagulation cascade was simply performing its intrinsic
function of sensing and repairing vascular injuries. In the latter, as long as the synthetic
biological Sensor is in circulation (~ minutes after i.v. injection), the cascade is
programmed to perform a new function: engage in receptor-expression tumor vessels (in
the absence of any injury) through the phosphatidylserine-dependent activity of a re-
engineered human tissue factor protein.
Together these systems demonstrate not only that nanoparticles can be engineered
to communicate with one another in vivo, but that synthetic bio/nanotechnological
devices can be utilized to provide unnatural inputs and outputs to endogenous biological
information networks and program them to perform tasks they had not explicitly evolved
to. This provides a new perspective on the information processing underlying both
normal and pathologic biological processes and opens new opportunities for hijacking
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molecular and cellular trafficking mechanisms to direct nanoparticle targeting. In its
simplest embodiment, this could resemble approaches to insect extermination where
foraging drones are tricked into carrying poisons back to the colony. More advanced
strategies could actively orchestrate these networks to amplify, redirect, focus, and
otherwise control the propagation of information through these networks to enhance
disease sensing, targeting, and therapy. For example, while we demonstrated that
information could be efficiently transmitted between two synthetic devices in vivo, this
process could certainly be improved through exogenous manipulation of this network
(i.e. unnecessary pathway inhibition, desired pathway supplementation) in an analogous
manner to metabolic engineering approaches(326, 327). An additional benefit of
engineering nanosystems to leverage biological signaling pathways for the bulk of signal
processing and transmission is that the complexity of nanoparticles can be minimized,
while generating sophisticated network behaviors.
Direct and indirect mechanisms of nanoparticle interaction were separately
explored in this thesis. This work is meant to provide a starting point for the future
engineering of higher-order nanosystems, comprised of numerous nanoparticle
populations and incorporating a spectrum of interaction mechanisms. Towards this goal,
just as biological systems rely on the robust synthesis of their components (DNA, RNA,
protein, glycans, etc.), the development of complex multi-component nanosystems that
themselves resemble processes like blood coagulation instead of merely activating them,
will require nano-parts of superior fidelity, reliability, and reproducibility. Further, the
intended and unintended interactions and communications between nanoparticles and
living systems will need to be much more thoroughly understood. As such, tools for
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deciphering these in a highly parallel fashion will be needed. Particularly, for in vivo
applications, methods for rapidly and simultaneously revealing the macroscopic and
microscopic biodistribution of multiple nanoparticles, characterizing their 'state' (e.g.
integrity of nanoparticle surface chemistries, understanding what proteins have bound to
the surface, % payload released, whether the nanoparticle is receptor bound or free, etc.),
and understanding the tissue's state (e.g. naive?, manipulated?, what information
pathways are activated?, etc.) will be necessary tools for understanding and accurately
predicting nanosystem functions. While the goal of developing bio-synthetic analogues of
complex biological systems such as blood coagulation remains far away on the long
horizon, we now have the tools to sincerely begin engineering higher-order systems of
interactive nanoparticles that can operate at biology's length scale and begin to emulate
its complexity. A simple look at the natural world around us should reveal that this is a
pretty exciting place to be.
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